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Abstract
The Salmonella typhimurium vaccine construct, GIDlOl, which constitutively 
expresses L. major gp63 was used as an oral vaccine against experimental cutaneous 
leishmaniasis in the susceptible BALB/c mouse. After 2 oral immunisations with 
GIDlOl, lesion development was reduced following L. major infection. This vaccine 
therefore represents a considerable improvement over the previous attenuated S. 
typhimurium vaccine SL3261-gp63 which was unable to confer any protection to 
susceptible mice. After two oral doses of GIDlOl, spleen and mesenteric lymph node 
(MLN) cells from BALB/c mice were found to proliferate in vitro to parasite antigens 
and produce substantial amounts of IFN-y and IL-2 but no IL-4 or IL-5. The 
production of these cytokines was CD4"^-cell dependant. Serum taken from immunised 
mice was found to contain parasite specific IgG2a but no parasite specific IgGl. In 
addition, no delayed type hypersensitivity (DTH) response to L. major was detected in 
vaccinated mice. These data are consistent with the notion that GIDlOl administration 
results in the induction of a protective ThLlike response to L. major.
L. major gp63 was also expressed in the attenuated S. typhimurium strain, 
BRD509, under the control of either the nirB promoter which responds to anaerobic 
conditions (GID105) or the osrnC promoter which is induced under high salt 
conditions (GID106). The construct GID105 displays more stable plasmid retention 
during colonisation in vivo when compared with the constitutive construct GIDlOl.
After oral administration, the construct GID106 does not colonise spleen or liver at all 
although it is found in the MLN. In addition, this construct loses plasmid more quickly 
in vivo compared to the GIDlOl strain. An antibody response to gp63 is generated in 
BALB/c mice after one oral dose of GIDlOl, GID105 or GID106, while only the 
anaerobic construct GID105 is able to induce a significant cellular response to antigen. 
Spleen and MLN cells from mice administered GID105 respond in vitro to parasite 
antigen in a ThI-like manner. A single oral delivery of GID105 or GID106 is 
sufficient to reduce lesion swelling in susceptible mice after L. major infection, while
a single dose of GIDlOl does not confer any protection. Two doses of GID105 also 
reduces liver parasite burdens during L. donovani infection, while GIDlOl or GID106 
provide no protection. Therefore construct GID 105 can confer a degree of protection 
to L, major infection after a single oral dose and to L. donovani after two doses, 
representing a further improvement of the gp63 construct.
A plasmid was generated which contains the cDNA for L. major p24/LACK 
under control of the inducable NirB promoter. This plasmid was introduced into the 
attenuated S. typhimurium strain BRD509. Expression of p24 by this construct 
(GID202) was demonstrated under anaerobic conditions by western blotting. After oral 
administration of GID202 to BALB/c mice bacteria were detected in the spleen, liver 
and MLN from around 3-7 days post administration until 21-28 days. Plasmid stability 
of the construct during colonisation was found be around 100% in all organs. BALB/c 
mice which were orally administered one or two doses of GID202 before L. major 
infection developed exacerbated disease. CBA mice given two oral doses of GID202 
also generated an exacerbated infection although CBA mice which received a single 
dose were slightly protected. Spleen and MLN cells from mice administered GID202 
responded in vitro in a Thl-like manner to both recombinant p24 and the 
immunodominant peptide of p24. These data demonstrate a disease-promoting effect 
of vaccination with p24 expressed in S. typhimurium correlating with a normally 
protective Thl response in vitro.
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1.1 Leishmaniasis
Leishmaniasis is a disease of global importance as at present there are around 
12 million infected individuals and much of the world's population live in endemic 
areas (1). At least 2 major epidemics of leishmaniasis, in Sudan (2) and India (3) are 
currently taking place. There is no reliable vaccine against any form of this disease and 
treatment of infection relies principally on the use of pentavalent antimonial 
compounds which are costly, highly toxic and not always effective (4). However, 
recent advances in understanding the immunology of leishmaniasis have elucidated the 
factors responsible for protection and susceptibility to infection, providing a foundation 
for the future development of a vaccine in addition to the rational design of effective 
therapeutic agents.
1.1.1 Clinical disease
There are three major clinical forms of leishmaniasis which together create a 
spectmm of disease ranging from self healing cutaneous lesions to fatal visceral disease 
(5).
Cutaneous leishmaniasis (also called Oriental Sore), develops as a skin lesion at 
the site where a sandfly has previously take a blood meal. These lesions are usually 
self-limiting, although a chronic condition can develop caused by certain parasite 
species known as Diffuse Cutaneous Leishmaniasis (DCL). In this case, the injected 
organism spreads to other subcutaneous tissues, resulting in extensive swelling at many 
sites in the skin. While the majority of infected individuals will heal a cutaneous 
lesion, there is often an unsightly scar left at the injection site.
Visceral leishmaniasis (or Kala Azar) also begins with lesion development 
around the site of inoculation but the infection slowly spreads to involve visceral
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tissues, such as spleen, liver and bone marrow. Hepatosplenomegaly, diarrhoea, 
weight loss and severe immunosuppression occur as the disease progresses which 
ultimately leads to death unless adequate treatment is provided (5).
Muco-cutaneous leishmaniasis (MCL) (or Espundia) results from the 
reactivation of infection in individuals who have cured an initial cutaneous lesion many 
years previously. However, this reactivation does not take place at the initial infection 
site but is restricted to the mucous membranes of nose, mouth and pharynx. 
Spontaneous recovery from this condition is rare.
1.1.2 Species classification and global distribution
The parasites responsible for these diverse clinical diseases all belong to the 
genus Leishmania. These protozoan organisms belong to the class Zoomastigophorea 
and order Kinetoplastida, suborder Trypanosomatina (6). Their inclusion within this 
order is based primarily on the possession of a kinetoplast which is a round aggregation 
of DNA outside the nucleus which is readily observed under light microscopy using a 
DNA stain. This kinetoplast DNA is contained within a single, large mitochondrion 
and the position this occupies within the flagellate stage of the parasite allows easy 
differentiation of Leishmania from other Trypanosomatina (6).
The various Leishmania species can be grouped according to the geographical 
area in which they are found and the clinical disease they produce. This generates four 
distinct species groupings.
Two species which cause visceral leishmaniasis in northern and east Africa, 
southern Europe and parts of Asia are collectively known as agents of "Old World 
Visceral Leishmaniasis", The main species in this group is L. donovani which is the 
most widely studied of all visceral species (5). L. infantum (sometimes referred to as
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L. donovani infantum ) is a minor species which is endemic in parts of southern Europe 
and is thought normally to produce an asymptomatic infection in healthy adults (7).
"New World Visceral Leishmaniasis" is an identical disease to that caused by L. 
donovani . However, this disease is found in Mexico, Central and South America and 
is caused by L. chagasi infection.
The group of species responsible for "Old World Cutaneous Leishmaniasis" is 
more diverse and comprises three distinct species (6). L. tropica and L. major are 
found in Asia, Africa, the Middle East and parts of southern Europe. L. aethiopica is 
found only in east and north-east Africa and is known to be an agent of DCL.
A larger species group which causes "New World Cutaneous Leishmaniasis" 
can be subdivided, as only some of these can later produce MCL (5). L. mexicana 
does not cause MCL and has several distinct sub-species (sometimes treated as 
individual species) called L, m. mexicana , L. m. garnhami , L. m. venezuelensis , L. m. 
amazonensis and L. m.. pifanoi . These are found in Mexico, Central and South 
America as well as in the southern states of the USA. L. m. amazonensis , L. m. pifanoi 
and L. m. mexicana can cause DCL while other L. mexicana species cause only 
cutaneous lesions. L. braziliensis has a number of sub-species some of which can 
cause MCL. L. b. braziliensis and L, b. panamensis are known to cause MCL while 
L. b. guyanensis is thought to only cause cutaneous infections. These species are 
found in Central and South America.
Although each parasite species will commonly cause the diseases outlined 
above, there are reports of certain species causing clinical disease outwith the noimal 
groupings. There are reports of cutaneous disease caused by L. chagasi which will 
usually only transmit visceral infection (8). Conversely there are reports of visceral 
disease caused by L. tropica in Gulf War veterans with no indication of any cutaneous 
lesions (9). This particular disease is termed viscerotropic leishmaniasis. These data
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indicate that parasite species are not always restricted to the classifications outlined 
above. The factors responsible for disease outside the normal species restrictions are 
not known but the immune status of the host may be critical in this regard (10).
1.1.3 Life cycle in sandfly
Leishmania species are all symbiotic, inhabiting the macrophages of vertebrates 
and the gut of sandflies during their lifecycle (6). They exist as two morphologically 
distinct forms, the promastigote and amastigote, corresponding to which of the two 
hosts they happen to be in. The promastigote is the parasite fonn found in the sandfly 
and is an extracellular, long, thin, flagellate protozoan. The amastigote, within a host 
macrophage, is smaller, round and has no flagellum.
The promastigote stage of the Leishmania spp. inhabit female sandflies of the 
genus Phlebotomus (Old World) or Lutzomyia (New World). The parasite exists 
within the sandfly gut, attached to midgut epithelial cells via the surface 
glycoconjugate Lipophosphoglycan (LPG), which has affinity for lectins expressed on 
the surface of these cells (11). These parasites divide rapidly, are non-infective and are 
termed procyclic promastigotes (12). In addition to providing a means of attachment to 
gut cells, LPG, which forms a dense glycocalyx over the entire promastigote surface 
may protect the parasite from enzymatic damage within the insect gut (13), A dense 
carbohydrate gel is also secreted from the promastigote, which may provide a physical 
barrier between the parasite and the gut environment (14).
LPG has four defined structural domains, consisting of a phosphatidylinositol 
lipid anchor, a phosphosaccharide core, a number of repeating oligosaccharide units 
and a short oligosaccharide cap. The lipid and core structure are conserved between 
species (15) whereas the repeating and cap oligosaccharides vary in size and number 
(16). In a process termed metacyclogenesis (17), the LPG on the surface of L. major 
undergoes a biochemical transformation which involves a doubling of the number of
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repeating oligosaccharide units and a change in the terminal oligosaccharide side- 
chains from j3-galactopyranose to cx-arabinopyranose (18). This maturation allows the 
procyclic to detach from the lectins on the gut cell surface. L. donovani procyclics 
undergo a similar conformational change which allows detachment from the gut cell 
but without any alteration in the terminal saccharide units (19).
After detachment from the mid-gut, the mature, metacyclic forms migrate to the 
sandfly proboscis, a process which may involve parasite-mediated damage to the 
cardiac valve which then allows entry into the pharyngeal pump (20). The 
multiplication and maturation process of the parasite within the sand fly takes around 
7-10 days as parasites harvested from infected flies are non-infective until around this 
time (12).
1.1.4 Mammalian life cycle
1.1.4.1 Infectivity
Metacyclic promastigotes do not divide and are highly infective (12). The 
expression of the mature form of LPG correlates well with the infectivity of 
promastigotes (21), and parasites devoid of surface LPG recover their virulence with 
the addition of purified LPG molecules (22). While other surface molecules such as 
the promastigote surface protease (PSP or gp63) have also been implicated in parasite 
virulence (23), this depends on the species of parasite studied. In New World species 
gp63 levels correlate well with infectivity (23) whereas in Old World species such as L. 
major no such correlation is detected (21).
LPG is thought to confer infectivity to the promastigote by nature of its dense 
elongated capsule-like staicture which covers the entire parasite surface (16). This has 
been shown to prevent complement mediated damage to the parasite surface membrane 
(24). Procyclic promastigotes are extremely sensitive to complement lysis via the
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alternative pathway when placed in the presence of serum (25). Metacyclic 
promastigotes fix complement using the classical pathway of activation but are not 
lysed even by the formation of the membrane attack complex C5b-C9 (26).
Sandfly salivary gland substances, when co-injected with L. major 
promastigotes, can also increase the infectivity of the parasite (27). How this is 
mediated is unknown but constituents within sand fly salivary gland material have been 
shown to inhibit macrophage activation in vitro (28).
1.1.4.2 Macrophage entry
The mechanism of promastigote entry into macrophages is not clearly 
understood and a number of diverse receptor-1 igand interactions between the 
promastigote and macrophage have been implicated in the process (29). PSP and LPG 
on the parasite surface, and Complement Receptors 1 and 3 (CRl and CR3), the 
mannose-fucose receptor (MFR), the receptor for advance glycosylation end products 
(AGE), the fibronectin receptor (FNR) and the Fc receptor (FcR) on the macrophage 
have all been suggested to mediate parasite entry.
Complement binding of C3 by LPG or other surface molecules is thought to be 
important in targeting promastigotes to the CRl receptor which will allow macrophage 
entry in the absence of a respiratory burst. In the presence of serum C3b binding to 
CRl was shown to be the major interaction involved in binding of metacyclic 
promastigotes of L. major to human macrophages (30). C3b binding on the surface of 
L. major metacyclics also enhanced the subsequent intracellular survival of the 
amastigote compared with uptake in the absence of serum (31). While other receptor 
events have been implicated in parasite uptake, this work has not always involved the 
use of the infective, metacyclic stage and thus CRl is the most likely mechanism of 
entry.
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Another complement receptor, CR3, has been implicated in macrophage entry 
but this pathway is believed to activate the respiratory burst and therefore is unlikely to 
be involved (32). In the initial cloning of gp63 there was predicted to be an RGD 
sequence (33) which is a sequence known to be used in the recognition of ligands by 
integrin receptors (34), However, a corrected gp63 sequence contained no RGD motif 
(35), making the interpretation of experiments describing the involvement of an RGD 
sequence in the binding to CR3 difficult (36). It is clear, however, that in the absence 
of serum, gp63 can participate in macrophage binding, as gp63 coated liposomes were 
engulfed by macrophages ten times more efficiently than uncoated liposomes (37).
In addition to complement receptors, a number of other candidate surface 
molecules on the macrophage have been examined. Experimental evidence suggests 
that the mannose-fucose receptor (MFR) may mediate parasite entry due to the ability 
of excess mannose to inhibit parasitisation of macrophages in vitro (37). The 
glycosylated structures on the promastigote surface do contain considerable quantities 
of mannose. However, the MFR elicits an oxidative burst after ligation and therefore 
would seem unlikely to offer a safe means of entry to the promastigote (38).
The fibronectin receptor is able to mediate parasite attachment to macrophages
(39), However, regulation or blocking of this receptor failed to affect parasite binding 
to macrophages (36).
Other receptors such as the receptor for advanced glycosylation end products
(40) and the Fc receptor (41) have been suggested as macrophage receptors for 
leishmania entry but are less well studied. A role for the FcR in a primary leishmania 
infection would require the presence of parasite specific antibodies which seems 
unlikely. There are a number of other parasite membrane proteins with unknown 
functions, such as PSA-2 (42) and gp46 (43), which may also have an as yet 
unrecognised involvement in macrophage parasitisation by Leishmania.
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1.1.4.3 Intracellular survival
After internalisation, the promastigote transforms into an amastigote within the 
phagolysosome. Here, the amastigote is able to resist enzymatic degradation and an 
acidic pH of around 4.7-S.2 (44). The LPG molecule on the amastigote surface may 
provide protection against this environment, as LPG deficient strains of L. major are 
killed within 18 hours after internalisation (22). However, unlike the promastigote, the 
LPG structure present on amastigotes does not form a dense glycocalyx (45) and 
therefore it may be that other surface molecules are important in allowing survival 
under these conditions. It has been postulated that gp63 might degrade lysosomal 
enzymes due to its protease activity (46). This is unlikely, as gp63 is substantially 
down-regulated during the amastigote stage of the parasite (47). The amastigote, 
within the phagolysosome, divides by binary fission, is released when the macrophage 
lyses and in turn enters other macrophages to multiply. The receptors used for entry of 
the amastigote stage into macrophages are not well understood. Amastigotes, purified 
from lesions contain surface bound immunoglobulin and complement component C3b 
on the surface, suggesting that they may utilise the FcR or CRl on the macrophage in 
order to gain entry (48). The parasite life cycle in the vertebrate host is completed 
when a subsequent sandfly ingests an infected macrophage or free amastigote, in the 
process of taking a blood meal.
1.1.4.4 Persistence of infection
There is a considerable amount of evidence which suggests that Leishmania 
parasites can establish a life-long persistent infection, which is usually asymptomatic, 
after cure of a primary infection. Persistence of parasites after successful treatment of 
visceral leishmaniasis in humans has been reported (49). A detailed study of 23 
different mouse strains detected viable parasites in mice one year after cure of 
cutaneous disease (50). The increasing incidence of leishmaniasis in HIV-infected 
patients may represent, in part, a reactivation of latent infection as the host becomes
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immunosuppressed (51). The host cell involved in this chronic parasitisation may not 
necessarily be the macrophage, as recent reports have documented the presence of L  
major in lymph node dendritic cells during persistent infection (52). The ability of 
Leishmania parasites to persist in recovered patients may have considerable 
implications with regard to the generation of a vaccine against disease, as disease-cured 
individuals may represent a reservoir of infection.
1.2 Genetic regulation of leishmaniasis
1.2.1 Human infection
Little is known of the genetic control of leishmaniasis in human infection but it 
is clear that genetic factors are involved in the determination of susceptibility and 
resistance to disease. In a study of mucocutaneous leishmaniasis within two racially 
distinct communities in Bolivia, the severity of pathology associated with infection and 
the immune responses to parasites were different (53). The native Indian population 
had mainly chronic slow-growing, non-destructive lesions with low DTH responses to 
parasite antigens, whereas the Negro population had rapidly growing, mucocutaneous 
lesions which resulted in severe damage to the face, in the presence of strong DTH 
responses. Much of the data on the genetic control of Leishmania infection comes 
from studies of experimental models of infection in mouse models.
1.2.2 MxmiiQ L. donovarii infection
The genetic factors responsible for resistance and susceptibility to L. donovani 
infection are well understood. There are two major stages of disease with different 
genes involved in the regulation of each (54).
During the early stages of L. donovani infection, resistance to infection is 
controlled by a non-MHC linked gene called Lsh  which is found on mouse
29
chromosome 1 (55). The early control of S. typhimurium and Mycobacterium  
infections in mice is thought to depend on the same gene although in these models it is 
termed Ity or Beg (56,57). The Lsh gene product may therefore represent a common 
innate factor involved in the defence against intra-macrophage infection. Mouse 
strains expressing the Lsh® allele are profoundly deficient in the control of initial 
parasite replication within the macrophage, which takes place in Lsh^ mice and is T-cell 
independent (58). The Lsh gene was recently cloned (59) and the encoded product 
was found to be structurally similar, but not identical, to a nitrate transporter encoded 
by the CrnA gene of Aspergillus nidulans (60). As resolution of Leishmania infection 
is dependent upon the production of reactive nitrogen intermediates (61, 62, 63), the 
function of the Lsh gene product may be in the transport of nitrates into the 
phagolysosome which mediates the control of infection. Mouse strains which are Lsh® 
have a single base pair change from the Lsh"^  gene which may cause the generation of a 
non-functional gene product, thus preventing LeMwaw/a killing (59).
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The later phase of murine L. donovani infection (> 2 weeks) in mice which are 
Lsh® is controlled mainly by MHC-associated genes (64) and also by genes at the H-11 
(65) and Ir-2 (66) positions. Three different disease profiles controlled by MHC- 
associated genes are detected in Lsh® mice, according to the parasite burdens in the 
liver (64, 67). Mice of H-2® or H-2^ haplotypes cure disease early, mice of H-2^ 
haplotype cure eventually, while mice of H-2^, H-29 or H-2^ haplotype do not cure. 
Alleles at the H-11 or Ir-2 locus can also determine the outcome of L. donovani 
infection. Expression of one allele at H-11 converts the normally cure strain, B10, to a 
non-cure strain (65). Expression of this allele of H-11 has a similar effect on L. major 
infection (65), making H-11 the only gene known to affect both L. donovani and L. 
major infection. In a similar manner to H-11, expression of an alternative allele of Ir- 
2, called Ir-2^, can convert BIO.LP-H-3^ mice from cure to early cure phenotype (66).
1.2.3 Murine L, major infection
Unlike L. donovani, murine L. major infection has no discernible innate and 
acquired phase of immunity and is completely unaffected by the expression of Lsh 
gene alleles (68). MHC-associated effects are also difficult to demonstrate in L. major 
infection as mice of similar H-2 haplotypes can be resistant or susceptible depending 
upon the background strain of the animal (69). BALB/c and BALB/b mice are very 
susceptible to experimental cutaneous leishmaniasis and will ultimately succumb to 
fatal disease. This extreme susceptibility maps to a single gene (70), sometimes 
refereed to as the "Susceptibility to Cutaneous Leishmaniasis" gene (Scl-1), which has 
been mapped to chromosome 11 (71).
1.3 Immunology of leishmaniasis
Many of the immune events involved in the resistance and susceptibility of 
mouse strains to Leishmania infection have been elucidated in the past few years (69). 
The immunology of leishmaniasis is the best understood of all parasitic infections and 
experimental murine leishmaniasis is a recognised model system for the study of the 
differential activation of T-cell subsets in infectious disease.
1.3.1 Human infection
It has long been known that individuals who recover from natural Leishmania 
infection are immune to further challenge (72, 73). In a large study of L. tropica 
reinfection, the success rate of experimental infection was reduced from 64% to 6% if 
the patient had experienced a previous natural infection (74). However, if rechallenge 
with parasite is attempted as a primary lesion is actively progressing, an exacerbation 
of disease is noted (74). Previous natural infection with one parasite species also 
provides protection against other species of Leishmania parasites (75). The mechanism 
of protective immunity in these individuals is not clear. What is known is that cell-
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mediated and humoral responses can be demonstrated in infected and cured patients 
and that these responses vary according to disease type.
1.3.1.1 Cutaneous leishmaniasis
Recovery from cutaneous Leishmaniasis in humans is characterised by the 
development of a strong cell-meditated immune response to parasite antigens as well as 
a more variable humoral response. A strong DTH responses is generated to killed 
parasites injected into the skin (76) and peripheral blood lymphocytes proliferate in 
vitro to leishmania antigens (77). Where parasite specific antibody has been detected, 
the titre has been directly linked to the disease severity (78,79).
Diffuse cutaneous leishmaniasis (DCL) is characterised by the absence of a 
DTH response to parasite antigens, which is antigen specific, and low numbers of 
lymphocytes within the lesions (80, 81). It has been suggested that the development of 
DCL may be due to a failure of antigen presenting cells to deliver necessary accessory 
signals to T-cells during the early stages of infection (82). This may account for the 
parasite specific anergy observed in this disease and the inability to contain parasite 
replication.
1.3.1.2 Mucocutaneous leishmaniasis
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The lesions of MCL patients contain very few parasites and there is a strong 
DTH response to parasite antigens which is elevated above levels seen in cutaneous 
patients (83). The factors responsible for the presence of a strong cellular response in 
the virtual absence of parasites are unknown.
'■i
1.3.1.3 Visceral leishmaniasis
L. donovani infection in humans is associated with strong humoral responses to 
the parasite and a defective cell-mediated response. High titres of specific antibody 
can be detected in L. donovani infected individuals (84,85) and elevated levels of non­
specific IgM due to polyclonal B-cell activation (85, 86). Patients with L. 
donovani infection do not develop a DTH response to parasite antigens (10, 85) and 
peripheral blood lymphocytes from these patients are only weakly responsive to 
parasite antigens in vitro (87). Indeed, T-cell responses to mitogens is also impaired in 
visceral patients (86), suggesting that a wide-ranging immunosuppression occurs. 
Responsiveness to mitogens and Leishmania antigens is recovered after successful drug 
treatment (73)
1.3.1.4 Human T cell subsets
Murine T-cells have been shown to polarise into distinct T-cell subsets defined 
by differential cytokine production (88). Thl cells secrete IFN-y and IL-2 upon T cell 
receptor (TcR) ligation and are thought to control cell-mediated functions such as DTH 
which are important in the control of intracellular pathogens (89). Th2 cells which 
secrete IL-4, IL-5 and IL-10 upon antigen stimulation control resistance to extracellular 
pathogens by stimulating humoral immune functions and eosinophilia (89).
It is clear that human T-cells can polarise under certain conditions to generate 
T-cell subsets analogous to those found in the murine system (90). A polarised T-cell 
response can be demonstrated to occur in vivo in chronic disease states such as leprosy 
(91). It has become increasingly apparent that this model of polarised T-cell 
differentiation can be found during human leishmaniasis.
Peripheral blood lymphocytes from patients who have cured an L, major 
infection produce IFN-y but no IL-4 in response to parasite antigens (92). The
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production of IFN-y in vitro by human lymphocytes can activate macrophages to kill 
parasites in vitro (93).
The absence of IFN-y production by lymphocytes from seroconverted children 
living in an endemic region of Brazil was a reasonable predictor for the development of 
visceral disease (94). In addition, patients suffering from visceral leishmaniasis have 
elevated levels of IL-4 detectable in serum (95). Thus, during visceral disease a 
predominant Th2 response is manifest. However, lymphocytes from cured visceral 
patients produce both IFN-y and IL-4 in vitro in response to parasite antigens (96) and 
human T-cell clones from cured visceral patients were shown to secrete IFN-y, IL-4 or 
both when stimulated in vitro with antigen (97).
Thus, the presence of IFN-y correlates with cure of both cutaneous and visceral 
disease while IL-4 is predominant during active visceral disease. This polarised Thl 
and Th2-like cytokine production bears striking similarity to the murine model of L  
major infection.
1.3.2 Experimental murine leishmaniasis
As mentioned above, most mice infected with L. major will develop an 
ultimately self-healing lesion around the inoculation site and will remain refractory to 
further challenge with this parasite. Mice on a BALB background are extremely 
susceptible to L. major infection and develop a non-healing lesion and ultimate 
visceral infection. The factors involved in the resistance and susceptibility of different 
mouse strains to cutaneous infection with L. major and L. tropica have been studied in 
detail as a model of the spectrum of disease seen in human infection with leishmania.
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1.3.2.1 Cellular v's humoral immunity
A vast amount of data would indicate that recovery from L. major infection in 
the mouse is dependant upon the development of cell-mediated immunity, while 
humoral responses are of little importance (69, 98,99, 100).
Anti-leishmanial antibodies can participate in complement mediated lysis of L. 
donovani promastigotes grown in vitro (101) and can also enhance parasite uptake by 
macrophages in vitro (102). Fab fragments of anti-LPG monoclonal WIC-79.3, which 
bind to the parasite surface, have been shown to prevent the establishment of L. major 
infection in susceptible BALB/c mice when coadministered with a low parasite dose 
(103). Similarly, other leishmanial-specific monoclonal antibodies could protect 
against L. mexicana and L. major infection if administered with a low dose inoculum 
(104, 105). In addition to these data demonstrating a protective effect mediated by 
monoclonal antibodies, protective immunity mediated by vaccination with 
promastigote surface protein gp46 was shown to correlate with levels of antibody to 
this protein (106)
While these data would suggest a protective role for humoral responses against 
leishmaniasis there is much evidence to the contrary. Antibody levels or isotype 
differences in murine cutaneous infection of different mouse strains do not correlate 
with resistance to disease (107). Passive transfer of serum or antibody fractions from 
immune mice do not affect infection of BALB/c mice (108). In addition, Biozzi AB/L 
mice which have defective antibody responses are resistant to L. major infection (109). 
B-cell depletion in resistant mice was reported to exacerbate disease which suggests a 
functional role for B-cells in the development of protective immunity (110). However, 
resistance to infection could be restored in this model by T-cells alone, implying that 
T-cells are critical in determining disease outcome. Furthermore, later attempts at B- 
cell depletion have failed to influence the outcome of infection in resistant mice (111).
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Depletion of B-cells in BALB/c mice reduced lesion sizes suggesting that B-cells are in 
fact counter-productive to the development of protective immunity (112).
From these data there would appear to be little role for antibody in determining 
the outcome of cutaneous leishmaniasis in the murine model. The mechanism by 
which monoclonal antibodies can mediate protection in vivo is unclear. It has been 
suggested that the monoclonal antibodies or Fab fragments to surface molecules on the 
promastigote may simply hinder the promastigote from attaching to macrophages and 
in doing so prevent infection. In accord with this, a lowering of antibody dose, or 
raising of parasite numbers administered, was shown to ablate the protective effect 
observed with this treatment (103).
Cellular immune responses have been demonstrated to mediate protection 
against primary infection in resistant mice and vaccinated susceptible mice and also in 
secondary infection of susceptible mice cured by immunological intervention.
A thymic nude mice (nu/nu), which are T-cell deficient, are susceptible to L, 
major or L. tropica infection even on a resistant CBA or C57BL/6 background (113, 
114). Adoptive transfer of syngeneic T-cells to these mice restores the ability to resist 
infection (114). Resistant mice, rendered T-cell deficient by thymectomy and 
irradiation also demonstrate a delay in cure of infection (115). Protective immunity 
can be transferred to syngeneic naive mice by T-cells from resistant mice which have 
cured a primary infection (116). Similarly, T-cells from susceptible mice which have 
been immunised against infection can transfer protection to naive recipients (117). As 
mentioned previously, the exacerbation of infection in resistant C3H mice by anti-/^ 
antibody treatment is reversed by transfer of T-cells alone (110). These data suggest a 
critical requirement for T cells in the generation of immunity to experimental 
leishmaniasis.
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1.3.2.2 004"^ T-cells in resistance
The expression of CD4 or CDS molecules on the surface of T-cells after thymic 
development separates most T-cells into two separate lineages. Reconstitution of T- 
cell deficient mice with CD4'*’ T-cells alone is sufficient to restore the resistance to 
disease observed with unfractionated T-cell transfer, as outlined above (114, 118). 
CD4''' cells from resistant mice which have resolved a primary infection can also 
transfer immunity when administered to syngeneic recipients (116, 117, 119).
The susceptibility of BALB/c mice can be overcome by sub-lethal whole body 
y-irradiation (120), injection with anti-CD4 monoclonal antibody (121) or cyclosporin 
A treatment (122). After the infection resolves, these mice are refractory to further 
leishmania challenge and mount a strong DTH response when injected with killed 
parasites (123). CD4^ T-cells from these mice can transfer this DTH response and 
resistance to L. major infection if administered to naive susceptible mice (117, 123).
Resistance to infection can also be conferred to BALB/c mice by certain 
immunisation protocols. Repeated intravenous or intraperitoneal injections of 
irradiated, heat-killed or sonicated promastigotes enables these mice to survive 
subsequent challenge infection (124). This immunity from infection could be 
transferred to naive BALB/c mice by transfer of the CD4^ T-cell population only 
(117). However, these cells are distinct from the population which transfer protection 
after cure of infection as they do not mediate DTH responses to parasite antigens. 
Indeed, these cells can suppress the induction of DTH responses in cured mice (125). 
In summary, it appears that CD4’^ T cells are required for resistance to cutaneous 
leishmaniasis and for the induction of protective immunity in susceptible mouse 
strains.
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1.3.23 CD4^ cells in susceptibility
The intrinsic susceptibility of BALB/c mice to L. major infection can also be 
attributed to CD4'*’ T-cells. Early work in this area demonstrated that sublethally 
irradiated resistant mice are not able to clear infection if they are reconstituted with 
haematopoietic cells derived from naive susceptible mice (126). As already discussed, 
BALB/c mice are not intrinsically unable to mount an effective immune response as 
they can be induced to cure infection through various immunological interventions 
(120, 121, 122). The protective effect of such therapy can be overcome by transfer of 
naive susceptible T-cells (120). Therefore, not only do T-cells from susceptible mice 
fail to mediate cure but they can also suppress an ongoing protective response. These 
suppressive T-cells were also found to reside within the CD4^ compartment of the T - 
cell population (119). In addition, CD4^ T-cell lines derived from BALB/c mice were 
shown to be able to suppress the generation of protective immunity in resistant (127) 
and immunised susceptible (128) mice.
Certain immunisation protocols can also cause disease exacerbation. Injection 
of killed L. major parasites by intravenous or intraperitoneal routes provide BALB/c 
mice with protection from challenge infection (124), as previously discussed. However 
injection of the same antigen preparation by the subcutaneous route caused 
exacerbation of infection (129). T-cells from such immunised mice could also 
suppress the protective immunity induced in mice immunised intravenously or 
intraperitonealy (130). When analysed further the cells mediating this anti-protective 
effect were found to be CD4"  ^T-cells which had the ability to mount a Jones-Mote 
DTH response, which peaks around 12-15 hrs rather than the classical 24-48hr, to 
parasite antigens (130). Thus both susceptibility and resistance are determined by a 
subset of T-cells which are CD4^. These T-cells were thought to represent different T- 
cell lineages which either mediated effector function or suppressor function. The 
induction of either subset of CD4^ T-cells was critically important in determining the 
outcome of disease.
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1.3.2.4 CD4^ T cell subsets
It was demonstrated by Mossman et al (88) that CD4^ T-cells can be divided 
into at least two subsets according to lymphokine secretion. T-cells which respond to 
antigen to secrete IL-2, IFN-y and TNF-|3 (Lymphotoxin) are labelled Thl cells while 
cells which release IL-4, IL-5 and IL-10 are termed Th2 cells (89). In addition to the 
non-overlapping secretion of the products mentioned above, a number of lymphokines 
are also secreted by both subsets, including IL-3, GM-CSF and TNF-a (89). Thl cells 
are thought to mediate cellular immune functions such as DTH (131), while Th2 cells 
provide efficient help for the generation of humoral responses (132). Thl cells can in 
fact participate in the provision of B-cell help for antibody production but differ from 
Th2 cells in the selection of IgG isotypes as Thl cell responses induce IgG2a 
responses, while Th2 cells select for IgGl isotypes and IgE (133).
The demonstration that T-cell subsets exist in vitro was shortly followed by 
data implicating these in the cure or progression of experimental L. major infection 
(134, 135). In infected, resistant C57BL/6 mice, CD4+ T-cells in the spleen and lymph 
node produce elevated levels of mRNA for IFN-y and IL-2 compared to susceptible 
BALB/c mice (135). Conversely, CD4+ T-cells from BALB/c mice during infection 
produced IL-4 and IL-10 mRNA in the spleen and lymph nodes while C57BL/6 mice 
had undetectable levels of these cytokines (135). Serum levels of IgE were also 
elevated in infected BALB/c mice (134), as expected from data implicating IL-4 in the 
control of IgE isotype switching (136). Thus, CD4'*' T-cells were demonstrated to 
develop polarised Thl or Th2 responses in vivo in response to L. major infection, 
accounting for the ability to transfer protection and suppression with a CD4^ 
population as discussed previously.
That Thl and Th2 cells can control the response to experimental Leishmania 
infection has been well documented by the transfer of T-cell lines and clones that 
express functional differences in cytokine secretion after TcR ligation. Transfer to
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BALB/c mice of T-cell lines which responded to L. major antigen in vitro to secrete 
either IL-2 and IFN-y or IL-4 resulted in protection or exacerbation respectively (137). 
Similar T-cell transfer experiments in severe combined immunodeficient (SCID) mice 
resulted in an identical transfer of protection with Thl lines or exacerbation with Th2 
lines (138). In addition, a T-cell clone which recognises a soluble L. major antigen to 
secrete IL-2 and IFN-y but not IL-4 or IL-5 can transfer protection to BALB/c mice 
(139). However, a further T-cell clone which can transfer exacerbation of infection to 
BALB/c mice was found to secrete IFN-y and IL-2 in response to parasite antigen
(127). Therefore, while much of the available data would point to a protective role for 
Thl cells in leishmaniasis there is evidence to suggest that at least some Thl cells may 
in fact participate in the development of progressive disease.
1.3.2.5 Cytokines
In addition to the cells themselves, the role of the various cytokines secreted by 
T-cell subsets in protection and exacerbation of disease has received much attention.
The importance of IFN-y in resistance to L. major infection has been 
demonstrated by cytokine depletion in vivo using monoclonal antibodies. C3H/HeN 
mice which normally resolve L. major infection are unable to control infection after 
weekly administration of a neutralising IFN-y monoclonal (140). A similar result was 
obtained by infection of resistant mice which have a targeted disruption in the IFN-y 
gene (141). These animals are unable to control lesion development after L. major 
infection, indicating that IFN-y is necessary for cure of experimental leishmaniasis. 
Interestingly, these mice, in the absence of IFN-y spontaneously generate a Th2
response to infection, suggesting that Th2 responses in these mice can occur but are 
regulated by IFN-y. While it is clear therefore, that IFN-y is required to resolve 
infection in resistant mice, the administration of IFN-y to susceptible BALB/c mice is 
insufficient to generate protective immunity (142, 143). Delivery of IFN-y at the time 
of infection can modulate T-cell subset development but does not affect the eventual
40
outcome of disease (143). Sustained IFN-y delivery to macrophages in vivo by L  
major parasites themselves is also unable to change the course of infection (144).
The role of another Thl cytokine, IL-2, in protection and susceptibility to 
infection has also been examined. While IL-2 is not produced by Th2 cells, its 
presence is required for the development of Th2 responses in vitro (145) and in vivo 
(146). Neutralisation of IL-2 in susceptible BALB/c mice at an early stage in infection 
is sufficient to prevent progressive disease (147). This neutralisation of IL-2 correlated 
with a reduction in mRNA for IL-4 and an upregulation in IFN-y in the draining lymph 
node. Thus the protection mediated by anti-IL-2 therapy may be due to the control of 
IL-4 production at disease initiation. Administration of anti-IL-2 to resistant, C57BL/6 
mice did not affect lesion development or cure from disease (147) implying that IL-2 
has little functional significance in resistant mice during infection. Administration of 
exogenous IL-2 to resistant mice during infection was reported to exacerbate disease 
which was mediated by direct effects of IL-2 upon parasite growth (148).
While IFN-y is necessary but is not sufficient for protective immunity to L. 
major there is evidence for a more substantial role for IL-4 in the generation of non­
healing responses. Susceptible BALB/c mice, administered with a monoclonal 
antibody to IL-4 during early infection cure from disease completely (142). This cure 
correlated with the production of Thl-like cytokines in the draining lymph node. 
However, the intraperitoneal injection of recombinant IL-4 to resistant C3H/HeN mice 
was reported to be insufficient in the generation of susceptibility although the normal 
Thl response was curtailed (149). Delivery of recombinant IL-4 to the lesion site in 
BALB/c mice was shown to exacerbate disease progression when administered at an 
early stage of infection (150) while delivery of IL-4 after lesion development resulted 
in the reduction of lesions (150, 151). While these data are inconclusive in supporting 
the sufficiency of IL-4 in the generation of Th2 responses, the role of IL-4 has been 
further explored using transgenic animals. Transgenic mice on a resistant, 129/Sv, 
background which over-express IL-4 in the B-cell compartment were shown to be
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diffident in controlling L. major infection (152). Thus IL-4 is necessary and sufficient 
to generate a non-healing response in experimental leishmaniasis. In addition, a study 
of several mouse strains which exhibited varying degrees of resistance to L. major 
infection, the expression of IL-4 mRNA correlated well with the severity of lesion 
development (153). Conversely, the ability to express IFN-y mRNA in response to
infection did not correlate well with resistance. Thus, the Th2 cytokine IL-4 is 
dominant over IFN-y production and seems to control lesion development.
IL-10, another Th2 cytokine may be involved in the regulation of 
immunity to L, major in vivo . As already mentioned, mRNA for IL-10 is found in the 
draining lymph nodes of susceptible but not resistant mice during infection (135). 
However, the neutralisation of IL-10 production during L. major infection of BALB/c 
mice, did not affect the progression of disease (154).
In summary, it has been demonstrated that the generation of resistance 
or susceptibility to L. major infection is largely dependant upon the production of Thl 
or Th2 cytokines with a particular requirement upon the level of IFN-y in the cure of 
infection and the production of IL-4 in mediating susceptibility.
1.3.2.6 Killing of Leishmania
T-cell derived cytokines directly control parasite replication due to their 
macrophage activating and deactivating properties. IFN-y mediated macrophage 
activation causes the upregulation of surface molecules such as MHC II, as well as the 
synthesis and secretion of a number of new gene products. It has been demonstrated 
that IFN-y can participate in the activation of parasitised macrophages to kill L, major 
(155) and L. donovani (156) in vitro . Killing requires the production of reactive 
nitrogen intermediates (RNI), such as nitric oxide (NO), via a newly-synthesised 
cytosolic protein called inducible nitric oxide synthase (iNOS). The production of NO 
is catalysed by the iNOS enzyme in a reaction involving the conversion of L-arginine
42
and molecular oxygen to NO and L-citrulline (63). The ability of activated 
macrophages to kill amastigotes in vitro and in vivo correlated with the production of 
NO (157, 158), The importance of NO in macrophage killing of Leishmania was 
demonstrated by the inhibition of iNOS using arginine analogues, such as L-N^- 
monomethyl-arginine (L-NMMA) (158).
Killing of parasites after induction of NO by IFN-y involves macrophage TNF- 
a  production as an antibody to TNF-a can abrogate such leishmanicidal mechanisms 
(159). Furthermore, TNF-a can synergise with IFN-y to induce NO production (160, 
161). Indeed, cytokines which cause TNF-a production by macrophages during 
activation with IFN-y, such as IL-3 (162), IL-4 (163) and IL-7 (164) can all synergise 
for the induction of parasite killing in vitro . The importance of TNF-a in mediating 
parasite destruction in vivo was confirmed by studies demonstrating that delivery of 
recombinant TNF-a to infected mice reduced lesion development (165), while anti- 
TNF-a caused an exacerbation of disease (166), although the final phenotype of 
disease was not altered. It should be noted, however, that TNF-a in the absence of 
IFN-y cannot activate murine macrophages to clear infection (160) and it thus plays a 
secondary role to IFN-y. Mice with a genetic disruption in the p55 TNF-a receptor 
gene are unable to clear L. major and develop a chronic low-level infection (167). 
Therefore TNF-a is involved in parasite destruction in vivo and provides a synergistic 
upregulation of IFN-y macrophage killing via NO induction.
Th2 cytokines such as IL-4 and IL-10 can down-regulate macrophage activation 
caused by IFN-y and so restrict parasite killing. IL-4 can inhibit the expression of the 
iNOS enzyme and NO production in IFN-y activated macrophages (168) although, as
already discussed, the timing of IL-4 administration is critical in this process. IL-10 
can also downregulate iNOS induction caused by IFN-y stimulation (169) and has been
shown to prevent the killing of T. gondii by activated macrophages via this mechanism 
(170). Other cytokines such as TGF-p have also been shown to inhibit macrophage 
activation (171) and intracellular killing of L. major (172) but the role of such
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mediators in experimental infection is not clear. Thus, Th2 cytokines can participate in 
macrophage deactivation caused by the Thl cytokine IFN-y and so restrict parasite 
killing by inhibiting macrophage induction of NO. Thl and Th2 cytokines also cross- 
regulate the growth and function of the opposing subset, providing another level of 
interface which determines the outcome of L. major infection.
1.3.2,7 Crossregulation of T cell subsets
Thl cytokines have been shown to inhibit certain Th2 cell functions. In in vitro 
experiments, IFN-y can inhibit the proliferation of Th2 cells to IL-2 or IL-4 (173, 174), 
but does not affect Thl cells in this manner. This is now thought to derive from the 
differential expression of the IFN-y receptor p-subunit on the surface of these cells 
(175), allowing Th2 cells to receive negative signals from IFN-y. BALB/c mice, 
injected with both IFN-y and L. major, had reduced production of IL-4 in draining 
lymph node cells compared to mice administered parasites alone (143) although this 
was insufficient to cause cure from disease. As previously noted, resistant mice, 
unable to produce IFN-y make a functional Th2 response to infection (141). This 
default to the Th2 phenotype suggests that in nonnal mice, the presence of IFN-y 
suppresses the induction of these cells. However, IFN-y is insufficient to cause Thl- 
cell differentiation in TcR transgenic mice on a BALB/c background (176) implying 
that other factors may be important in this process.
Conversely, IL-10 is known to inhibit cytokine secretion by Thl cells (177) and 
can also limit Thl cell proliferation by indirect action on antigen presenting cells (178, 
179). Thus, cytokines produced by Th2 cells can inhibit Thl cell function, while Thl 
cells can have a similar effect on Th2 cells. Therefore, the initial generation of either 
cell subset will inhibit the generation and function of the other, causing a polarised 
response to infection. The initial events which cause T-cell subset generation are 
therefore critical in determining the outcome of disease.
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1.3.2.8 Induction of T cell subsets
Thl and Th2 cell subsets are thought to derive from a common precursor cell, 
called ThO, which is present early during in vitro cultures (180) and can secrete a wide 
range of cytokines of both Thl and Th2 types (181, 182). The generation of a Thl or 
Th2 response from this initial precursor cell is thought to be determined by a number of 
factors (98), including the nature of the antigen, the lineage of antigen presenting cell 
involved, the local cytokine environment created by other cells and by the interaction 
of various costimulatory molecules between T-cell and APC. Recent developments in 
this field will be discussed later in more detail (See General Discussion).
In addition to the ability of IL-4 to modulate IFN-y mediated macrophage 
activation, and participate in the induction of humoral responses, it can also select for 
the induction of Th2 responses. Thus, the presence of IL-4 in culture can cause 
uncommitted CD4^ cells from pigeon cytochrome c-specific TcR transgenic mice to 
progress along the Th2 pathway (183). As already discussed, resistant mice with B- 
cells which overexpress IL-4 develop a Th2 response to L. major infection and fail to 
cure (152). When the early T cell response to L. major was examined in resistant and 
susceptible mice, both strains developed a mixed ThO like cytokine profile (184). In 
resistant mice, IL-4 production was quickly reduced while in BALB/c mice this 
remained high (184). All immunological interventions which cause cure of L. major 
infection in a BALB/c mouse, such as sub-lethal irradiation, cyclosporin A treatment, 
anti-CD4, anti-IL-4 or anti-IL-2 monoclonal antibody administration are only effective 
if used during the first few days of infection, coinciding with the uncontrolled IL-4 
peak (98). All are also thought to mediate cure from disease by the ability to limit this 
production of IL-4 during early disease, implying that the generation of a deleterious 
Th2 subset requires the presence of IL-4. In addition to these observations, mice with 
disruptions in the IL-4 gene are unable to mount a functional Th2 response and clear 
infection with Nippostrongylus braziliensis (185). Together these data suggest a 
functional role for IL-4 in the development of Th2 responses.
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IL-12, a recently cloned heterodimeric cytokine (186) which causes T-cell and 
NK cells to proliferate (187) and secrete IFN-y (188), has also been shown to be 
important in the generation of the induction of the Thl cell subset (189). IL-12 is 
produced by macrophages in response to inflammatory stimuli and by certain B cell 
lines (190). When used in vitro , IL-12 can select for Thl cell growth and suppress 
Th2 cell development from uncommitted murine T-cells (189). In vivo administration 
of IL-12 is sufficient to cure L. major infection of BALB/c mice when it is delivered 
early in infection (191, 192). As previously mentioned, administration of IFN-y alone
is not sufficient to cause cure from disease, suggesting that IL-12 mediates it's 
protective effects only partly through the induction of IFN-y. The protective effect of 
IL-12 may be due to its effects upon IL-4 synthesis, as IL-4 production in these mice 
was also reduced during the course of treatment (192). The importance of IL-12 in 
experimental infection has been demonstrated in experiments where the neutralisation 
of IL-12 production in resistant, C57BL/6 mice rendered them unable to control the 
progression of disease (192). Thus in L. major infection, IL-12 is critically important 
in the induction of Thl cells and subsequent protective immunity.
1.3.2.9 Other cell types
While there is much evidence supporting the role of CD4^ T-cells in the control 
of experimental leishmaniasis, there is data to suggest that other cell types may also be 
involved during this process.
CD8^ T-cells are thought to play a role in protective immunity to L. major 
infection, particularly in the resistance to a secondary infection. An increase in the 
number of lymph node CD8^ T-cell occurs at the onset of lesion cure in resistant mice 
(193) and depletion of CD8^ cells using monoclonal antibody treatment resulted in 
lesion exacerbation in both susceptible and resistant mice (194). However, the 
phenotype of these mice was unchanged, as resistant mice eventually cured infection
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and susceptible mice failed to resolve lesions. In L. major reinfection of resistant 
CBA mice, depletion of CD4'*’ and CDS'*" T-cells exacerbated disease markedly whereas 
depletion of either subset alone did not (195). Thus, there is evidence for a more 
substantial involvement of CDS"*" T cells in limiting secondary L. major infection. 
CDS'*' T-cells have been demonstrated to be able to mediate parasite killing in vitro via 
the production of IFN-y (196) and subsequent macrophage activation to produce NO 
(197). In vivo, CDS*" T-cells were shown to participate in the production of IFN-y in 
responses to a secondary L. major infection (198). Although these data imply a 
protective role for CDS'*' cells in the control of lesion development, CD8^ cells are 
unable to transfer protective immunity to nude mice (118). In addition, targeted 
activation of CDS'*" T-cells by MHC class I peptide vaccination and infection of (32- 
microglobulin-deficient mice, which have no functional CD8*' T-cell responses, failed 
to substantiate a role for CDS’*" T-cell mediated protection (199).
A minor T-cell population which expresses a rearranged yô T-cell receptor 
instead of an a (3 receptor has also been implicated in protective immunity to 
experimental leishmaniasis. At least a proportion of these gamma/delta (yÔ) T-cells are 
though to respond to restricted set of antigens (200) possibly through antigen 
presentation via the CDl molecule, although the precise nature of antigen recognition 
by these cells is unclear. These cells have been shown to accumulate in the lesions of 
individuals with cutaneous leishmaniasis (201) and are elevated in the peripheral blood 
of patients suffering from cutaneous, mucocutaneous and visceral leishmaniasis (202). 
An increase in yô cell numbers was observed in both BALB/c and CBA/J mice during 
infection which, if depleted using a monoclonal antibody, resulted in the development 
of larger lesions and increased parasite numbers (203). It has been recently 
demonstrated that these yô cells can polarise to produce Thl and Th2 like cytokine 
secreting subsets during Listeria monocytogenes or Nippostrongylus braziliensis 
infection (204). However, these subsets have not been investigated in L. major 
infection to date. As the majority of these yô cells do not express CD4 or CD8 
molecules (205) (although a proportion do express the CDS a  molecule), and resistance
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to experimental cutaneous leishmaniasis is transferable by CD4^ cells alone (117,118), 
they would appear to be of secondary importance.
Another cell population, the natural killer (NK) cell has received some interest 
with regard to its function in experimental L. major infection. Mice deficient in NK 
cell cytotoxicity, bg/bg mice, display no differences in the course of L. major infection 
compared to normal resistant mice (206). NK cell production of IFN-y early during 
infection has been recorded and may be important, in addition to IL-12, in the 
development of Thl cells (184). While NK cells, yô T-cells and CD8^ T-cells may 
participate in protection against L. major infection there is a crucial requirement for 
the CD4^ T-cell in the generation of protective immunity.
1.3.2.10 A. donovani infection
The course of L. donovani infection in different mouse strains depends largely 
upon the expression of alleles of the Lsh gene, as previously discussed. While this 
model of infection differs in many respects to experimental L. major infection, the 
mechanisms of protective immunity are similar, with some notable exceptions. Cell 
mediated immunity is required for disease cure rather than humoral responses, as T cell 
depletion experiments show (207). T cells from mice which have resolved infection 
can also transfer resistance to naive hosts (208). However, the ability of nude mice to 
control L. donovani infection was only achieved by the adoptive transfer of both CD4^ 
and CD8^ T-cells and not either subset alone, implicating a more fundamental role for 
CDg+ T-cells in cure of infection (209). In addition, differential Thl and Th2 cytokine 
production is not believed to be responsible for cure and susceptibility in experimental 
murine L. donovani infection (210, 211). While there is a strong correlation between 
parasite killing and the induction of IFN-y production (210,211) there is no converse 
production of Th2-like cytokines in mice unable to clear infection (210). Rather T- 
cells from chronically infected mice develop an inability to produce Thl cytokines as 
the disease progresses, with no concurrent rise in Th2 responses. This infection model
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involves the intravenous injection of the amastigote stage of the parasite. The lack of 
functional Th2 responses may therefore be attributed to the route of challenge, as in L. 
major infection use of this route in vaccination preferentially stimulates Thl responses 
(124). That Thl responses are important in cure of disease in this model is seen by 
data demonstrating cure of established L. donovani infection in BALB/c mice by IL-12 
treatment (212). Thus, although in murine L, donovani infection a clear Thl/Th2 
paradigm is not observed treatment with a cytokine which induces Thl responses is 
sufficient to cure disease.
1.3.3 T cell subsets in other parasitic infections
The understanding of experimental leishmaniasis as a disease caused by diverse 
T-cell responses to infection has led to the extrapolation of this concept to other 
parasite models with interesting results. Thl and Th2 cell polarisation can be observed 
in other chronic parasitic infections, however, the nature of the parasite and it's 
localisation within the host determine which T cell subset provides protective 
immunity.
Another group of kinetoplastidid organisms, the Trypanosoma spp., some of 
which inhabit macrophages, cells of the central nervous system and muscle cells (6) 
also require the presence of Thl cytokines to be killed. Cure from Trypanosoma cruzi 
infection is dependent upon a CD8^ and a CD4^ T cell responses (213), perhaps 
reflecting the additional requirements for non-macrophage parasite killing by CDS"^  
cells. IFN-y can mediate killing of T. cruzi in vivo (214) and in vitro (215) via 
macrophage induction of NO (216) which is inhibited by IL-10 or TGF~j3 (217). 
Susceptible, B6 mice have increased IL-10 production during T. cruzi infection 
compared to resistant mice, which can partially inhibit IFN-y mediated macrophage 
activation (218). Thus the polarised Thl/ Th2 paradigm seems also to hold true in 
aspects of murine trypanosomiasis although a more defined requirement for CD8^ T 
cells is observed.
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Other protozoan infections such as malaria and toxoplasmosis, which have 
intracellular life-cycle stages (219, 220), also show evidence of Thl mediated 
protection during experimental infection. Thl cells are reported to be involved in the 
generation of immunity (221) and also in the generation of pathology during murine 
malaria (222). In Plasmodium chabaudi adami infection, a Thl cell line can transfer 
immunity to nude mice (221), while in P. chabaudi chabaudi infection, transfer of a 
Thl or Th2 clone can reduce parasitaemia (223). The protective role of these different 
T cell subsets may represent a requirement for diverse responses in the killing of 
different life cycle stages of the parasite. In Toxoplasma gondii infection in mice, both 
CDS"^  and CD4"^  cells are responsible for protective immunity and production of IFN-y 
(224). IFN-y can activate macrophages to kill resident parasites in vitro (225) which 
can be inhibited by IL-10 (170). Thus in other protozoan infections, there is seen to be 
an involvement of Thl cells and/or Thl cytokines in parasite clearance similar to that 
seen in L. major infection.
Chronic infection of mice with the trematode. Schistosoma mansoni cause the 
induction of a dominant Th2 response (226), particularly to the parasite egg (227). 
Protective immunity, due to vaccination with irradiated cercariae is mediated by a Thl 
response (226). Inhibition of Th2 responses using anti-IL-4 and anti-IL-5 failed to 
affect immunity to S. mansoni (228) indicating that the Th2-type effector mechanisms 
which can kill S. mansoni in vitro (229) are not required in vivo to clear infection. 
However, there is evidence that a Thl response, TNF-a production and macrophage
activation can also cause pathology in the form of granulomas during schistosomiasis 
(230). It is worth noting that murine infection with S. mansoni does not miiTor human 
schistosomiasis, as correlates of protective immunity in human studies suggest the 
involvement of Th2-like mechanisms (231). However, it is clear that in experimental 
murine schistosomiasis Thl mechanisms can mediate protective immunity.
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The murine model of human trichuriasis involves infection with Trichuris 
muris, a nematode which lives in the large intestine (232). The resistance of inbred 
mouse strains to T. muris infection correlates with the ability to generate a Th2 
response to parasite antigens (233,234). Resistance is associated with the expansion of 
CD4^ cells which can secrete IL-4, IL-5 and IL~9 (233) and this resistance can be 
inhibited by anti-IL-4 monoclonal antibodies (235). In susceptible mice which 
maintain a chronic infection, there is elevation of IFN-y production while resistance 
can be achieved by administration of IL-4 or a neutralising antibody to IFN-y (235). 
Thus, in response to this extracellular, multicellular organism a Th2 response mediates 
effective clearance. The involvement of a protective Th2 response has also been 
documented in response to other worms such as Nippostrongylus braziliensis (236), 
Heligmosomoides poly gyrus (236) and Trichine lia spiralis (237).
Thus, the regulation of immunity by Thl and Th2 cells is not limited to models 
of leishmaniasis but has a wider relevance in the control of many parasitic infections, 
although the nature of a protective response may vary between parasite species.
1.3.4 T cell subsets in bacterial and viral infections
It is not only in chronic parasite infections that T-cell polarisation is obseiwed to 
occur, as Thl cell responses have been demonstrated to be of importance in 
intracellular bacterial and some viral infections. Mice with targeted disruptions in IFN- 
y or IFN-y receptor genes demonstrate exacerbated infection with the intracellular 
bacteria Listeria monocytogenes (238), Mycobacterium bovis (239) and M. 
tuberculosis (240). These experiments implicate a functional requirement for IFN-y 
mediated macrophage activation in the response to intra-macrophage microbial 
pathogens which is thought to be mediated by Thl cells (241). In human tuberculoid 
and lepromatus leprosy Thl or Th2 cytokines can be detected in lesions (91) and Thl 
and Th2-like clones can be found in the peripheral blood (242). The polarisation of 
these T cell subsets is thought to be involved in the spectrum of pathology associated
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with this infection. In viral infection of mice with Respiratory Syncytial Virus (RSV),
T-cell clones have been generated from infected mice which display distinctive T cell 
polarisation (243). These Thl or Th2-like cell clones can transfer pathology to naive, 
resistant mice upon infection with RSV (244). While certain bacterial and viral 
pathogens do therefore elicit T cell subsets during infection the importance of these in 
mediating protection or pathology and the requirement for other cellular responses, 
such as antibody or CDS'*' T cells varies between organisms.
1.4 Vaccination against leishmaniasis
The generation of a vaccine against leishmaniasis seems theoretically possible, 
as patients recovering from infection remain refractory to further challenge (72, 73).
However, the creation of a safe, effective vaccine against this parasite has to date 
proved elusive, although a number of important developments suggest that this may 
still be achieved. Much of the information regarding vaccination against leishmaniasis 
has been gathered from studies in the murine model of L. major infection, as outlined 
above, although there have been attempts to vaccinate human populations.
1.4.1 Human vaccination
The only vaccination strategy which has provided effective protection against 
leishmaniasis in humans is termed "leishmanization" and involves the low dose 
injection of a live cutaneous species (245) . Leishmanization has been carried out for 
many years in the Middle East and the southern Soviet Republics (74) and formed the 
basis of a large vaccination program in Iran in 1982 (246). This method of vaccination 
is certainly effective, providing protection to around 90% of those injected (74, 246), 
but is extremely unsafe. Some vaccinated individuals develop large, painful, slow 
healing lesions which may become sites of secondary infection or may adversely affect 
other skin conditions (247). The ability to resolve cutaneous lesions can be lost in 
immunosuppressed individuals, such as HIV infected patients (51), and can depend
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also upon the nutritional state of the person at the time of infection (248). This process 
has been curtailed in the Soviet Republics and Israel due to these safety issues.
The use of an attenuated strain of L. donovani as a live vaccine did not provide 
any detectable resistance to further infection as the incidence of infection was similar in 
the treated and untreated populations (249). Some investigators have suggested that 
the failure of this vaccine resulted from the inability of the strain to develop an initial 
cutaneous lesion which usually correlates with the generation of immunity (247).
A killed vaccine preparation containing five strains of Leishmania was used to 
vaccinate a population in Brazil but the outcome of this programme is uncertain as the 
incidence of disease dropped in this area during the period after immunisation, making 
evaluation of protective immunity impossible (250). However, the majority of 
vaccinated patients did demonstrate positive skin tests to injected antigen. More recent 
trials with killed parasites co-injected with live bacille Calmette-Guerin (BCG) resulted 
in a reduction of established cutaneous lesions (251) indicating that, with an 
appropriate adjuvant, protective responses can be generated in humans using a killed 
vaccine.
Despite the failure of these attempts in vaccinating human populations, data 
from murine experimental leishmaniasis suggests that the generation of a safe, effective 
vaccine will be possible.
1.4.2 Murine vaccination
There have been a number of vaccination procedures used against experimental 
murine cutaneous leishmaniasis including the use of live attenuated parasite strains, 
killed parasites and undefined antigen preparations, purified and recombinant antigens, 
proteins expressed in live vectors and peptide vaccination. Similar to human 
leishmanization, cure of murine L. major infection in a resistant mouse confers
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protection from secondary challenge demonstrating that protective immunity can be 
induced.
An avirulentL. major clone created by chemical mutagenisis which is deficient 
in the synthesis of the surface molecule LPG was used to vaccinate susceptible 
BALB/c mice (252). Mice administered intravenously with this clone demonstrated 
reduced lesion development upon virulent challenge, although complete cure of 
infection was not observed. CD4'*' cell lines from immunised mice, when transferred to 
naive BALB/c mice, were able to inhibit lesion development to a similar degree after 
virulent challenge (253). This T cell population produced more IFN-y , TNF-a and IL- 
2 and less IL-4 than lines generated from non-immunised BALB/c mice, indicating that 
Thl polarisation had occunnd after vaccination.
Vaccination with killed L. major has been studied in detail and is referred to 
above. Immunisation with parasites killed by sonication or with soluble L. major 
antigen is effective at preventing disease if administered intravenously or intra- 
peritoneally (124). However, significant exacerbation is observed with subcutaneous 
immunisation of the same antigen preparation (129). These experiments demonstmte 
the importance of the route of immunisation and may be explained by presentation of 
antigen to naive T cells via different antigen presenting cells. B cells have been 
demonstrated to preferentially select for Th2 cells reponses during L. mexicana 
amazonensis infection while macrophage antigen presentation preferentially induces 
Thl cells (254). The mechanism by which different cell populations select for the 
development of Thl or Th2 cell development is not clear but may depend upon 
differential secretion of co-stimulatory cytokines during antigen presentation (98) or 
the expression of diverse cell surface stimulatory molecules such as B7-1 and B7-2 
(255). IL-12, as previously mentioned, is thought to be critical in the development of 
protective Thl responses. Indeed, subcutaneous vaccination of BALB/c mice with a 
soluble antigen extract of L. major and IL-12 provides complete protection from 
infection (256).
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While considerable success has been achieved in vaccinating mice using 
parasite antigen preparations or killed parasites, the use of purified or recombinant 
antigens has not proved as effective. A number of purified and recombinant parasite 
molecules have been used to immunise resistant and susceptible mice against L. major 
infection, including LPG, gp46 and gp63.
Immunisation with purified LPG reduced lesion development in resistant, 
C3H/He mice and susceptible, BALB/c mice although immunisation did not confer the 
ability to cure disease (103). Liposomes containing LPG proved to be an efficient 
vaccine against L. mexicana infection and protection was transferred to naive mice by 
T cells (257). Further studies have demonstrated that the carbohydrate fraction of LPG 
will actually exacerbate disease (258) and that T cell responses to purified LPG in vitro 
by lymphocytes from cutaneous patients can be inhibited by treating LPG with 
proteinase K (259). These data suggest that the protection achieved with LPG 
immunisation is due, in fact, to LPG-associated proteins which have been subsequently 
described (260).
The membrane protein gp46 (M-2 protein) is a promastigote stage specific 
surface glycoprotein, with unknown function (261). The gene sequence for gp46 
contains substantial homology to the Promastigote Surface Antigen-2 (PSA-2) gene 
family (262) which contain a group of at least three distinct proteins (263). 
Immunisation with purified gp46 and various adjuvants reduced lesion development 
caused by L. m. amazonensis infection in susceptible mice (106). The level of 
protective immunity provided by gp46 vaccination in different strains of mice 
correlated with the gp46 specific antibody response although cellular responses were 
not examined. Recombinant vaccinia viruses, engineered to express gp46, conferred 
some protection against L. m. amazonensis infection after immunisation of BALB/c 
mice (264). Although 45% of mice were reported to be completely cured 8 months 
after challenge, this was only effective at a relatively low dose parasite infection. The
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protective response was shown to correlate with a mixed Thl/Th2 cytokine response to 
parasite antigens, although these responses were extremely low and were examined a 
long time after infection, and are perhaps indicative of the memory response rather than 
the response required to cure initial infection (264).
Gp63 has received much attention as a potential vaccine candidate as it is the 
most abundant surface membrane protein on the promastigote stage of Leishmania 
parasites with around 500 000 copies per cell, accounting for 0.5-1% of the total cell 
protein content (265). Gp63 is encoded by a multigene family containing single 
dispersed gene copies as well as tandem repeats that give rise to polycistronic mRNA 
(266). The genes are constitutively transcribed in the promastigote and amastigote 
stage (266), although there is some debate as to whether amastigotes express the 
translated protein (47, 267). Gp63 has been shown to function as a protease in vitro on 
a number of proteins (46, 268, 269), although the natural substrate is not known.
Serum from patients suffering from cutaneous and visceral disease contain high 
antibody titres to gp63 (270). Strong T cell responses to purified or recombinant gp63 
have also been observed using lymphocytes from patients with active or cured 
cutaneous, mucocutaneous or visceral disease (271). In mice, native gp63 has been 
used successfully to immunise resistant mice against cutaneous disease, either alone as 
a purified protein (272) or incorporated into liposomes (257). However, vaccination 
with recombinant gp63 did not provide any protection to resistant or susceptible 
BALB/c mice upon infection with L. major (273).
Peptides from gp63 can immunise for Thl or Th2 cell responses in vivo 
depending upon the sequence chosen. Initial studies using seven peptides, predicted to 
be T cell epitopes by algorithm analysis of the gp63 sequence, found one peptide 
capable of inducing Thl responses and protective immunity to L. mexicana infection 
after subcutaneous immunisation (274). An examination of 24 peptides from gp63 
found a number which were immunogenic in mice, induced DTH and Thl responses
56
A recently described Leishmanial antigen, p24/LACK has been shown to 
function as an effective vaccine in susceptible BALB/c mice when administered with 
recombinant IL-12. A dominant immune response is detected to p24 during the first 
week of infection in both susceptible and resistant mice indicating that this antigen 
may be important in determining the early Thl or Th2 response. In addition, a 
protective T cell clone which can transfer resistance to infection is known to 
recognise this molecule. Why this antigen provokes a strong immune response is 
unclear. It has homology to another eukaryotic protein, Receptor for Activated C 
Kinase (RACK) which is a protein kinase C docking molecule present in the 
cytoplasm of many cells. The function of p24/LACK in the parasite is unknown but 
it is present in all species studied so far.
and conferred protective immunity against L. major in resistant, CBA mice (275). A 
detailed study of overlapping peptides spanning the entire length of L. major gp63 
found that the most immunodominant peptides generated a Thl-like response in vivo 
while peptides which generated a less efficient proliferative response showed a Th2- 
like profile (276).
Gp63 has also been expressed in both BCG (277) and Salmonella typhimurium 
(278) as candidate live vaccines. A single vaccination of the BCG clone expressing 
gp63 reduced lesion development in CBA mice after challenge with L. mexicana or L  
major (277). Susceptible BALB/c mice were protected from L. mexicana infection 
after receiving this construct and also demonstrated a reduction in lesion development 
upon low dose L. major challenge (277). Gp63 expressed in S. typhimurium was 
efficient at protecting resistant mice from lesion development and this correlated with a 
Thl-like response to antigen in vitro by spleen cells from immunised mice (278). 
However, no protection was observed when this construct was used to vaccinate 
susceptible, BALB/c mice. Thus, of the available candidate antigens used to vaccinate 
against murine cutaneous leishmaniasis, gp63 is the most completely studied and has 
given the most encouraging responses.
1.5 Salmonella vectors
The use of live delivery systems in vaccine development has advanced the 
frontiers of vaccine research. Several attenuated organisms which have lost the ability 
to cause disease or have been engineered genetically to be avirulent have been studied 
with a view to the development of vaccines against natural infection (279). Live 
vaccines allow the generation of strong, cellular, long-lasting immune responses which 
many killed or subunit vaccines do not provide (280). Agents studied as live vaccine 
vectors include vaccinia virus, avipoxviruses, adenoviruses, polioviruses, salmonella, 
herpesviruses and BCG, among others (281). These organisms also allow the insertion 
of foreign genes into the genome which can be expressed in vivo as the vaccine
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establishes it's limited life-cycle. It is therefore possible to envisage the generation of a 
live attenuated organism which, while protecting against infection with the wild-type 
pathogen, also provides effective immunity to diverse species (280).
There are, however, potential problems associated with the use of live 
attenuated vaccines. Reversion to virulence is a major problem which can, in part, be 
overcome by recent developments in the understanding of the molecular nature of 
bacterial and viral pathogenesis (282). Multiple, defined genetic disruptions in genes 
essential for virulence can render agents safe for human use. There are also problems 
relating to vector immunogenicity, as increased attenuation can often lead to decreased 
ability to induce immune responses (282).
Some of the best candidates for use as live vaccine vectors are attenuated strains 
of Salmonella which have been shown to function effectively as vaccines against 
human typhoid fever and have the additional benefit that they can be administered 
orally (283). Although this is obviously an inherent advantage in vaccinating against 
any pathogen, it is particularly useful when one considers the development of vaccines 
against diseases in the Developing World, as oral administration would reduce the 
costs associated with large scale vaccine deliveiy (284). It has also been observed that 
"the majority of infectious diseases are initiated by pathogens entering the body via 
exposed mucosal surfaces" and vaccination by a similar route may confer better 
protection against such diseases. (282) Live Salmonella also have advantages when 
contemplating large scale vaccine preparation due to the stability of the organisms 
during storage and the ease with which they can be grown in bulk cultures (285).
1.5.1 Salmonella life cycle and pathogenesis
An understanding of the pathogenesis of human typhoid fever caused by S. 
typhi and S. paratyphi comes from experimental murine infection with Salmonella 
strains which cause a very similai disease. These include S. typhimurium and S .
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enteritidis which cause enterocolitis in humans but typhoid fever-like symptoms in 
mice and many domestic animals (285)
After oral inoculation of S. typhimurium to a susceptible mouse and survival of 
the stomach environment, S, typhimurium penetrate the wall of the small intestine 
through specific areas called Peyer's patches (286). In human typhoid fever, these 
areas represent the position of perforated ulcers which are the major cause of mortality 
during infection (287, 288). Previously thought to have little functional significance, 
Peyer's patches represent lymphoid follieles at which the immune system can sample 
the gut environment for immunesurvei 1 ence (289).
Entry into a Peyer's patch is controlled by specialised epithelial cells, termed M 
cells (due to the presence of "microfolds" on the luminal surface) which overly the 
basement membrane covering the lymphoid area (290). These cells allow the 
controlled flow of particles from the lumen into contact with lymphoid cells (291). In 
addition, these specialised cells are often tightly associated with lymphoid cells which 
sit within an invagination between M cells and adjacent enterocytes (286). While 
phagocytosis of particles by enterocytes leads to transport to lysosomes, particles or 
organisms which are ingested by M cells are delivered to lymphoid cells (292).
A number of enteropathogens such as S. typhi , S. typhimurium , Yersinia 
enterocolotica and reoviruses selectively attach to M cells in the lumen and then 
subvert the nature of this cell in order to gain access to tissues (289). A comparison of 
an invasive and non-invasive strain of S. typhimurium found that the non-invasive 
strain was deficient in M cell attachment, emphasising the necessary nature of this 
interaction for infection (293). Invasive strains induce membrane ruffling at the 
surface of epithelial cells which mediates entry (294). Although the attachment and 
induction of membrane ruffling is specific to certain invasive organisms, the uptake is 
not, as non-invasive bacteria or even latex beads can be ingested by epithelial cells if 
membrane ruffling is first induced (294). The relative membrane interactions between
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the bacteria and the epithelial cell in the internalisation process are not known (295), 
although it is clear that invasion by S. typhimurium requires protein synthesis by the 
bacteria (296, 297) and both actin polymerisation (298) and an inositol phosphate flux 
(299) by the epithelial cell.
After invasion, Salmonella quickly kill the M cell before infecting neighbouring 
enterocytes (286). The bacteria can now gain entry into the deeper tissues but also 
continue to develop a destructive ulcer at the site of infection. If this ulcer progresses 
to a perforated state this allows other opportunistic gut organisms to gain entry to the 
tissues with often fatal consequences (300). Salmonella organisms, after gaining entry 
to the Payer's patch via M cells then translocate to the lamina propria and mesenteric 
lymph nodes where they can invade and survive within macrophages (285). Further 
colonisation of macrophages within the spleen and liver then takes place.
The ability to survive within macrophages after phagocytosis is critical to the 
pathogenesis of this organism (301). Salmonella enter macrophages via a membrane 
ruffling event similar to that observed with epithelial cells although in this case the 
bacteria induce ruffling of a larger membrane area (302). The organisms survive 
within a large vesicle similar in size to macropinosomes which are large endocytic 
vesicles inducible by phorbol ester treatment and distinct from smaller phagosomes 
(303). Existence within such a large vacuole may cause a dilution of any induced 
microbicidal compounds and a delay in acidification, allowing the bacteria to survive 
initial antibacterial defences (302). The acidification of the phagosome may also be 
actively delayed by the Salmonella themselves, as killed organisms induce a quicker 
reduction in vacuolar pH if ingested by macrophages (304).
Little is known of the mechanisms by which Salm onella  survive in 
macrophages after initial invasion, although it is clear that acidification of the vacuole 
does eventually occur (304). The transcription of the bacterial phoP-activated gene 
{pag ) promotes intra-macrophage survival and is switched on within hours of
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phagocytosis (304, 305) although it is not clear how this virulence factor operates. The 
initiation of pag transcription is controlled by two other proteins, PhoQ and PhoP 
which allow the bacteria to detect acidification of the phagosome (306). Replication of 
the bacteria occurs within macrophages before release and invasion of other cells. 
Limited experiments on human volunteers suggest that a similar course of infection to 
the one described above in mice also takes place during human typhoid fever (307).
1.5.2 Ivcmxxmiy io Salmonella wÏQcûon
In a manner similar to murine L. donovani infection, mice infected with S. 
typhimurium divide into susceptible and resistant according to the presence of different 
alleles of the Lsh/Ity/Bcg gene. Challenge of Ity  ^mice results in the initial control of 
infection which is not T cell mediated (308) and further T cell mediated bacterial 
clearance (309). As with L. donovani this initial control may be due to the functional 
activity of a nitrogen transport protein encoded at the Ity locus (59). BALB/c mice, 
however, cannot control infection with virulent salmonellae and succumb to fatal 
infection.
Immunisation of BALB/c mice with live attenuated strains of S. typhimurium 
can induce protective immunity to further vimlent challenge (310). There is a period of 
non-specific immunity which occurs as the initial replication of the attenuated 
organisms reaches a plateau, conferring resistance to infection with Listeria  
monocytogenes as well as virulent Salmonella (311). This non-specific protection is 
mediated primarily by activated macrophages and NK cells (312), can be transferred to 
naive mice by macrophages (313) and is inhibited by anti-IFN-y monoclonal antibodies 
(314). This coincides with a period of non-specific T and B cell immunosuppression 
mediated by activated macrophages which can be inhibited by exogenous IL-4 (315).
Resistance to virulent infection after this initial phase is antigen specific and 
requires the presence of T cells (316). Surprisingly, T cells and/or macrophages are not
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sufficient in the transfer of this immunity to naive susceptible animals (317) although 
transfer of T cell lines is sufficient to protect against strains of low virulence (318). For 
protective immunity to virulent challenge, serum transfer from immunised animals is 
required in addition to T cells (319). These antibodies are thought to opsonise 
extracellular organisms and so help to contain infection. Macrophage activation and 
recmitment by IFN-y and TNF-a are critical in the killing of intracellular organisms 
(316) and can cause S. typhimurium killing if administered in vivo before infection 
(320). Lysis of infected cells by cytotoxic T cells is also suggested to contribute to 
salmonella clearance (321) as infection elicits a strong CDS'*" CTL response (322). As 
intracellular salmonella are retained within a vacuolar membrane it is difficult to 
explain antigen delivery to the class I pathway. An attenuated Salmonella strain 
expressing influenza A nucleoprotein did not deliver viral antigen to the MHC class I 
pathway during infection of CHO cells (323) suggesting that antigen presentation for 
the generation of CDS’*" T cell responses in vivo may derive from an unconventional 
class I pathway which is only found in macrophages (324).
1.5.3 Attenuated Salmonella
Various S. typhi and S. typhimurium mutants have been studied as possible 
vaccine candidates against human typhoid fever and the murine equivalent. Germanier 
and co-workers described a mutant S, typhimurium strain that was deficient in the 
production of lipopolysaccaride due to mutations at the gal E locus (325). The 
bacteria were defective in the enzyme UDP-galactose epimerase and were both highly 
attenuated and immunogenic. A similar mutant of S. typhi was generated called Ty21a 
which has now been used in a number of large-scale human vaccine trials (326, 327, 
328) and has proved to be as effective as the killed typhoid vaccine in vaccinating 
against typhoid fever (327). While this strain is now licensed as a vaccine in a number 
of countries the genetic factors responsible for attenuation remain undefined (282). 
There are a number of differences between the Ty21a strain and the wild-type Ty2 
strain which cannot be explained by disruption of the galE locus. In addition, a
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genetically defined strain with a galE mutation remained virulent (329) in humans 
emphasising the undefined nature of Ty21a attenuation. The lack of information 
concerning the genetic attenuating factors involved and the obseiwation that three doses 
of this vaccine are required for effective immunity (327) has resulted in further 
manipulation of S. typhi and S. typhimurium strains to create a defined, attenuated 
mutant with greater immunogenicity.
A S. typhimurium strain with a defined disruption of the aroA gene was 
reported to be severely attenuated and highly immunogenic in vivo as a single oral 
dose could protect BALB/c mice against virulent challenge (310). The aroA gene 
encodes the enzyme 5-enolpyruvyl-shikimate-3-phosphate synthase which is required 
for synthesis of aromatic rings in the chorismate pathway (330). This attenuation 
leaves the bacteria unable to synthesise the compounds p-amino-benzoic acid (pAB) 
and 2,3-dihydroxybenzoate (DHB) among others (310). These compounds are used in 
the generation of iron binding proteins and for DMA synthesis and repair. The lack of 
such compounds in the mammalian host severely attenuate the bacteria in vivo. 
Although the generation of other products such as the aromatic amino acids is also 
disrupted in these mutants it is the lack of available pAB and DHB in vivo that cause 
attenuation of the bacteria, as injection of these compounds during colonisation results 
in virulent infection (310). A S. typhi strain with a similar disruption generated a 
strain attenuated for human infection (331).
Further strains have been developed based on the aroA mutant, which contain 
other mutations to render the possibility of reversion to virulence extremely remote. S. 
typhi strains with mutations at both aroA and purA, a locus required for purine 
synthesis, resulted in the generation of a strain which was extremely safe but poorly 
immunogenic when given to humans (332). A similar S. typhimurium strain was also 
extremely attenuated, developing a persistent low level infection in BALB/c mice 
which was insufficient to generate immunity (333). Therefore, while the targeted 
disruption of two diverse pathways does increase attenuation, it leaves the bacteria
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unable to achieve the level of colonisation required for the induction of effective 
immunity. Double mutants within the chorismate pathway such as aroA " , aroC ' or 
aroA aroD " are severely attenuated yet retain immunogenicity. S. typhimurium 
mutants with two aro mutations were shown to be effective single dose vaccines in 
cattle (334) although similar S. typhi mutants, while being highly immunogenic, 
retained the ability to cause fever in human volunteers (335).
Many other S. typhimurium and S, typhi mutants which are genetically defined 
have been produced as knowledge of salmonella virulence factors has progressed. S. 
typhimurium strains with disruptions at the cya locus or crp locus are unable to make 
cyclic AMP or respond to cAMP (336). Similar S, typhi mutants were tested in 
humans and one of twelve recipients developed fever (335) indicating that this strain 
was not sufficiently attenuated for human use. Other strains which have been 
examined in animal models include those with mutations atphoP (306), ompR (337), 
htrA (338) and hemA (339). A strain of S. cholerae-suis with a mutation in the cdt 
(colonisation of deep tissue) gene were unable to mount a systemic infection after oral 
delivery (340) and may be useful as a heterologous vaccine carrier against mucosal 
pathogens. An investigation as to the balance between immunogenicity and safety of 
these strains may lead to the generation of those suitable for human use.
1.5.4 Attenuated Salmonella as heterologous carriers
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In addition to the potential of attenuated S. typhimurium and S. typhi strains to 
vaccinate against typhoid fever, they have also received much attention regarding their 
potential as carriers of diverse antigens from a number of other pathogens (284, 285, 
341). Salmonella mutants induce strong humoral and cellular immune responses and 
therefore can be manipulated to induce such immune responses to foreign antigens. 
Antigens of bacterial, viral and parasite origin have been expressed in S. typhimurium 
as prospective vaccines against a number of diseases.
Ty21a has been used to express a number of antigens in an attempt to generate 
a multi valent vaccine against various enteric bacterial pathogens. The introduction of a 
plasmid into the Ty21a strain generated a strain which express the |3-subunit of E, coli 
heat labile enterotoxin (LT-B) (342). Ty21a has also been used to develop a construct 
expressing Shigella sonnei surface antigens (343) and a construct expressing Vibrio 
cholerae antigens (344). While these bivalent vaccines have been generated in S. 
typhi, most attempts to generate dual vaccines against diverse pathogens have 
concentrated on the use of attenuated S. typhimurium strains, as experimental vaccines.
Experimental vaccines against bacterial pathogens have been constructed using 
S. typhimurium mutants expressing E. coli fimbrial adhesin K88 (345), or LT-B (346), 
Bordetella pertussis P69 (347), a membrane constituent of Brucella abortus (348) M  
leprae antigens (349) and Tetanus toxin fragment C (350). AroA mutants expressing 
p-galactosidase induced strong antibody and DTH responses to p-galactosidase in
immunised mice, indicating that antigens delivered by this method are immuogenic
(351). The construct expressing the P69 antigen of B. pertussis in the double mutant 
strain BRD509 was able to induce protective immunity to challenge with B. pertussis
(352). Reduction in disease correlated with the induction of substantial cellular 
responses to P69.
A number of viral antigens have also been expressed in S. typhimurium , An 
initial report describing expression of P, berghei circumsporozoite antigen in S. 
typhimurium suggested that the protective immunity induced by this strain was due to 
the induction of CTL responses (353). Further work has demonstrated the induction of 
strong CTL responses to antigens expressed in salmonella (322, 354, 355) indicating 
that Salmonella may function as effective vectors for the delivery of viral antigens. 
However, influenza nucleoprotein (NP) expressed in attenuated S. typhimurium were 
unable to stimulate class I restricted T cell responses in vitro after macrophage 
infection, while class II restricted T cell clones were efficiently stimulated (356). In 
vivo studies confirmed these data, as infection of mice with S. typhimurium expressing
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NP generated NP-specific class II restricted responses in the absence of class I 
responses (357). While some class 11-restricted cytotoxicity was detected, there was 
efficient induction of Thl-like CD4^ T cell responses to antigen indicating that this is 
the primary response induced to heterologous antigens delivered using Salmonella. As 
previously mentioned, S. typhimurium were unable to deliver antigens to the class I 
pathway during infection of CHO cells (323). Therefore the mechanism of CTL 
induction by antigens expressed in S. typhimurium strains is unclear, while the ability 
to deliver antigens to the class II pathway and induction of CD4'*' T cells has been 
repeatedly demonstrated (278, 356, 357). The prospective role of Salmonella mutant 
strains in the induction of CD8^ T cell responses and protective immunity against viral 
infection requires further investigation.
As protective responses during primary L. major infection are mediated by 
CD4'*' cells. Salmonella seem ideal vectors to deliver Leishmania antigens. The gene 
encoding L. major gp63 was expressed in a single aro A mutant of S. typhimurium 
and this construct used to immunise mice (278). Resistant CBA mice after two oral 
doses of this construct had reduced lesion development upon L. major challenge.
However, similar vaccination of BALB/c mice provided no protection to challenge 
infection. Immunisation with this constmct induced Thl-like CD4^ T cell reponses to 
gp63 which coiTelated with protective immunity (278). In addition to L. major gp63, a 
number of other antigens of parasite origin have been expressed in S. typhimurium, 
including P. berghei circumsporozoite antigen (353), P. falciparum blood stage 
antigens (358), and a Schistosoma mansoni glutathione S-transferase peptide (359).
S. typhimurium have also been engineered to express murine cytokines which 
are bioactive in vivo. S. typhimurium expressing murine IL-ip confer protection 
against lethal gamma irmdiation due to functional IL-ip activity, when administered to 
mice (360). Murine IL-4 has also been expressed in S. typhimurium and shown to 
have bioactivity in vivo (361). While the use of recombinant cytokines with adjuvant
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activity in vaccination has been documented (362) the use of cytokine expressing S, 
typhimurium in vaccination has not been addressed.
In conclusion, attenuated S, typhimurium can be used as carriers of 
heterologous antigens to the immune system in animal models and future progression 
from a single attenuated typhoid fever vaccine to a multi valent vaccine against diverse 
pathogens may be possible.
1.5.5 Other live vaccine vectors
While S. typhimurium are considered effective vaccine vectors there are a 
number of other live vectors which are just as efficient in the generation of immunity to 
expressed antigens, although some of these also have inherent problems.
Attenuated BCG have been used to deliver a number of heterologous antigens 
to the immune system (277, 363) including L. major gp63 (277). BCG offers a safe, 
well tested vector, as over 2.5 billion people have been immunised with this organism 
(363). It has also been well studied in vitro and can be manipulated to express foreign 
proteins (364). However, like many live vaccines there are concerns about the ability 
of mycobacteria to replicate in immunocompromised patients (363). In addition, BCG 
grows very slowly in culture which can make manipulation of strains difficult and time 
consuming. The number of individuals already immunised with BCG could also, in 
itself, represent a considerable disadvantage as strong anti-vector immune responses 
may reduce the efficacy of BCG to deliver foreign antigens. Attenuated strains of other 
bacterial pathogens such as Listeria and Shigella have also been studied as vaccine 
vectors (363).
Vaccinia virus has also been shown to be effective in functioning as a live 
vaccine vector, delivering a number of diverse antigens to the immune system (280, 
281, 363). Unlike many other viruses, vaccinia allows incorporation of large amounts
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of DNA into the genome (280). Antibody and CTL responses to foreign antigens have 
been demonstrated using vaccinia virus vectors. (363). However, there are problems 
concerning reversion to virulence after immunisation with vaccinia and attempts have 
been made to further attenuate the virus for human use (365). Other viral vectors such 
as avipoxviruses which are incapable of spreading infection in human cells and 
attenuated polioviruses are also being considered as possible viral vectors for the safe 
deliveiy of foreign antigens (281).
There are therefore a number of live attenuated vaccine vectors which can be 
utilised for the expression of foreign genes. With most of these organisms the 
problems of reversion to virulence and immunogenicity remain to be resolved.
1.6 Aim of thesis
Successful vaccination against experimental murine leishmaniasis is known to 
depend critically upon the induction of a protective Thl response. The capacity of S. 
typhimurium to induce Thl responses in vivo to heterologous antigens suggests that 
attenuated Salmonella may be ideal vectors for vaccination against leishmaniasis. A S. 
typhimurium construct (SL3261/gp63) which expressed L. major gp63 was shown to 
reduce lesion development in resistant CBA mice and induce a Thl response to gp63. 
However, this construct failed to provide any protection to the susceptible, BALB/c, 
strain.
The aim of the work described in this thesis was to improve upon the vaccine 
strain SL3261/gp63 in order to provide protection against susceptible BALB/c mice. 
This was attempted by:
(a) the use of the attenuated S. typhimurium strain BRD509, which contains two 
deletions in Aro genes and has a lower frequency of reversion to virulance, to express 
gp63. The effects of this upon immunogenicity and protection were investigated.
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(b) the use of inducable promoters to express gp63 in the vaccine strain, BRD509, with 
a view to the construction of a strain which provides protection with a single dose. The 
promoters NirB and OsmC were examined in this respect. In addition, this work sought 
to examine the protective immune responses involved in the induction of immunity 
after oral administration with attenuated S. typhimurium constructs expressing gp63. 
The relationship between plasmid stability of these constructs and immunogenicity was 
also investigated.
This work also describes the construction and use of a Salmonella construct 
expressing a recently described L. major antigen, p24/LACK. This antigen is known to 
provide complete protection to susceptible BALB/c mice after coadministration with 
IL-12. This vaccine protocol also causes the induction of a Thl-like response to p24. 
Therefore the combination of this antigen and oral salmonella vectors, which 
preferentially induce Thl responses, was thought to provide an excellent vaccine 
against experimental leishmaniasis. The use of this construct as a vaccine against L. 
major in resistant and susceptible mice and an investigation of plasmid stability and 
immunogenicity was attempted.
The work described in this thesis, therefore, represents an attempt to advance an 
existing vaccine against L. major infection in the mouse model by the use of a different 
Salmonella strain, inducable promoters and new antigens. These investigations may 
aid the generation of a live attenuated oral vaccine against human leishmaniasis.
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Chapter 2 
Materials and Methods
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2.1 Plasmids and oligonucleotides
Plasmids
Details of all plasmids used in this study, with their relevant properties and 
sources, are shown in Table 2.1.
Table 2.1; Plasmids
Plasmids Relevant properties Source or reference
pkk-Imm63-67 L. major gp63 cDNA, ampicillin resistance, tac promoter
Dr. W. R. McMaster, 
U niversity of British Colombia, Canada.
pNirB/gp63 L. major gp63 cDNA, ampicillin resistance, NirB promoter
Dr. D. Xu,Dept, of Immunology, Western Infirmary, Glasgow, U.K.
pOsmC/gp63 L. major gp63 cDNA, ampicillin resistance OsmC promoter
Dr. D. Xu
pET-LACK.01 L. major p24 LACK cDNA Df. N. Glaichenhaus, Université de Nice, France.
pNirB/p24 L. major p24 LACK cDNA,ampicillin resistance,NirB promoter
This study
Oligonucleotides
All oligonucleotides were synthesised by Genosys Biotechnologies, Inc. 
(Cambridge, U.K.)
The following primers were used for cloning of cDNA into pNirB:
L. major p24
5' GGCATATGGAGTTCCTGCGCGACGGTCAC 
3' CCGGATCCTTACTCGGCGTCGGAGATGGACCA
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2.2 Bacterial strains
Bacteria strains Escherichia coli and Salmonella typhimurium were routinely 
cultured in Millers-modified Luria Broth (L-broth) (Gibco BRL, Life Technologies, 
Paisley, U.K.) consisting of 1% SELECT Peptone 140, 0.5% Yeast Extract and 1% 
NaCl, or on Millers-modified Luria Agar (L-Agar) (Gibco) consisting of 1% SELECT 
Peptone 140, 0.5% Yeast Extract, 1% NaCl and 1.2% Agar. Both L-broth and L-agar 
were sterilised before use by autoclaving on liquid cycle (121°C for 2 hours). Bacterial 
strains containing plasmids were routinely cultured in the presence of ampicillin (100 
pgtmX) (Pharmacy, Western Infirmary, Glasgow, U.K.) to select for transformed 
bacteria.
E. coli and S. typhimurium strains
All E. coli and S. typhimurium. strains used are listed in tables 2.2 and 2.3 
respectively.
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Table 2.2: E, coU strains
Strain Relevant properties Source and/or reference
TG-1 supE, hsdA5, (lac-proA- 
B), F' [tra D36, pro A B \ 
lacU, lacZAM15]
Dr. D. Xu,
Dept. of Immunology, 
Western Infirmary, 
Glasgow, U.K. (366)
TGl/NirB/p24 pNirB/p24 in TG-1 This study
Table 2.3: S. typhimurium strains
Strains Relevant properties Source and/ or reference
BRD509 SL1344 AroA" AroD" Dr. G. Dougan, 
B i oc he mi s t r y  D e p t . , 
Imperial College of Science, 
Technology and Medicine, 
London. (352)
GIDIOI pkk-Imm63-67 
in BRD509
Dr. D. Xu,
Dept of Immunology, 
Glasgow University.
GID105 pNirB/gp63 in BRD509 Dr. D. Xu
GID106 p O s m C / g p 6 3  in 
BRD509
Dr. D. Xu
GID202 pNirB/p24in BRD509 This study
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2.3 Mice, parasites and infection
23.1 Mice
BALB/c and CBA mice were obtained from Harlan Olak ( Bicester, U.K.) and 
maintained in the Joint Animal Facility, University of Glasgow, Glasgow. BALB/c 
and CBA mice in some experiments were bred and maintained in the animal facilities 
at Strathclyde University, Glasgow. Female mice aged 6-10 weeks were used in all 
experiments.
2.3.2 Growth and maintenance of Leishmania 
Leishmania major
Leishmania major strain MRHO/SU/59/P, also known as LV39, was used 
throughout. The isolate was maintained in the laboratory by continuous passage in 
BALB/c mice to maintain virulence, as previously described (117). Non-ulcerated 
lesions of mice, infected four to five weeks previously in the right, hind footpad with 
1x10^ parasites in 50]A Phosphate Buffered Saline (PBS [1.9mM NaHzPO^, S.lmM 
Na^HPO^, 154mM NaCl, pH 7.2-7.4]), were removed and cut into small pieces in a 
petri dish (90mm) containing 10ml PBS. Parasites were further dispersed by forcing 
the suspension through a 5ml syringe placed against the bottom of the petri dish. The 
suspension was filtered into a universal using Monofilament Nylon Filter Cloth 
(NITEX) (Cadisch and Sons Ltd, London, U.K.) to remove remaining debris and 
washed twice by centrifugation at 1300g for 10 minutes at 4“C . After the final wash 
the pellet was resuspended in 5m 1 of Complete Schneiders Drosophila Medium 
(CSDM), consisting of Schneiders Drosophila Medium (SDM) (Gibco) containing 20% 
FCS (Gibco), 0.05% Gentaniycin Sulphate (Gibco) and 2.5 % L-glutamine (Gibco). 
The parasites were then incubated for 3-4 days at 28°C in 25cm^ tissue culture flasks 
(Corning, New York, U.S.A.) to transform amastigotes. For storage, parasites were
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then centrifuged at 1300g and resuspended in 2mls of CSDM containing 10% Dimethyl 
Sulfoxide (DMSO) (Sigma Chemical Co., Dorset, U.K.). A 10/^ 1 aliquot of this 
suspension was removed, diluted 1: 100 in PBS containing 2.5% Formalin (Sigma 
Chemical Co.) and the number of parasites counted using an Improved Neubauer 
Flaemacytometer (Merck Ltd, Dorset, U.K.). Parasites were diluted to 2 x lO'^/ml in 
CSDM containing 10% DMSO, aliquoted into 1ml freezer vials and kept at -70°C 
overnight before storage in liquid nitrogen at -198®C.
For growing L. major in vitro a vial was thawed from liquid nitrogen at room 
temperature and the contents cultured for three days in 5mls CSDM at 28“C. Parasites 
were then passaged in vitro in CSDM, and every subsequent 7-10, days by adding 
250/d of culture to 40mls of CSDM in a 80cm^ tissue culture flask (Corning) and 
culturing at 28°C. Parasites were not maintained in vitro for longer than 4 passages 
for fear of loss of virulence.
L. donovani
L. donovani was maintained by continuous passage in Syrian hamsters, as 
previously described (367). Spleens were harvested from infected hamsters and cut 
into small pieces in lOmls RPMI 1640 (ICN Biomedicals Inc., Costa Mesa, CA., 
U.S.A.) and homogenised using a 15ml ground glass homogeniser (Jencons [Scientific] 
Ltd., Leighton Buzzard, U.K.). Debris was removed from the homogenate by 
centrifugation at 80g for 5 minutes at 4°C. The resulting supernatant was centrifuged 
at 1300g for 10 minutes at 4°C to pellet amastigotes and resuspended in 20 mis 0.05% 
saponin (Sigma Chemical Co.) to lyse remaining red blood cells. Cells were 
immediately centrifuged at 1300g for 10 minutes at 4°C to limit amastigote exposure to 
saponin, before being resuspended in 20mls RPMI. Amastigotes were further washed 
twice in RPMI and the pellet resuspended in 2mls RPMI. An aliquot was diluted 1:100 
or 1:1000 in RPMI and amastigotes counted using an Improved Neubauer 
Haemacytometer, after allowing the parasites to settle for 10 minutes. Parasites were 
diluted to IxlO^/ml and l-2mls injected into each hamster intraperitoneally. Parasites
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were passaged again after animals began to show pronounced weight loss and abdomen 
swelling which occurred approximately 6-8 weeks after infection.
2.3.3 Infection of mice with Leishmania
L. major
L. major was grown in vitro as described above. Parasites at day 7-10 after 
passage were centrifuged at 1300g and washed twice in sterile PBS. Promastigotes 
were counted as described above and resuspended at the appropriate concentration 
before being injected into mice subcutaneously in the left, hind footpad in a volume of 
50jA. Footpads were monitored for thickening using a spring-dial calliper 
(Schnelltaster, Kroeplin, Surrey, U.K.). BALB/c mice typically received 5x10^-1x10^ 
parasites per injection whereas CBA mice received 1x10' .^
L. donovani
L. donovani amastigotes were harvested and purified from hamster spleens as 
described above. For infection of mice, amastigotes were resuspended at 5x10'^ /ml in 
RPMI and 200^1 injected intra-venously into the tail vein. At various time points after 
infection mice were monitored for parasite loads by sacrificing animals and obtaining 
organ imprints on glass slides of liver and spleen as previously described (368). These 
slides were fixed in 100% methanol (Fisons, FSA Laboratory Supplies, Loughborough, 
U.K.) for 20 minutes followed by staining in 10% Giemsa solution (BDH Laboratory 
Supplies, Poole, U.K.) for 30 minutes. Parasites and cell nuclei were counted from 
organ imprints using oil immersion light microscopy. The LDU (Leishman-Donovan 
Units) of each organ was calculated by multiplying the organ weight by the number of
observed amastigotes per 1000 nuclei.
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2.4 DNA manipulation
2.4.1 Q uantitation of DNA, RNA and oligonucleotides by 
spectrophotometric analysis
In order to determine the concentration of DNA or RNA in solution, the optical 
density was determined at wavelengths 260nm and 280nm in 10mm quartz cuvettes 
(Jencons) using an Ultrospec 4050 spectrophotometer (LKB Biochrom Ltd, 
Cambridge, U.K.). The optical density at 260nm allows calculation of the 
concentration of nucleic acid in the sample. An OD of 1 corresponds to approximately 
50pg/m\ of double-stranded DNA, 40/<g/ml of single stranded DNA or RNA, or 
20/^g/ml of single stranded oligonucleotides. The ratio between 260nm and 280nm 
provides an estimate of the purity of nucleic acid in solution. Pure preparations of 
DNA and RNA have OD260/OD280 values of 1.8 and 2.0 respectively.
2.4.2 Restriction enzyme digestion
Restriction enzymes were purchased from Boehringer Mannheim (Boehringer 
Mannheim U.K. Ltd, East Sussex, U.K.) or Promega (Promega Corporation, Madison, 
WI, U.S.A.) as were the buffers used to create optimal digestion conditions. All 
reactions were performed according to manufacturers instructions; typically lUnit of 
enzyme per jwg of DNA was incubated at 37°C for 1-2 hours in the appropriate buffer. 
Table 2.3 details the restriction enzymes used, cleavage sites and buffers.
79
Table 2.4: Restriction enzymes
Restriction enzyme Recognition site Optimal buffer
Ndel 5'-CA • TATG-3' 
3'-GTAT • AC-5'
Buffer B
(lOmM Tris-HCl, 5mM MgCla, 
lOOniM NaCl and ImM 2- 
Mercaptoethanol)
BamH I 5'-G • GATCC-3'
3'-CCTAG • C-5'
Buffer B
PstI 5'~CTGCA • G-3’ 
3'-G*ACGTC-5’
Buffer H
(50mM Tris-HCl, lOmM MgCH, 
lOOmM NaCl and ImM 
Dithioerythritol)
A va I 5’-C • (T,A)CG(A,G)G-3’ 
3'-G(A,G)GC(T,A) • C-5'
Buffer B
EcoR I 5'-G*AATTC-3' 
3'-CTTAA • G-5'
Buffer H
2.4.3 Agarose gel electrophoresis
An appropriate amount (typically 1%) of Ultra pure Agarose (Electrophoresis 
Grade, Gibco) was added to a measured volume of electrophoresis buffer (0.5 x TBE, 
[0.045M Tris-borate, 0.00 IM EOT A]) and boiled by heating in a microwave oven 
(Proline Powerware 800, Comet, Glasgow, U.K.). The agarose was allowed to cool to 
approximately 60°C and ethidium bromide (Sigma Chemical Co.) added to a final 
concentration of 0,5pig/ml. The agarose was then poured into a gel mould (Pharmacia, 
LKB Biotechnology AB, Uppsala, Sweden) and allowed to set. The comb was 
carefully removed and the gel mounted in a horizontal "submarine" electrophoresis
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tank (Pharmacia Gel Electrophoresis Apparatus GNA-100, Pharmacia) filled with 
electrophoresis buffer. The DNA samples or l]4% of DNA 1Kb ladder (Gibco) were 
mixed with loading buffer (0.25% bromophenol blue [Sigma Chemical Co.], 0.25% 
xylene cyanole FF [Sigma Chemical Co.] and 15% Ficoll 400 [Sigma Chemical Co.] in 
water) and loaded into the gel. The gel was run under constant voltage at l-5V/cm for 
30-60 minutes and examined for DNA bands stained with ethidium bromide under 
ultra-violet illumination (Ultraviolet Transilluminator, UVP Inc., Cambridge, U.K.) 
before photography (Polaroid DS-34 Direct Screen Instant Camera, Sigma Chemical 
Co.).
2.4.4 DNA ligation
2.4.5 Bacterial transformation
Plasmid DNA was introduced into E. coli using CaCl2 (369). Bacteria were grown in 
3mls of L-broth overnight at 37°C from colonies on L-agar . This suspension was 
diluted 1:20 in L-broth and grown for a further 2 hours in order to obtain a mid-log 
phase culture (OD600 of 0.5). Bacteria were then cooled on ice for 5 minutes, 
centrifuged at 800g and washed once in ice cold O.IM CaC^. The resulting pellet was 
resuspended in 1ml of O.IM CaCl2 and stored on ice. 10/ds of ligation mix (see 2.4.4) 
or 0.5jWg of plasmid DNA was mixed with 200/^ 1 of bacteria and stored on ice for 30-40 
minutes. Bacteria were then subjected to heat shock at 42°C for exactly 2 minutes and
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DNA ligation was performed according to suggested manufacturers conditions 
in a final volume of 20]A. For cohesive ligation, vector and insert DNA were mixed at 
a ratio of 1 : 3 in XApi of distilled water and heated at 50^C for 5 minutes in a water 
bath before being placed on ice. One Unit of T4 DNA ligase (Gibco), and 5pi\ of 
Ligation buffer (0.25M Tris-HCl [pH 7.6], 50mM MgClz, 5mM ATP, 5mM DTT, 25% 
w/v Polyethylene glycol-8000, Gibco) were then added and the ligation mix incubated 
overnight at 4°C.
.
placed immediately on ice for 1 minute. 1ml of L-broth was then added and bacteria 
incubated at 37°C for 1 hour. 120/d of this broth was plated onto L-agar plates in the 
presence or absence of ampicillin and incubated at 37°C overnight. Plasmid was 
prepared from clones growing on ampicillin plates and the plasmid DNA verified by 
restriction enzyme digestion or by PCR.
2.4.6 Electroporation of bacteria
Bacteria from an L-agar plate colony were grown overnight in a volume of 
3mls of L-broth. A small amount (250jwl) of this bacterial suspension was added to a 
further 30mls of L-broth and incubated in an orbital incubator (INR-250 Orbital 
Incubator, Sanyo Gallenkamp Pic., Loughborough, U.K.) for 2-4 hours, achieving a 
log-phase culture. This culture was centrifuged at 800g for 10 minutes, resuspended in 
25mls of sterile, ice-cold 10% glycerol (Fisons) in water before being centrifuged 
again. The pellet was resuspended in 500p\ of ice-cold 10% glycerol/water and 
bacteria stored on ice. To 60j4\ of bacteria, plasmid DNA (approximately 200ng, 
resuspended in water) was added in a volume of Spl. This suspension was added to a 
chilled 0.2cm Gene Puiser® cuvette (BioRad Laboratories, Richmond, California, 
U.S.A.) and electroporated (GenePulser®, BioRad Laboratories) under the following 
conditions:
E.coli S. typhimurium
1.25 Kv 1.75KV
25piF 25]aF
600 Ohms 600 Ohms
Immediately after poration, 1ml of L-broth was added to the cuvette after which this 
broth was transferred to a 1.5ml eppendorf tube and incubated for 2 hours at 37°C in a 
water bath. The bacteria were then plated onto L-agar plates in the presence and 
absence of ampicillin (100jL<g/ml) and incubated overnight at 37°C. Bacteria growing 
on ampicillin L-agar plates were further grown overnight in L-broth and plasmid was 
extracted to confirm successful poration.
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2.4.7 Quick plasmid preparation
This method was adapted from that of Brinboim and Doly (370). Bacteria were 
grown overnight at 37°C in 3mls L-broth containing 100/^g/ml ampicillin from L-agar 
plate cultures. The suspension was centrifuged at 13,800g in a bench-top microfuge 
(Biofuge 13, Heraeus Equipment Ltd, Brentwood, Essex, U.K.) for 1 minute in 1.5ml 
eppindorf tubes and the pellet resuspended in lOOptl of Solution I (2mg/ml lysozyme 
(Boehringer Mannheim) in 50mM glucose (Fisons), lOmM EDTA (Sigma Chemical 
Co.), 25mM Tris (BDH)-HCl pH 8.0). After 5 minutes at room temperature, 200j.d of 
Solution II (0.2M NaOH [Fisons], 1% SDS [BDH]) was added, the solution mixed 
well and incubated on ice for 5 minutes before 150/d of Solution III (3M Na Acetate 
pH 4.8 [Sigma Chemical Co.]) was added, mixed and the samples incubated for 10 
minutes on ice. Samples were then centrifuged in a microfuge at 13,800g for 10 
minutes and the supernatant poured into another eppendorf tube. An equal volume of 
Tris-HCl (pH 8.0) saturated phenol/chloroform (equilibrated phenol, chloroform, 
isoamyl alcohol [25:24:1]) was added, the samples mixed gently and centrifuged for 5 
minutes at 13,800g. The upper aqueous phase was removed and DNA precipitated by 
adding 2.5 volumes of 100% ethanol (BDH) and storing at -20°C for 15 minutes or by 
adding 1 volume of isopropanol (Sigma Chemical Co.) and storing at 4 ‘^ C for 15 
minutes. DNA was pelleted by centrifugation at 13,800g for 10 minutes and washed 
with 1ml of ice-cold 70% ethanol at 13,800g for 7 minutes. The ethanol was decanted 
and the pellet dried under vacuum in a Vacuum Drier (Gyrovap, V. A. Howe & Co. 
Ltd, Banbury, Oxon., U.K.) before being resuspended in an appropriate volume of TE 
buffer (lOmM Tris-HCl [pH 7.6], ImM EDTA) or distilled water, as required. DNA 
concentration was estimated using OD measurements (2.4.1) and visualised using 
ethidium bromide agarose gel electrophoresis. As necessary, RNA was degraded by 
incubating plasmid DNA with 1-2]a \ of RNAse (DNAse-free) (Boehringer Mannheim) 
at 37°C for 1 hour. Plasmid DNA was then stored at -20°C.
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2.4.8 Large scale preparation of plasmid DNA
Bacteria containing plasmid for purification were grown from L-agar plates 
containing 100j[^g/ml ampicillin. Colonies were inoculated into 3Omis of L-broth 
containing 100/.<g/ml ampicillin and grown overnight at 37°C. This culture was added 
to 1.25 litres of L-broth containing ampicillin and grown at 37°C for 6-8 hours while 
shaking in an orbital incubator. To improve the yield of low copy number plasmids, 
160jWg/ml of chloramphenicol (Western Infirmary Pharmacy) was added and the 
culture incubated for a further 16 hours at 37° C while shaking. The bacteria were 
pelleted by centrifugation at 6370g for 7 minutes at 4°C in a High-Speed Centrifuge 
(J2-MC Centrifuge, Beckman - RIIC Ltd, High Wycombe, Buckinghamshire, U.K.) 
using a JAIO rotor (Beckman). The pellet was resuspended in 50mls of Buffer PI 
(50mM Tris/HCl, lOmM EDTA, pH 8.0, Qiagen Ltd., Dorking, Surrey, U.K.) before 
50mls of Buffer P2 (0.2M NaOH, 1% SDS, Qiagen) was added, mixed and the solution 
stored at room temperature. After 5 minutes, 50-75mls of ice cold Buffer P3 (3M 
Sodium acetate [pH 4.8], Qiagen) was added, mixed and the suspension stored on ice 
for 10 minutes. This bacterial lysate was then centrifuged at 17,700g for 20 minutes at 
4°C and the supernatant filtered through NITEX. If the supernatant did not appear 
clear at this point it was subjected to a further centrifugation at the same speed. The 
plasmid DNA was purified from this supernatant in caesium chloride-ethidium bromide 
gradients (2.4.9) or by anion-exchange chromatography (2.4.10) using a Qiagen 
plasmid kit (Qiagen).
2.4.9 Purification of plasmid DNA using Caesium Chloride-Ethidium 
Bromide Gradients
Plasmid DNA in the supernatant from 2.4.8 was precipitated by adding an equal 
volume of isopropanol (as described in 2.4.7) and was then resuspended in TE buffer. 
Solid CsCl was added to the suspension (Ig/ml) in addition to 0.8mls of ethidium
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bromide solution (lOmg/ml) for every lOmls of suspension. The solution was mixed 
and sealed into Beckman Quick Seal tubes (Beckman). The tubes were centrifuged at 
250,000g for 36 hours in a Beckman Ultracentrifuge (Ti70.1 rotor, Beckman) at room 
temperature. After visualisation under ultra-violet light, the lower band of DNA, 
corresponding to closed circular plasmid DNA, was collected using an 18-gauge 
needle. The ethidium bromide was removed from the DNA by 4-6 extractions with 
equal volumes of isoamyl alcohol until the solution appeared clear. The DNA was 
mixed with an equal volume of isoamyl alcohol (Fisons) and centrifuged at 300g for 3 
minutes at room temperature. The lower phase was extracted using a pasteur pipette 
and the process repeated. The CsCl was removed from the DNA by precipitation with 
2 volumes of ethanol at 4°C for 15 minutes, followed by centrifugation at 10,000g for 
15 minutes at 4°C. The DNA pellet was washed once with cold 70% ethanol and 
resuspended in 1ml of TE buffer. The concentration of the DNA was calculated from 
OD260 readings and the DNA stored at -20°C until required.
2.4.10 Purification of plasmid DNA using a Qiagen plasmid kit
The Qiagen plasmid purification procedure uses a Qiagen Resin compacted into 
a small column which allows selective purification of super coiled plasmid DNA. 
Qiagen Resin is an anion exchanger with a hydrophilic surface coating containing 
Diethylaminoetyl (DEAE) groups. The large pore size of the resin combined with the 
high density of anion exchange groups provide a wide separation range when eluting 
with varying salt concentrations. The separation range of Qiagen resin extends from 
O.IM to 1.6M salt, allowing plasmid purification at high salt concentrations. The 
Qiagen-tip 2,500 (Qiagen) was first equilibrated using 35mls of QBT buffer (750mM 
NaCl, 50mM MOPS, 15% ethanol, pH 7.0, 0.15%Triton x-100, Qiagen) and the 
supernatant from section 2.4.8 applied to the column. The column was then washed 
with 200ml of QC buffer (IM NaCl, 50mM MOPS, 15% ethanol, pH 7.0, Qiagen) and 
the DNA eluted by adding 35mls of QF buffer (1.25M NaCl, 50mM Tris-HCl, 15% 
ethanol, pH 8.5, Qiagen). The DNA was precipitated from the QF buffer with 0.7
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volumes of isopropanol (Sigma Chemical Co.) and centrifuged at 20,000g for 30 
minutes at 4°C in a JA17 rotor (Beckman). The pellet was washed once with 5mls cold 
70% ethanol, air dried for 10 minutes and then resuspended in 2-3mis of TE buffer or 
distilled water.
2.4.11 "Freeze-squeeze" purification of DNA fragments (371)
DNA bands for purification were cut from an ethidium bromide stained agarose 
gel illuminated using an Ultraviolet Transilluminator and placed in a 1.5ml eppindorf 
tube. 1ml of "freeze-squeeze" buffer (0.3M Na acetate [pH 4.8], ImM EDTA [pH 
7.0]) was added and the tube placed in the dark for a period of time according to the 
size of the DNA fragment. For 100-2Kb fragments the gel was placed in the dark for 
10 minutes; for fragments greater than 2Kb this was increased to 30 minutes. The 
"freeze-squeeze" buffer was removed and the tube placed in a dry ice/ethanol bath for 
30 minutes. The frozen gel was removed from the tube and placed into a Centrifuge 
Filter Unit (Costar, Cambridge, Massachusetts, U.S.A.) without thawing. The tube was 
centrifuged in a bench-top microfuge (Heraeus) at 13,800g for 10 minutes and the 
liquid volume increased to 400jwl with TE buffer if necessary. An equal amount of 
Phenol/chloroform was added, the sample mixed well and centrifuged at 13,800g for 2 
minutes. The upper, aqueous layer was carefully transferred to another 1.5ml 
eppindorf tube. Chloroform, in equal volume was added, mixed and the sample 
centrifuged again at 13,800g for 1 minute. The chloroform extraction was then 
repeated. To this extract, 0.1 volumes of 3M Na acetate (pH 7.0) and 2.5 volumes of 
100% ethanol were added and the sample left at -20° C for 10 minutes. The 
precipitated DNA was pelleted by centrifugation at 13,800g for 30 minutes and washed 
with 70% ethanol before drying in a vacuum dryer. The DNA fragment was 
resuspended in a small volume (10-15//1) of TE buffer and a 1/<1 sample visualised 
using an ethidium bromide stained agarose gel to verify purification.
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2.4.12 Polymerase Chain Reaction (PCR)
All buffers and enzymes used for PCR were purchased from Promega and used 
according to the manufacturers instructions. Template DNA (0.1/^g/ml) or reverse- 
transcribed cDNA was placed in a 0.5ml eppindorf tube and the following reagents 
added: lOpX of lOx PCR buffer (lOOmM Tris-HCl, 500mM KCl [pH 9.0], and 1.0% 
TritonX-100); 5pi\ of MgCL (25mM); 4/d of 2.5mM dNTP's; 1/d of each primer (0.2- 
0.3/fM), and the volume made up to 99.5/d with sterile distilled water. The mixture 
was boiled in a water bath for 5 minutes and allowed to cool before 0.5/d of Taq 
polymerase (2.5 Units) was added to each tube. The reaction mixture was overlaid 
with one drop of mineral oil (Sigma Chemical Co.) and placed overnight on a Thennal 
Cycler (PHC-3 Dri-Block® Cycler, Techne [Cambridge] Ltd, Cambridge, U.K.) 
programmed with the following cycles; 94°C for 1 minute (dénaturation), 55°C for 2 
minutes (annealing), 72°C for 3minutes (polymerisation). This cycle was repeated 30- 
40 times and the final amplified mixture stored at 4°C. After amplification, 15//1 of 
PCR product was visualised on an ethidium bromide- agarose gel as described.
2.5 Protein manipulation
2.5.1 Sodium Dodecyl Sulphate -PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE)
SDS-PAGE was used to check foreign protein expression by E. coli and S. 
typhimurium constructs in vitro and from bacteria harvested in vivo. Glass plates 
were washed in 70% ethanol and allowed to air dry before assembly of the SDS-PAGE 
apparatus (Mighty Small™ II Vertical Slab Unit SE250, Hoefer Scientific Instruments 
U.K., Newcastle-under-Lyme, U.K.). The lower gel was prepared and consisted of; 
5mls of (4x)lower gel buffer (1.5M Tris-HCl [pH 8.8], 0.4% SDS [BDH]), 15 mis of a 
mix of water and AC/BIS (30% Acrylamide [BDH], 0.8% N, N' -Methylene-bis- 
Acrylamide [Sigma Chemical Co.] in water), according to the desired percentage of
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acrylamide in the final gel, and 0.3mls of 10% ammonium persulphate solution (BDH). 
To this mixture, 45/^ 1 of Tetra-methyl-ethylene diamine (TEMED) (Pharmacia Biotech, 
St. Albans, U.K.) was added and the gel poured immediately before polymerisation 
occurred. The top of the gel was overlaid with 1ml of distilled water and allowed to set 
for 1-2 hours. The water was removed and the top gel prepared, containing 6mls water, 
1.5mls AC/BIS, 50/d 10% ammonium persulphate, 2.5 mis of (4x)upper gel buffer 
(0.5M Tris-HCl [pH 6.8], 0.4% SDS) and 10/d of TEMED. The upper gel was poured 
on top of the lower gel and allowed to set around a plastic comb. After the upper gel 
had set, the gel was placed into the electrophoresis tank which contained running buffer 
(25mM Tris-HCl, 200mM Glycine [BDH], 1% SDS) and placed under constant current 
at 25mA for 5-10 minutes.
Preparation of bacterial samples for electrophoresis
A 1ml sample of bacterial suspension (after induction of expression if 
appropriate [see 2.5.3]) was centrifuged at 13,800g for 1 minute and the supernatant 
discarded. The pellet was resuspended in 25}A of PBS using a whirlimixer (Fisons). To 
this sample, 25]a\ of 2x-sample buffer was added (50mM Tris-HCl [pH 6.8], lOOniM 
dithiothreitol [Sigma Chemical Co.], 2% (w/v) SDS, 0.1% (w/v) bromophenol blue 
[Sigma Chemical Co.] and 10% (V/V) glycerol [Fisons]) and the sample boiled for 10 
minutes in a water bath. Samples (15//1) were then loaded onto the gel along with one 
lane containing 3-5/d of Rainbow Protein Molecular Weight Markers (Amersham 
International Pic, Little Chalfont, Buckinghamshire, U.K.) and the gel run under 
constant current of 50mA for 1-2 hours.
2.5.2 Western blotting and dot blots
Proteins separated by SDS-PAGE were transferred electrophoretical 1 y onto 
nitro-cellulose membrane (BioRad Trans-blot® Transfer Medium, BioRad Laboratories 
Ltd, Hemel Hempstead, Hertfordshire, U.K.) at 100mA constant current overnight
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using a Mini Trans-blot Electrophoretic Transfer Cell (BioRad). The buffer used for 
transfer contained 1 volume of lOxtransfer buffer (250mM Tris-HCl, 150mM glycine), 
2 volumes of methanol and 7 volumes of water.
The nitro-cellulose membrane was washed twice in PBS before blocking in 3% 
milk powder for 1 hour at room temperature (1% FCS was occasionally used in 
addition to 3% milk powder for blocking). The membrane was washed twice in 
PBS/Tween-20(0.05%)(Sigma Chemical Co.) and incubated for 2 hours with an 
appropriate antibody (see Table 2.5) diluted in 1.5% milk powder in PBS/Tw at room 
temperature. After two washes in PBS/Tw the membrane was incubated for 2 hours at 
room temperature with an appropriate antibody conjugate (see Table 2.6) diluted in 
1.5% milk powder in PBS/Tw. After two washes in PBS/Tw and one final wash with 
PBS, the membrane was exposed to an insoluble horseradish-peroxidase substrate 
solution (lOmg of 3,3'-Diaminobenzidine Tetrahydrochloride [Sigma Chemical Co.] 
dissolved in 15ml Tris Buffered Saline [pH 7.6] with 12/d of fresh 30% Hydrogen 
Peroxide [BDH]) and allowed to develop. The reaction was stopped by immersing the 
membrane in distilled water.
Dot blots were performed by plating cultures onto nitro-cellulose filters 
(Biosupport Membranes, Pall Process Filtration Ltd., Portsmouth, U.K.) which were in 
contact with L-agar plates containing 100//g of ampicillin. After overnight growth at 
37°C the open plates were placed face-down over a chloroform (BDH) bath for 30 
minutes. The nitro-cellulose filters were then washed in PBS and subjected to the 
blotting procedure described above.
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Table 2,5; Primary antibodies for western blots
Antibody Concentration used Source
AnM-L.major gp63 
(mouse monoclonal [mAb 
No. 235])
1:100 dilution Dr. W. R. McMaster, 
University of British 
Colombia, Vancouver, 
Canada.
Anti-L. major p24 
(mouse polyclonal)
1:500 dilution Dr. N. Glaichenhaus, 
Université de Nice, 
France.
Table 2.6: Antibody conjugates
Antibody Concentration Source
Rabbit anti-mouse IgG, 
HRP conjugated
1:1000 dilution BioRad
Goat anti-mouse IgG, HRP 
conjugated
1:1000 dilution Sigma Chemical Co
Rabbit anti-mouse IgG, AP 
conjugated
1:1000 dilution for ELISA 
1:10,000 dilution for 
blotting
Sigma Chemical Co.
Rat anti-mouse IgGl, 
Biotin conjugated
1:16,000 dilution for 
ELISA
Pharmingen
Rat anti-mouse IgG2a, 
Biotin conjugated
1:1000 dilution for ELISA Pharmingen
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2.5.3 Inducing protein expression in bacteria 
Inducing NirB promoter (372)
Overnight broth cultures of bacteria were diluted 30 fold into 7ml screw-cap 
bijou containers with 4mg/ml Glucose (BDH), 100/^g/ml ampicillin in L-broth. The 
tubes were filled as full as possible to limit the supply of oxygen to the bacteria. The 
bacteria were then incubated for 4-6 hours before being analysed for protein 
expression.
Inducing OsmC promoter
Overnight cultures of bacteria were diluted 20 fold in 0.3M NaCl solution in L- 
broth containing 100/fg/ml ampicillin and cultured for 2-4 hours before analysis of 
protein expression was performed.
2.6 Immunisation with Salmonella constructs
2.6.1 Bacterial culture and immunisation
A single colony of S. typhimurium. from an L-agar plate was grown in 0.5-1 
litre of L-broth overnight at 37° C without shaking. The optical density at 600nm of 
this suspension was measured and the bacteria centrifuged at 8670g for 7 minutes at 
4°C using a JA-10 rotor(Beckman) in a High Speed Centrifuge (Beckman). The pellet 
was resuspended in sterile PBS to obtain a bacterial concentration of approximately 2.5 
X 1010/ml, The volume of PBS was calculated from the OD600 reading x 20, per litre 
of suspension. A typical one litre overnight culture has an OD600 of around 0.2 and 
would therefore be resuspended in 4ml of sterile PBS. The bacterial concentration of 
this suspension was checked by plating out dilutions of the suspension on L-agar plates 
after administration.
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Mice received sterile 5% NaHCOg (Fisons) solution orally using a
gavage needle, immediately before Salmonella in order to neutralise stomach pH. The 
Salmonella suspension was administered orally by gavage needle in a volume of 0.2- 
0.4mls. Penetration of internal organs by the bacteria was assessed by killing one 
animal per group, one week after administration, and culturing Mesenteric Lymph 
Node (MLN) homogenates on L-agar plates (as described in 2.6.2) or by measuring 
anti-salmonella antibody responses in the serum of mice 2 weeks after administration 
(2.7.3).
2.6.2 Bacterial growth and plasmid stability in vivo
Bacterial colonisation and plasmid stabilitym vivo was measured by counting 
bacteria recovered from spleens, livers and mesenteric lymph nodes of immunised mice 
as previously described (333). Mice were administered 0.2mls of Salmonella as 
described in 2.6.1 and killed at various time points later. Spleens, livers and mesenteric 
lymph nodes from three mice per time point were placed in lOmls of sterile PBS and 
homogenised using a 15ml glass homogeniser. Ten fold dilutions of this homogenate 
were plated, in triplicate, in a volume of 100/d onto L-agar plates in the presence or 
absence of 100/<g/ml ampicillin (Western Infirmary Pharmacy) and plates grown 
overnight at 37°C. The number of colonies which grew in the absence of ampicillin 
was used to calculate Salmonella colonisation of organs and the number growing with 
ampicillin was used to calculate plasmid stability.
2.7 Immunological analysis
2.7.1 Preparation of parasite antigens
A number of different parasite antigen preparations were used for 
immunological analysis. Parasites were grown in vitro as described in 2.3.2 and
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harvested at 7-10 days after passage. In experiments where live parasites were used, 
these were merely washed twice with sterile PBS, counted and resuspended at the 
required concentration in Complete RPMI, consisting of RPMI 1640 containing 10% 
heat-inactivated FCS, 2mM L-glutamine, lOOU/ml penicillin (Gibco), 100/fg/ml 
streptomycin (Gibco) and SOpiM 2-mereaptoethanol (Sigma Chemical Co.). Formalin- 
fixed parasites were obtained by fixing parasites (2xl0^/ml) in 0.5% formaldehyde 
(Sigma Chemical Co.) in PBS for 5 minutes at room temperature followed by three 
washes in sterile PBS before resuspending in Complete RPMI. Soluble Antigen was 
prepared by freezing and thawing parasites (2xl0^/ml in PBS) 5 times followed by 
centrifugation at 13,800g for 10 minutes. The resulting supernatant was filtered using 
a OASpm filter (Millipore S.A., Molsheim, France) and diluted in Complete RPMI. 
Parasites were also sonicated (20kHz, 1 minute) using a Branson Sonifier 250 (Branson 
Ultrasonics Corporation, Danbury, CT, USA) in PBS (2xl0®/ml) and resuspended in 
Complete RPMI. Salmonella lysate was prepared from an overnight culture of 
BRD509. 1ml of suspension was centrifuged at 13,800g and the pellet resuspended in 
1ml of sterile distilled water and left at room temperature for 10 minutes. The lysate 
was centrifuged again and the supernatant stored at -20°C until used.
2.7.2 Parasite quantitation in footpads
The number of parasites present in infected footpads was quantified as 
previously described (278). At various time points after infection, footpads were 
removed from mice by cutting the foot above the ankle. Footpads were cut into small 
pieces in CSDM in a petri dish (90mm) and then filtered through NITEX. The 
resulting suspension was cultured for 48 hours at 28°C. Plates were then pulsed with 
^H-thymidine at IjwCi per well for 24 hours and harvested using an automatic cell 
harvester. Incorporated radioactivity was counted using a 13-counter (LKB, Betaplate, 
Turku, Finland).
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2.7.3 Induction and measurement of Delayed-Type Hypersensitivity 
(DTH)
Immunised mice were injected in the left-hind footpad with 1x10^ live L. major 
promastigotes in 50/d of PBS. Both footpads were measured at regular intervals for up 
to 96 hours using a spring dial-calliper (Kroeplin). Change in footpad thickness was 
assessed as the footpad thickness of injected footpad minus footpad thickness of 
uninjected.
2.7.4 Measurement of specific antibody responses
Antibody responses were measured in mice immunised 2 weeks previously with 
0.2 mis of S. typhimurium expressing L. major gp63. Blood was obtained by bleeding 
from the retro-orbitalplexus using Heparinised Capillary tubes (Hawksley & Sons Ltd., 
Lancing, Sussex, U.K.) and serum obtained by centrifugation at 350g. An ELISA 
method was used as previously described (278). Soluble L. major antigen (4xlO^/ml), 
recombinant gp63 (Dr. W. R. McMaster, University of British Colombia, Vancouver, 
Canada) or Salmonella lysate diluted in O.IM Na2 C0 3  (pH 8.2) was coated onto 
ImmuIon-4 96-well plates (Dynatech Laboratories Ltd., Billingshurst, West Sussex, 
U.K.) in a volume of 50/fl/well and incubated overnight at 4°C. Plates were washed 
twice in PBS containing 0.05% Tween-20 and blocked with 100/<l/well of 20% FCS in 
PBS and incubated at 37°C for 1 hour. Plates were again washed twice using PBS/Tw, 
and serial dilutions of serum samples added to wells in a volume of 50/<l, before plates 
were incubated for 2-3 hours at 37°C. Serum from infected mice and a monoclonal 
antibody against gp63 (Dr. W. R. McMaster) were used as control serum against gp63. 
Plates were washed 6-8 times in PBS/Tw and then conjugated antibodies added to 
detect IgG, IgG2a or IgGl (Table 2.6) in a volume of 100/d and incubated at 37°C for 
2 hours. ELISA's for IgG2a or IgGl were washed a further 6-8 times and 100/d of 
Extravidin-Peroxidase (Sigma Chemical Co.) added at a concentration of 3/<g/ml. All 
ELI SA's were then washed 8 times in PBS/Tw before developing using TMB
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Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories, Gaithersburg, 
Maryland, U.S.A). The colour change on the plates was measured using a MR5000 
Microplate Reader (Dynatech) at 630nm.
2.7.5 Antigen specific proliferation in vitro
Antigen was prepared as described in 2.7.1 and diluted in Complete RPMI to 
the required concentration before adding 100/d/well to 96-well tissue culture plates 
(Costar). Where Concanavalin A (Sigma Chemical Co.) was used in proliferation 
assays, this was dissolved in Complete RPMI at Img/ml and aliquots stored at -20°C 
until used. Aliquots were then added to Complete RPMI at the required concentration 
and added to 96-well tissue culture plates in 100/d volumes.
Spleen and MLN cells were removed from mice and single cell suspensions 
obtained by gentle homogenisation using a 15ml glass homogeniser. Cells were 
filtered to remove debris using NITEX and washed 3 times in RPMI. Cells were 
resuspended in 2mls of Complete RPMI and again filtered before counting using an 
Improved Neubauer Haemacytometer, under phase-contrast microscopy. The cell 
concentration was adjusted to 4xl0^/ml and 100/d added to each well in quadruplicate 
cultures. Cells were cultured at 37°C in 5% CO2 , pulsed with ^H-Thymidine (l/^Ci per 
well), harvested on an automatic cell-harvester and radioactivity counted in a j3-counter 
(LKB).
2.7.6 Antigen specific cytokine responses in vitro
Cultures were set up exactly as described in 2.7.4 and supernatants collected at 
various times after incubation to assess antigen-specific cytokine production. The 
levels of IL-2, IL-4 and IFN-y were measured by ELISA using paired antibodies 
obtained from PharMingen (Cambridge Bioscience, Cambridge, U.K.). Immulon-4, 
96-well plates were coated with 50/d of the appropriate coating antibody at the
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concentration shown in Table 2.7 diluted in O.IM Na2 C0 3  (pH 8.2). Plates were then 
washed twice in PBS/Tw and blocked with 20% FCS in PBS (200/^1/well) for 1 hour at 
37°C. Plates were again washed in PBS/Tw before samples (in quadruplicate) and 
standard recombinant cytokine dilutions (in duplicate) were added in a volume of 50/^ 1. 
IFN-y was a kind gift from Dr. G. Adolf, Vienna and IL-2 and IL-4 were obtained from 
Genzyme. Plates were incubated for 2 hours at 37°C. Plates were then washed 6-8 
times in PBS/Tw and the appropriate detecting antibody added in a volume of 100/fl, 
diluted to the concentration shown in Table 2.7 in 5% FCS in PBS before incubation 
for 1 hour at 37°C. For the IFN-y ELISA, plates were washed a further 6-8 times in
PBS/Tw before alkaline-phosphatase-conjugated goat anti-rabbit IgG (Sigma Chemical 
Co.) was added in a volume of 100/d/well. Plates were washed 8 times in PBS/Tw 
before 100//l/well of the substrate added (1 mg/ml 3,3'-diaminobenzidine 
tetrahydrochloride in IM Tris, 3mM MgCD and the colour allowed to develop for 20- 
40 minutes. The colour change was measured at OD405nm using a Microplate reader. 
For all other ELISA's, after the biotinylated detecting antibody, plates were washed 8 
times in PBS/Tw before Extravidin-Peroxidase (Sigma Chemical Co.) was added 
(lOO/^l/well) at a concentration of 3/<g/ml in 5% FCS in PBS followed by incubation at 
37°C for 1 hour. Plates were again washed 8 times with PBS/Tw before 100//1 of TMB 
Micro well Peroxidase Substrate was added and the colour change detected using a 
Microplate reader at 630nm.
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Table 2.7; Antibody concentrations for ELISA
Cytokine Primary 
antibody 
(coating conc.)
Source Secondary
antibody
(conc.)
Source
IFN-y R46A2
(10/<g/ml)
DNAX
Corporation
Rb anti-IFN-y 
(5/<g/ml)
DNAX
Corporation
IL-4 Anti-IL-4 MAb Pharmingen Biotinylated 
anti-IL-4 MAb 
(ly^g/ml)
Phamiingen
IL-2 Anti-IL-2 MAb 
(2/fg/ml)
Pharmingen Biotinylated 
anti-IL-2 MAb 
(Ifiglml)
Phanningen
2.7.7 Cell depletion in vitro
The effect of CD4 or CDS cell depletion in vitro on cytokine production was 
assessed by adding anti-CD4 (rat hybridoma YTS 191) or anti-CDS (YTS 169) (19) 
monoclonal antibodies to cultures. Anti-CD4 and anti-CDS were grown as ascites in 
pristane-treated nude mice and partially purified by precipitation with 45% saturated 
ammonium sulphate. Cultures were set up as described in 2.7.5 and antibodies were 
added at lO/^g/ml.
2.8 Statistical analysis
Statistical significance of the data was analysed using Student's t-test. A p 
value of less than 0.05 was considered significant.
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Chapter 3
Immunisation with gp63 delivered orally in attenuated Salmonella typhimurium
(aroA" aroD")
' I98
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3.1 Introduction
An attenuated S. typhimurium construct (SL3261/gp63) expressing L. major 
gp63 has been described previously (278). This construct, when administered orally to 
CBA mice, which are genetically resistant to L. major infection, reduced lesion 
development upon challenge infection. Protective immunity in this model correlated 
with a Thl-like response to parasite antigens when spleen cells were cultured in vitro. 
While this S. typhimurium vaccine reduced lesion development in mice which 
eventually resolve L. major lesions it provided no protection to genetically susceptible, 
BALB/c mice after L. major infection.
The aroA" aroD' vaccine strain BRD509 has been described in detail previously 
(352). This attenuated S. typhimurium strain has two defined genetic disruptions in the 
genes aroA and aroD. Disruption of these genes at the aro locus render the bacteria 
deficient in pathways of aromatic amino acid biosynthesis. The bacteria are therefore 
unable to synthesise a number of products derived from this pathway including 2,3 Di- 
hydroxy-benzoic acid (DHBA), Para-amino benzoic acid (PABA) and the essential 
amino acids (330). The S. typhimurium strain used in the previous vaccine, SL3261, 
has a single deletion at this locus while BRD509 contains two. While this double 
deletion results in increased attenuation of the bacteria and a decrease in the chance of 
reversion to virulence, the effects of this upon the immunogenicity of foreign proteins 
expressed in this strain is unknown. This chapter details the construction of a S. 
typhimurium construct (GIDlOl), based on the strain BRD509, which expresses L. 
major gp63. This construct provides protection to susceptible, BALB/c mice after live 
challenge with L. major. The immune responses induced in mice after oral delivery of 
this construct are also described.
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3.2 Factors affecting oral S. typhimurium delivery
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There are a number of parameters which can influence the ability of S. 
typhimurium to penetrate epithelial cells in vitro, such as bacterial growth state (373), 
and the expression of a number of bacterial virulence factors (374). An attempt was 
made to ascertain the optimal conditions for BRD509 colonisation in vivo with regard 0
to bacterial growth state and stomach pH neutralisation before delivery.
3.2.1 Bacterial growth state
To monitor the effect of bacterial growth state upon colonisation, BALB/c mice 
were immunised orally with 5 x 10  ^attenuated y. typhimurium (BRD509) which had 
been grown in vitro for different periods of time. Eleven days after administration, 
mice were killed, and the number of viable bacteria present in the spleen, liver and 
mesenteric lymph nodes (MLN) deteimined by plating organ homogenates onto L-agar 
plates, as described in Chapter 2. The results of this experiment are shown in Table 
3.1. I
There was efficient colonisation of spleen, liver and mesenteric lymph nodes at |
11 days post administration with cultures of BRD509 grown for both 16 and 24 hours.
The cultures grown for 12 hours did not contain sufficient bacteria to allow an 
assessment of colonisation in vivo. While mice administered 16 or 24 hour cultures did '0
not differ significantly in the number of colonies recovered from the spleen, there was 
considerably more bacteria recovered from the liver and MLN of mice administered the 
16 hour culture. These data confirm that bacterial growth state does impact upon the 
ability to colonise in vivo. All future experiments are based on cultures grown for 16 
hours only.
Table 3.1: Effect of culture times on BRD509 colonisation
Time of culture 
(hours)
No. of colonies per 
SPLEEN (SEM)
No. of colonies per 
LIVER (SEM)
No. of colonies per 
MLN (SEM)
12 N.D. N.D. N.D.
16 320 (35) 2900 (346) * 3100 (404) *
24 690 (283) 490(162) 1300(173)
Cultures of BRD509 were grown for 12, 16 or 24 hours before being orally 
administered to BALB/c mice. After 11 days mice were killed and organs assessed for 
bacterial colonisation. Results show means and SEM from three mice per group. 
N.D. - Not Deteimined. (insufficient bacteria to administer) * p < 0.05 compared to 24 
hour culture.
3.2.2 Pre-dosing with carbonate solution
Some researchers pre-dose animals with sodium bicarbonate before orally 
administering S. typhimurium as a means to neutralise stomach pH and thus prevent 
bacterial killing. Other researchers deliver S. typhimurium directly with no 
neutralisation step. Experiments were conducted to determine if the neutralisation of 
stomach pH using sodium bicarbonate had any effect on the colonisation and survival 
of BRD509 in vivo. BALB/c mice were administered orally 5 x 10  ^ attenuated S. 
typhimurium. (BRD509) with or without oral pre-dosing with O.lmls of 5% Na2 COg 
solution and numbers of viable bacteria in spleen, liver and MLN determined at various 
time points later. The results of this experiment are shown in Figure 3.1.
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A. Spleen300 with carbonate w/o carbonate250 -
200  -
150 -
100  -
50 -
210 7 14 28
B. Liver
0  
mOf1
500 with carbonate 
w/o carbonate400
300
200
100
0 7 14 21 28
C. MLN6000 with carbonate w/o carbonate5000
4000
3000
2000
1000
0 7 14 21 28
days after administration
Figure 3.1; Effect of carbonate solution on colonisation of spleen, liver and MLN by 
BRD509. Each point represents mean and SD of three mice.  ^ p < 0.05 compared to 
with carbonate data.
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This experiment demonstrates that administration of sodium bicarbonate prior 
to BRD509 increases the bacterial colonisation of spleen, liver and MLN. In all future 
experiments mice received sodium bicarbonate before receiving S. typhimurium.
These data also show the colonisation of this attenuated strain in vivo over 
time. BALB/c mice administered 5 xlO^ BRD509 harbour bacteria in the spleen and 
liver until they are essentially eliminated by 2-3 weeks after the dose is given. The 
MLN usually contain considerably more bacteria than spleen or liver and these survive 
for up to 3-4 weeks after administration
3,3 Construction of 5, typhimurium  expressing L. major gp63 
(GIDlOl)
3.3.1 Construction of GID101
The construction of a S. typhimurium construct, based on BRD509, which 
expressed L. major gp63 was accomplished by Dr. D. Xu (Immunology Dept., 
Western Infirmary, Glasgow, U.K). and is described here only briefly. The plasmid 
pkk-Imm63-67 containing the cDNA for L. major gp63 was transferred to BRD509 
using p22 transduction (375) and transductants selected by growth in L-broth 
containing ampicillin. Purified plasmids from colonies which grew on ampicillin were 
verified by restriction enzyme digestion. The S. typhimurium strain BRD509, 
containing the plasmid pkk-Imm63-67, was named GIDlOl.
3.3.2 Expression of gp63 by GIDlOl
Western blotting was performed as described in Materials and Methods to 
assess gp63 expression by the strain GIDlOl. As the plasmid pkk-Imm63-67 contains 
a tac promoter which is constitutively transcribed (276), it was not necessary to induce
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expression. Constitutive expression of gp63 was evident by a band at approximately 
60kDa (Fig. 3.2). The native gp63 is glycosylated.
A B
69K
46K __
30K —
21 .5K  —
14 .3K —
Figure 3.2; Western blot detecting gp63 expression in GIDlOl using mAb no. 235. 
Lane A: BRD509 control. Lane B: GIDlOl.
3.4 Plasmid stability of GIDlOl
3.4.1 Plasmid stability in vitro
Plasmid stability of GIDlOl was assessed in vitro by culturing the construct in 
the absence of antibiotic selective pressure. This experiment was performed by Dr. D.
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Xu. The plasmid was quickly lost in vitro and was not maintained beyond three 
passages in the absence of selective pressure (Dr. Xu, personal communication).
3.4.2 Plasmid stability in vivo
BALB/c mice were orally administered 5 x 10  ^of GIDlOl and plasmid stability 
was assessed at various time points later in spleen, liver and MLN. Plasmid stability 
was assessed by counting the number of recoverable S. typhimurium which were not 
sensitive to the presence of ampicillin in L-agar plates, as described in Materials and 
Methods. Figure 3.3 shows the growth curve of GIDlOl in the spleen, liver and MLN 
of BALB/c mice. The plasmid in GIDlOl is relatively stably inherited by bacteria 
colonising the MLN but bacteria recoverable from the spleen and liver showed
pronounced plasmid loss throughout the course of the experiment.
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Figure 3.3: Plasmid stability of GIDlOl during BALB/c colonisation. Data show 
mean and SEM of three mice per time point. Data are representative of two individual 
experiments. * p < 0.05
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3.5 Protection against L. major infection
BALB/c mice were immunised orally with 2.5-10x10^ of GIDlOl or BRD509. 
Control mice received 0.2 mis of PBS orally. Two weeks later, this vaccination 
procedure was repeated and mice challenged in the footpad with L. major a further 
two weeks later. Mice which received two doses of GIDlOl developed significantly 
smaller lesions and showed a marked delay in the onset of disease compared to mice 
administered BRD509 (Fig. 3.4). Mice administered PBS developed lesions similar to 
those of mice which received BRD509. The lesion development paraWUed the parasite 
load in the infected footpads as assessed by serial dilution analysis of the infected 
footpad tissue, as described in Materials and Methods (Fig. 3.5). Mice administered 
GIDlOl showed less parasite growth in footpad homogenates.
These data demonstrate significant protection against lesion development in 
susceptible BALB/c mice, conferred by GIDlOl. However, it should be noted that this 
protection was insufficient to completely protect against challenge infection. Mice 
eventually developed lesions that necessitated their being killed, complying with Home 
Office guidelines. Notwithstanding, these experiments do clearly show a protective 
response induced by GIDlOl at the early stages of infection and indicate that gp63 
expression in the strain BRD509 confers advantages over the previous strain, SL3261.
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O— BRD509 
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0 .8 -
0.6
0.4 ”
0 .0 #
0 14 21 28 35 42 49 56 637
days after infection
Figure 3.4: Protection againstZ,. major infection by GIDlOl. PBS administered mice 
develop lesions similar to those of BRD509 and are not shown for clarity of figure. 
Data show mean and SEM of six mice per group.
This experiment was repeated twice with similar results and these are the data from 
the first experiment. *p<0.05
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Figure 3.5: Parasite quantitation in infected footpads of mice administered GIDlOl or 
BRD509. Data show mean and SD of three mice per group.  ^p < 0.05
3.6 Immune response to L, major
The immune response to L. major induced by GIDlOl was analysed in vitro. 
BALB/c mice were orally administered twice with either GIDlOl, BRD509 or PBS, as 
described in Materials and Methods. Spleen and MLN cells were removed from these 
mice 3-5 weeks later and stimulated in vitro with parasite antigens. Serum was also 
collected 3-5 weeks after immunisation and antibody responses to L. major antigens 
were assessed, as described in Materials and Methods. In parallel experiments, mice 
were injected with L. major in the footpad in order to measure parasite specific DTH 
responses.
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3.6.1 DTH response
BALB/c mice receiving two oral doses of GIDlOl did not develop a detectable 
DTH response to footpad challenge with L. major promastigotes (data not shown).
3.6.2 Antibody response
Serum from mice vaccinated with two doses of GIDlOl contained significant 
levels of IgG to both recombinant L. major gp63 and Soluble L. major Antigens 
(SLA) (Fig. 3.6). When further analysed, the serum was found to contain significant 
levels of IgG2a to both rgp63 (data not shown) and SLA (Fig. 3.7A) yet no IgGl to 
rgp63 (data not shown) or SLA (Fig. 3.7B) was detected. There was also a significant 
antigen specific IgG and IgG2a response in the serum of mice which had been 
administered the control S. typhimurium strain, BRD509, although this was much less 
than that of mice administered GIDlOl.
3.6.3 Proliferative response in vitro
BALB/c mice were immunised with GIDlOl, BRD509 or PBS twice, orally. 
Spleen and MLN cells were harvested 3-5 weeks later and cultured in vitro with 
formalin-fixed, sonicated or live L. major promastigotes or SLA, as described in 
Materials and Methods. Cells obtained from mice vaccinated with GIDlOl showed a 
strong proliferative response, at three days of culture, to live or sonicated parasites in a 
dose-dependent manner (Fig. 3.8A-B). There was also substantial parasite-specific 
proliferation detected at 5 days of culture (data not shown), although this was 
somewhat reduced in magnitude. These cells also proliferated when cultured with 
formalin-fixed promastigotes or SLA, but the level of response was much lower (Fig. 
3.8C-D). No significant response to any of the above antigens was detected in the cell 
cultures from mice which received PBS or the control S. typhimurium strain, BRD509.
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Figure 3.6; Parasite specific IgG after 2 oral doses of GIDlOl. Serum from 
immunised BALB/c mice was diluted 1:400 and assessed for IgG to rgp63 and SLA. 
Data show mean and SD for three mice per group and is representative of three 
individual experiments. ^p<0.05
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Figure 3.7; Parasite specific IgG2a and IgGl after two oral doses of GIDlOl. Serum 
from BALB/c mice was analysed at various dilutions for IgG isotype responses to 
SLA. Data show mean and SD for three mice and are representative of three individual 
experiments. * p < 0.05
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Figure 3.8 (A-B): Proliferative response of GIDlOl immunised cells to L. major 
antigens. Data show mean and SD of pooled cells from three mice. Data are 
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Figure 3.8 (C-D): Proliferative response of GIDlOl immunised cells to L. major 
antigens. Data show mean and SD of pooled cells from three mice and are 
representative of three individual experiments. * p < 0.05
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3.6.4 Cytokine production in vitro
Spleen and MLN cells from mice immunised orally with GIDlOl, BRD509 or 
PBS were cultured in vitro with SLA, as described in Materials and Methods. The 
SLA antigen preparation has been shown to be optimal in inducing cytokine production 
in this system (278). Cells from mice vaccinated with GIDlOl produced significant 
amounts of IL-2 and IFN-y in response to antigen in a dose dependent manner (Fig. 
3.9A-B). Both the production of IFN-y and IL-2 peaked at 48 hours of culture with 
antigen (Fig. 3.10A-B). In cell cultures from mice immunised with PBS or the control 
S. typhimurium strain, BRD509, there was no detectable production of IL-2 or IFN-y 
in response to antigen at any time point. No antigen specific IL-3, IL-4 or IL-5 was 
detected at any time point in any of the cell cultures (data not shown).
3.6.5 Cell depletion in vitro
Antigen specific IL-2 and IFN-y production was CD4'*'-cell dependent. 
Addition of anti-CD4 antibody (YTS 169), at lO/^g/ml, completely abolished IL-2 and 
IFN-y production in cell cultures from mice immunised with GIDlOl (Fig. 3.11A-B). 
Addition of anti-CD8 antibody (YTS191) at the same concentration did not 
significantly alter cytokine production.
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Figure 3.9: Cytokine production by cells from GIDlOl immunised mice to SLA in 
vitro. Data show mean and SD of cells from three pooled mice.
Data are representative of four individual experiments.
*p<0.05 compared to appropriate BRD509 group.
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Figure 3,10: Time course of cytokine production to SLA (1 x 10^/ml). BALB/c mice 
were orally administered two doses of either PBS, BRD509 (5x10^) or GIDlOl (5x10^ 
or IxlQiO) and stimulated in vitro with SLA 3-5 weeks later. Data show mean and SD 
of pooled cells from three mice per group and are representative of two individual 
experiments. * p < 0.05
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Figure 3.11: Effect of anti-CD4 (YTS 169) and anti-CD8 (YTS191) on cytokine 
production. Data show mean and SD of pooled cells from three mice. Data are 
representative of two individual experiments. * p < 0.05
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3.7 Immune response to S, typhimurium
3.7.1 Antibody response
Serum from mice administered BRD509 or GIDlOl contained significant levels 
of antibody against S. typhimurium (Fig. 3.12). Mice vaccinated with GIDlOl 
contained slightly higher semm IgG responses to S, typhimurium. No anti-5". 
typhimurium antibody was detectable in the serum of mice administered PBS alone.
2.0 PBS
BRD509
GIDlOl
0 .8 -
0 .6 -
0.4-
0.2
-O0.0
serum dilution
Figure 3.12; S. typhimurium specific IgG from serum of mice immunised with 
BRD509 or GIDlOl. Each point represents mean and SD of pooled serum from three 
mice. Data are representative of three individual experiments, * p < 0.05
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3.7.2 Proliferative response in vitro
Spleen and MLN cells from mice administered BRD509 or GIDlOl did not 
proliferate in vitro to a S, typhimurium lysate above background levels detected in 
cultures of cells from PBS administered mice in two individual experiments (data not 
shown).
3.7.3 Cytokine production in vitro
Spleen and MLN cells were cultured in vitro with a lysate from S. typhimurium 
and cytokine levels in supernatants were measured. Cells from mice administered 
GIDlOl or BRD509 produced a substantial level of IFN-y that was greater than the 
background level of IFN-y produced by PBS administered mice (Fig. 3.13).
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8  S. typhimurium lysate
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Figure 3.13; IFN-y production in response to S. typhimurium lysate at 72 hours of 
culture. Data show mean and SD of pooled cells from three mice and are 
representative of two individual experiments.  ^p < 0.05
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3.8 Discussion
The data presented above demonstrate that when L. major gp63 is expressed in 
the attenuated S, typhimurium strain BRD509, this construct provides protection to 
susceptible BALB/c mice upon live challenge. The protection, while not complete, is a 
substantial improvement upon the previous vaccine, SL3261/gp63, which did not 
afford susceptible mice any protection against infection.
Why gp63 expression in the double deletion mutant, BRD509, provides better 
protection than the same protein expressed in SL3261 is not clear. The double deletion 
causes increased attenuation of the bacteria so that they do not persist in vivo as long 
as SL3261 (Fig. 3.3, 278). While BRD509 are not readily detectable after day 21 in 
vivo, SL3261 persists until around day 42 after administration. The factors responsible 
for immunogenicity of recombinant proteins expressed in S. typhimurium are 
unknown. Previous work would suggest that increased attenuation of S. typhimurium 
reduces the immunogenicity of antigens they deliver (332, 333), while the data 
presented here would suggest that the opposite may be true. A more detailed 
comparative study on immunogenicity of proteins expressed in various S, typhimurium 
strains would be needed to address this issue.
The immune response of BALB/c mice after GIDlOl immunisation provide 
data upon the mechanisms involved in the protection from infection observed. There 
was no detectable DTH response in immunised mice to L. major promastigotes. DTH 
responses have been thought to be a good indicator of protective immunity against L  
major (123). There are however reported incidences of protective immunity in the 
absence of any DTH response (125) and thus the protection observed with GIDlOl 
occurring in the absence of a DTH response is not unusual. In as much as DTH 
responses have been associated with Thl cells (131), this data would indicate the 
involvement of other cell types in this protective response.
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Mice immunised orally with GIDlOl produced significantly higher levels of 
leishmania-specific IgG than control groups. The immunised group also contained 
high titres of IgG2a but no IgGl to parasite antigens. These results are consistent with 
the notion that GIDlOl preferentially induced a Th 1-like response to gp63. The 
detection of antigen specific IgG and IgG2a responses in BRD509 immunised mice 
may represent polyclonal B-cell stimulation by Salmonella LPS.
!
Spleen and MLN cells from immunised mice produced substantial levels of 
IFN-y and IL-2 in vitro when stimulated with parasite antigens. These cells also 
proliferated in culture with various parasite antigen preparations, to vaiying degrees.
Cells responded best to live or sonicated parasites but less well to SLA or fonnalin- 
fixed promastigotes. These differences are not due to differences in the kinetics of 
response, as all responses peaked at 2 days of culture, but may represent modification 
of gp63 by different antigen preparation protocols. IL-2 and IFN-y production to fe
antigen was CD4"  ^- cell dependant, further suggesting that there is a predominant Thl - 
like response to gp63 in vaccinated mice.
I
Taken together these data suggest the involvement of a Thl-like response in 
mediating the protection observed using this construct. The absence of DTH response 
may represent the further heterogeneity of T-cell subsets, as has been previously 
suggested (377).
Spleen and MLN cells from mice immunised with GIDlOl or BRD509 
produce more IFN-y in vitro to a Salmonella lysate than mice administered PBS. 
Serum from these mice also contained high levels of S, typhimurium specific IgG. 
There is therefore a strong antibody and cellular response to salmonella antigens 
induced after delivery of these constructs, indicating that the GIDlOl construct may 
function as a bivalent vaccine against both L, major and virulent S. typhimurium 
infection. Challenge of immunised mice with a virulent strain of S. typhimurium 
would be required to confirm this.
These data also confirm previous reports using other S. typhimurium strains 
which detail the effects of various factors upon the ability of the bacteria to colonise 
mice in vivo . As shown above, altering the growth state of S. typhimurium and the 
use of a carbonate solution can significantly alter the numbers of recoverable bacteria 
from immunised mice. The fact that these factors can have a marked effect upon 
colonisation underline the importance of optimising live vaccine delivery conditions, 
although the effects of poor delivery conditions upon immunogenicity have not been 
addressed directly by this study.
3.9 Summary
The vaccine construct GIDlOl represents a considerable improvement over the 
previous vaccine strain SL3261/gp63. GIDlOl, after 2 oral immunisations confers 
reduced lesion development to susceptible, BALB/c mice after L. major challenge 
infection. Spleen and MLN cells from immunised BALB/c mice respond in vitro to 
parasite antigens and produce substantial amounts of IFN-y and IL-2, while no IL-4 or
IL-5 was detected. The production of these cytokines was CD4"^-cel! dependant. 
Serum from immunised mice contain parasite specific IgG2a but no parasite specific 
IgGl. No DTH to L. major was detected in vaccinated mice. These data are 
consistent with the notion that GIDlOl administration results in a protective Thl-like 
response to L. major.
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Chapter 4
Gp63 expression in BRD509 using different promoters
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4.1 Introduction
A significant obstacle in the induetion of immune responses in vivo to 
heterologous antigens expressed in attenuated S. typhimurium is plasmid loss, as the 
bacteria multiply within the host (378). As there is no selective pressure to maintain 
the plasmid in vivo and as the production of a foreign protein in large amounts confers 
a considerable disadvantage in terms of energy expenditure, many plasmids are only 
retained transiently in the mammalian host after administration (Chapter 3, 278). 
Therefore, many S, typhimurium strains which express foreign antigens are poorly 
immunogenic and require repeated dosing to ensure antigen specific immune responses 
are induced (378).
Inducible promoters, which only allow gene transcription under certain 
environmental conditions have been used as a means of conferring greater plasmid 
stability and therefore better immunogenicity to foreign antigens delivered by S. 
typhimurium . The promoter, NirB, which responds to anaerobic conditions has been 
used to express tetanus toxin fragment C (TetC) in an attenuated S. typhimurium strain 
(372). The resulting construct induced strong immune responses to TetC after a single 
oral dose (378). This increased immunogenicity was thought to result from the stable 
retention of plasmid by this bacteria in vivo .
Another inducable promoter, OsmC, has recently been cloned from E. coli and 
is known to respond to changes in environmental osmolarity (D. Xu, Department of 
Immunology, Glasgow).
Both NirB and OsmC were used to express L. major gp63 in the attenuated S. 
typhimurium strain, BRD509, to address whether changes in promoter control would 
allow protection from L. major infection after a single oral dose.
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This chapter describes a comparison of three different S. typhimurium 
constructs which express L. major gp63 under the control of either a constitutive, 
anaerobic or osmotic promoter. The effects of altered promoter control are examined 
with regard to the stability of plasmid in vivo , immune response generated to gp63 and 
protection against challenge infection.
4.2 Construction of S. typhimurium  expressing L. major 
gp63 under different promoter control.
4.2.1 Plasmid construction
Plasmids pNirB/gp63 and pOsmC/gp63 were constructed by Dr. D Xu (Dept, of 
Immunology, Western Infirmary, Glasgow) and consisted of gp63 cDNA inserted 
downstream of promoters NirB and OsmC respectively (Fig. 4.1).
Ampr
P n i r B / g p 6
bps
pBR Ori
Posm
P o s m C / g p 6
3 3900 bps
pBR Ori
Figure 4.1: Construction of plasmids pNirB/gp63 and pOsmC/gp63. The cDNA for L  
major gp63 was inserted downstream of promoters NirB or OsmC. An ampicillin 
resistance gene allows selection for bacteria retaining these plasmids in vitro. These 
plasmids were constructed by Dr. D. Xu (Department of Immunology, Western 
Infirmary, Glasgow).
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4.2.2 Expression of gp63 in vitro
After transformation of the attenuated S. typhimurium strain, BRD509, with 
either pNirB/gp63 or pOsmC/gp63, bacteria strains were termed GID105 
(pNirB/gp63) or GID106 (pOsmC/gp63). Expression of gp63 in GID105 was induced 
under anaerobic conditions, as described in Materials and Methods, and detected by 
western blot using a monoclonal antibody (mAb No. 235). Strain GID105 did not 
express any gp63 under non-inducing conditions but a product was detected, at the 
correct molecular weight after induction under anaerobic conditions (Fig. 4.2). 
Expression of gp63 by GID106 was also assessed using western blot, with and without 
induction using high salt conditions, as described in Materials and Methods (Fig, 4.2). 
In this strain, there is detectable gp63 expression before induction which is further 
upregulated under inducing conditions.
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Figure 4.2; Western blot for gp63 in E coli (A) and S. typhimurium (B) constructs 
using mAh No. 235. A. gp63 expressed in E. coli a: pkk/gp63; b: NirB/gp63 (aerobic); 
c: NirB/gp63 (anaerobic); d: Osm/gp63 (high salt); e: Osm/gp63 (low salt);f: control. 
B. gp63 expressed in S. typhimurium a: BRD509; b: GID106 (high salt); c: GID105 
(anaerobic); d: GIDlOl.
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4.2.3 Plasmid stability in vitro
Plasmid stability of GID105 and GID106 was monitored in vitro, in the absence 
of antibiotic selective pressure, by repeated culture on L-Agar, as described in 
Materials and Methods, This experiment was carried out by Dr. D. Xu. As shown in 
Table 4.1, while GID105 showed no plasmid loss in vitro after 6 days in the absence 
of ampicillin, GIDlOl and GID106 experienced significant plasmid loss.
Day of culture GIDlOl (pkk) GID105 (NirB) GID106 (Osm)
1 85 100 84
2 82 100 82
3 78 100 76
6 6 100 23
Table 4.1; Plasmid stability of GIDlOl, GID105 and GID106 in vitro in the absence 
of ampicillin. Data show number of colonies, from an initial 100, which retain 
ampicillin resistance after culture without antibiotic selective pressure. Data are 
representative of three experiments.
4.2.4 Plasmid stability in vivo
Plasmid stability of GID105 and GID106 was assessed in the spleen, liver and 
MLN of BALB/c mice after oral delivery. Figure 4.3 shows that, similar to the in vitro 
results, GID105 shows virtually no plasmid loss in vivo throughout the period of 
colonisation in all these organs. There were, however, significant differences in the 
numbers of recoverable bacteria when compared with the control strain BRD509 (Fig. 
3.1). Although mice administered GID105 did not harbour bacteria after 28 days, there 
was a markedly higher number of bacteria harvested from all organs during the period 
of colonisation when compared to BRD509. In the spleen and liver there was a 10-100
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fold increase in bacteria while there was about a four fold increase in bacteria 
recovered from MLN.
GID106 showed very poor plasmid stability in vivo , with bacteria at around 7 
days after administration showing approximately 50% plasmid loss (Fig. 4.4). There 
were also differences in the colonisation capacity of this strain when compared to the 
control strain BRD509. There was no colonisation of spleen or liver at all, although 
MLN colonisation levels did not differ from BRD509 controls.
Recovered colonies of GID105 and GID106 that were ampicillin resistant were 
also able to express gp63 under inducing conditions, as assessed by western blot (data 
not shown).
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Figure 4.3; Plasmid stability of GID105 during colonisation of BALB/c mice. Data 
show mean and SEM of three mice per time point. Data are representative of two 
individual experiments.
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Figure 4.4: Plasmid stability of GID106 during colonisation of BALB/c mice. Data 
show mean and SEM of three mice per time point. Data are representative of two 
individual experiments.
* p< 0.05
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4.3 Immune response to L, major gp63 after a single oral
administration.
The immune response to gp63 after a single oral administration of either 
BRD509, GIDlOl, GID105 or GID106 was analysed in BALB/c mice. Mice were 
orally administered IxlO^^ bacteria, and spleen and MLN cells were harvested three 
weeks later to examine in vitro responses to antigen, as described in Materials and 
Methods. Serum was also collected at this time and used to measure IgG responses to 
gp63.
4.3.1 DTH response
BALB/c mice which received one oral dose of either GIDlOl, GID105, 
GID106 or the control S. typhimurium strain, BRD509, did not develop a detectable 
DTH response to live L. major challenge in the footpad (data not shown).
4.3.2 Antibody response
Measurement of IgG to recombinant gp63 and soluble L. major antigen (SLA) 
in the serum of immunised mice was determined by ELISA, as described in Materials 
and Methods. Serum from BALB/c mice which were administered one dose of either 
GIDlOl, GID105, GID106 or the control strain BRD509 three weeks previously, was 
diluted 1:40 and antigen specific IgG measured. As shown in Figure 4.5, there was a 
detectable response to SLA generated by all constructs which expressed gp63 while 
there was no specific response in the serum of BRD509 immunised mice. A similar 
pattern of IgG response was measured when recombinant gp63 was used as the antigen 
(data not shown). All constructs produced a low level of response compared to two 
dose administration of GIDlOl (Fig. 3.6) and there was no significant difference in 
magnitude of response between the constructs.
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Figure 4.5; Parasite specific IgG after one oral dose of either GIDlOl, GID105, 
GID106 or control strain BRD509 (5x 10  ^bacteria). Data show IgG responses in 1:40 
serum dilution against SLA. The background OD630 value of control mice 
administered PBS (0.107) has been subtracted from each value. Data show mean and 
SD for three mice per group and is representative of three individual experiments.
* p < 0.05 compared to BRD509 value.
4.3.3 Proliferative response in vitro
Proliferation of spleen and MLN cells from immunised mice to live L. tnajor 
was determined, as described in Materials and Methods. Cells from mice administered 
one dose of GID105 showed substantial levels of proliferation to live L. major at five 
days of culture, while no antigen specific proliferation was detected at this time point 
from cells of mice administered one dose of GIDlOl, GID106 or BRD509 (Fig. 4.6). 
Cells from all groups of mice did not proliferate to parasites at 3 days of culture (data 
not shown).
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Figure 4.6; Proliferative response of cells from mice administered one oral dose of 
1x101° of BRD509, GIDlOl, GID105 or GID106 when cultured in vitro with live L  
major. Data show mean and SD of pooled cells from three mice after subtraction of 
background value in PBS control cultures, due to parasite proliferation (67,670 cpm). 
Data are representative of two individual experiments,
* p < 0.05 compared to BRD509 values.
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4.3.4 Cytokine production in vitro
Levels of IFN-y, IL-2 and IL-4 were measured in culture supernatants of 
parallel cultures to those above. Cells used in these cultures were incubated in vitro 
with SLA at various concentrations and supernatants harvested at different time points 
later. Cells from mice administered one dose of GID105 produced IFN-y in vitro in 
response to antigen while mice administered PBS, BRD509, GIDlOl or GID 106 did 
not (Fig. 4.8). There was no detectable IL-2 or IL-4 production in any of these cultures 
(data not shown).
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Figure 4.7: IFN-y production in vitro from cells stimulated with SLA. Mice were 
immunised with one dose of PBS of 5x109 BRD509, GIDlOl, GID105 or GID106 
before spleen and MLN cells were placed in culture 3 weeks later. Data show mean 
and SD of cells from three pooled mice and are representative of two individual 
experiments. * p < 0.05 compared to BRD509 values.
4.4 Protection against Leishmaniasis
The three constructs, GIDlOl, GID 105 and GID 106 were compared for their 
ability to protect BALB/c mice against L. major and infection after a single oral dose 
of 5x1 Q9 bacteria. Protection against L. donovani infection after two oral doses was 
also examined.
4.4.1 Protection against L, major infection
BALB/c mice were administered one oral dose of either BRD509, GIDlOl, 
GID 105, GID 106 or were given PBS only. Two to three weeks after vaccination, mice
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were challenged with 1x10^ L. major promastigotes in the footpad and lesion 
development was monitored to assess vaccine efficacy. Mice administered GIDlOl 
showed no protection against infection after a single oral dose (Fig. 4.8A). GID 105 
conferred significant protection against L. major infection as lesion swelling was 
reduced during the infection compared to control mice (Fig. 4.8B). GID 106 also 
conferred significant protection against infection but to lesser degree than GID 105 
(Fig. 4.8C). Although lesion development was reduced using GID 105 and GID 106, 
mice did eventually succumbed to progressive infection at a later stage, similar to the 
results observed with two dose GIDlOl protection.
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Figure 4.8: Protection against L. major infection after one oral dose of either GIDlOl, 
GID 105 or GID 106. Mice were challenged with 1x10  ^ L. major promastigotes 2-3 
weeks after receiving bacteria. Data show mean and SEM of six or seven mice per 
group and are representative of two individual experiments,
 ^p < 0.05 compared to BRD509 values.
4.4.2 Protection against L. donovani infection
BALB/c mice administered two oral doses (IxlO^O) of either construct were 
challenged intravenously with 1x10^ L. donovani amastigotes, three weeks after the 
last dose. Five mice per group were sacrificed at 2 and 4 weeks after infection and 
liver impressions stained and counted to determine infection levels. LDU's were 
calculated for individual mice, as described in Materials and Methods. Mice 
vaccinated with GID 105 showed considerable reductions in parasite burdens at 2 and 4 
weeks after infection while GIDlOl or GID 106 vaccinated mice did not differ 
significantly from controls (Fig. 4.9).
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Figure 4.9: Protection against L. donovani infection after 2 oral doses with either 
GIDlOl, GID 105 or GID 106 (1x10^^). Data show mean and SEM of 5 individual mice 
per group. ® p < 0.05 compared to PBS controls.
4.5 Discussion
The ability to confer protective immunity to any pathogen after a single vaccine 
administration of is extremely advantageous. The requirement for multiple doses of 
certain current vaccines represents a impediment to large scale vaccine coverage of 
populations. A vaccine requiring only a single oral dose would be particularly 
advantageous when considering vaccinating against a major disease of the developing 
world, such as leishmaniasis, where considerations of cost are particularly important.
While the S, typhimurium construct, GIDlOl, provides a degree of protective 
immunity after two oral administrations, this chapter describes two other BRD509
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based constructs which use inducable promoters. There is evidence to suggest that the 
use of such promoters can allow the generation of strong immune responses to antigens 
delivered in S. typhimurium after a single dose (378).
The construct GID 105, expresses gp63 under anaerobic conditions. The control 
of expression is extremely tight, with no product detected as the bacteria grow in 
aerobic conditions. This construct also shows stable plasmid retention even in the 
absence of antibiotic selective pressure both in vitro and in vivo , which may be due 
directly to the efficient promoter control of gp63 expression. This strain behaves 
differently to the control strain BRD509 in vivo in that it colonised at a much higher 
level in all organs examined, although was still cleared in vivo after 28 days. Why this 
increased colonisation occurs is unclear, but it is possible that the expression of gp63 
by this construct provides some protection against adverse conditions within the host 
macrophage due to the proteolytic activity of gp63 (46).
The construct GID 106 shows sudden plasmid loss in the absence of selective 
pressure in vitro and in vivo . This may be due to the incomplete control of expression 
associated with this construct, as even under non-inducing conditions a product is 
detectable by western blot. This construct also has a different colonisation pattern in 
vivo compared with BRD509 as there are no detectable bacteria present at any time 
point in the liver or spleen, although MLN colonisation occurs normally. As little is 
known of this promoter, it is difficult to speculate as to why its use should apparently 
increase the attenuation of the bacteria in vivo. It may be that the use of the OsmC 
promoter to express gp63 may interfere with necessary metabolic pathways within the 
S. typhimurium as it colonises in vivo. Further studies on both the NirB and OsmC 
promoter are required to determine why they have such profound effects upon BRD509 
colonisation in BALB/c mice.
All constructs (GIDlOl, GID 105 and GID 106) were able to induce a detectable 
antibody response to gp63 after a single oral delivery but only the anaerobic construct,
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GID 105 was able to generate a substantial cellular response to antigen. As was the 
case with two doses of GIDlOl (Chapter 3), this response was of a Thl-type in that 
IFN-y but no IL-4 was produced in response to antigen in vitro., although the magnitude 
of the response was much reduced.
After a single oral delivery, GID 105 was also able to reduce lesion swelling in 
susceptible BALB/c mice upon challenge infection whereas a single dose of GIDlOl 
conferred no protection. Therefore, the ability to generate protective immunity after a 
single oral administration correlated with a Thl-like response in vitro to parasite 
antigens and not with the ability to generate antibody responses to gp63. The ability to 
generate a protective cellular response by this construct after a single dose may be due 
to the stable plasmid retention in vivo or may be due to the increased capacity to 
colonise organs during administration, compared with the GIDlOl strain.
The osmotic construct, GID 106, which did not produce demonstrable cellular 
responses to antigen in vitro was still able to confer a degree of protection to L. major 
challenge infection. The mechanism of protection in this system is not clear and 
requires further study.
As in the case of the protection associated with the administration of two doses 
of GIDlOl (Chapter 3), the protection conferred by a single oral dose of GID 105 or 
GID 106 is incomplete. Although vaccinated mice develop smaller lesions after 
infection, these lesions do not cure. While this is disappointing, it may reflect the 
maximum capacity for this single antigen to provide protection to susceptible mice. 
Previous vaccine work with gp63 in BALB/c mice has either demonstrated incomplete 
protection (257, 272, 277) or none at all (275, 278), depending upon the method of 
antigen delivery. Investigators have shown that gp63 expression by the parasite is 
down-regulated upon macrophage entry and may not be expressed at all on the 
amastigote stage of leishmania parasites (47). Recent work has shown that the 
vaccination of BALB/c mice with gp63 and IL-12 does not protect against infection
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(379), while the delivery of SLA (256) or p24/LACK (379) under this regime provides 
complete protection. Therefore, the work detailed in this chapter may represent the 
optimisation of a live vaccine using a poor vaccine candidate and reflect the maximum 
capacity of gp63 to provide protective immunity to susceptible mice. The 
identification of better vaccine candidates and the use of these in this S. typhimurium 
system, either alone, or in combination with a gp63 construct may allow for the 
production of a vaccine which completely protects the susceptible BALB/c mouse 
against L. major infection.
While gp63 seems to be of limited use in protecting susceptible mice against 
cutaneous Leishmaniasis the use of the construct GID 105 in vaccinating against L. 
donovani infection is more encouraging. When BALB/c mice were administered two 
oral doses of this construct, this resulted in a 70% reduction in LDU after parasite 
challenge. Although these studies did not examine parasite burdens at later time points 
it does suggest that this vaccine may have some potential against visceral 
leishmaniasis. A more complete study of this vaccine in L. donovani infection is 
required to address whether sterile immunity results at later time points.
4.6 Summary
L. major gp63 was expressed in S. typhimurium strain, BRD509, under the 
control of either the NirB promoter which responds to anaerobic conditions (GID 105) 
or OsmC which is induced under high salt conditions (GID 106). The construct 
GID 105 shows extremely stable plasmid retention as it colonises in vivo when 
compared with the constitutive construct GIDlOl. The construct GID 106 does not 
colonise spleen or liver at all after oral delivery and loses plasmid more quickly than 
GIDlOl in vivo , An antibody response to gp63 is generated in BALB/c mice after one 
oral dose of GIDlOl, GID 105 or GID 106, while only the anaerobic construct GID 105 
is able to induce a significant cellular response to antigen after a single oral dose. 
Spleen and MLN cells from mice administered with GID 105 respond in vitro in a Thl -
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like manner. A single oral delivery of GID 105 or GID 106 is sufficient to reduce lesion 
swelling in susceptible mice after L. major infection, while a single dose of GIDlOl 
does not confer any protection. Two doses of GID 105 also provides protection against 
L. donovani infection, while GIDlOl or GID 106 do not.
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Chapter 5: p24/LACK expression in BRD509 Vaccination against L, major
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5.1 Introduction
The immune response at the very early stage of L. major infection is thought 
to be critically important in determining the outcome of disease. Therapeutic 
intervention in susceptible mice using ÏL-12 or anti-IL-4, allow the development of a 
Thl response and eventual cure from disease (142, 191, 192). However, the timing of 
such intervention determines its eventual success in the highly susceptible, BALB/c 
mouse. If intervention is delayed until after the first two weeks after infection, when 
there is still no apparent clinical disease, the dominant Th2 response has already 
established and intervention is ineffective. Therefore, the polarisation of T-cell subsets 
occurs very early after infection and is not readily altered once established.
The factors responsible for the divergent polarisation of T-cells seen in 
susceptible and resistant mice in response to L. major infection are not known but 
there are a number of plausible suggestions. Among the factors which are known to 
affect T cell polarisation in vitro or in vivo are: the cytokine environment at the time 
of antigen challenge; the antigen type; and the route of immunisation used to deliver 
antigen (98). A recent study addressed the possibility that different antigens are 
responsible for T cell polarisation in L. major infection (380). This involved the 
analysis of T-cell receptor usage after infection in susceptible and resistant mice. It 
was shown that there is a restricted expansion of Vo8Vp4 bearing T-cells in both 
susceptible and resistant mice early after infection, indicating that there may be a 
response to the same immunodominant antigen in both strains of mice. While this does 
not completely rule out the possibility that different antigens may be responsible for 
divergent T-cell subsets in some cases, it does suggest that T-cell polarisation during 
early L. major infection may result from altered responses to the same 
immunodominant antigen. Therefore, the induction of a Thl response to this antigen in 
susceptible mice may be an effective vaccine strategy. Indeed, this antigen, 
p24/LACK, was recently cloned and used to vaccinate susceptible mice in combination 
with recombinant IL-12 (379). These mice were shown to be completely protected
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against challenge infection and developed strong Thl responses early after parasite 
challenge.
This chapter describes the construction of S. typhimurium strain GID202 which 
expresses p24/LACK under the control of the anaerobic NirB promoter. The use of 
this construct in vaccination against L. major infection is discussed as well as the 
immune responses induced in BALB/c mice after oral delivery of this construct.
5.2 Construction of GID202
5.2.1 Construction of plasmid pNirB/p24
The cDNA for p24/LACK was amplified by PCR from plasmid pET-LACK.ôl 
(obtained from Prof. N. Glaichenhaus, University of Nice, Nice, France.). Primers 
were constructed which contained restriction enzyme sites for BamHl and Ndel, as 
shown in Figure 5.1A. The amplified product was approximately 0.5 kB in size (Fig. 
5.2) and was purified from an agarose gel by "freeze-squeeze" purification (see 
Materials and Methods). Both the plasmid, pNirB/gp63 and the p24/LACK PCR 
fragment were digested using BamHl and Ndel restriction enzymes (Fig. 5.3) and the 
digested DNA purified from agarose gels using the "freeze-squeeze” purification 
method. Digested p24/LACK cDNA and digested pNirB were ligated overnight, as 
described in Materials and Methods (Fig. 5. IB).
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Fig 5.1A: PCR amplification of p24/LACK (showing restriction enzyme sites and start codon).
5' primer
ATG
Nde- P24/LACK cDNA 1
3 ’ primer
Fig 5.IB; Coloning of p24/LACK into pNirB/gp63 (Showing pNirB/gp63 digestion with Nde-1 and BamH-1 followed by ligation with digested p24/LACK PCR fragment).
NirB promoter L. major gp63  
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pN»rB/qp63 
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P24/LACK oDNA pNirB (d iges ted)
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digested p24/LACK PCR product
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Figure 5.2; PCR amplification of cDNA for P24/LACK using pET-LACK.ôl as a 
template. The product was approximately 0.5Kb in size. Lane A: no plasmid control. 
Lane B: O.lpg plasmid. Lane C: O.Spig plasmid. Lane D: l.Opig plasmid.
A B C Dn
Figure 5.3: Agarose gel showing BamHl and Ndel digestion of both p24/LACK PCR 
product and the plasmid pNirB/gp63. Lane A: Ikb markers. Lane B: p24 PCR cDNA. 
Lane C and D: pNirB/gp63.
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The resulting ligation mix was used to transform TGI E. coli by heat- 
shocking in CaCl2 , as described in Materials and Methods. Plasmid was purified from 
clones which grew on L-agar in the presence of ampicillin and these plasmids were 
digested to determine if successful ligation had occurred (Fig. 5.4). A number of 
colonies which contained the correct pattern of restriction digestion were grown and 
analysed for protein expression by dot blot.
A B C D E F G H
Figure 5.4: Digestion of plasmids from ligated clones grown on ampicillin L-Agar 
after bacterial transformation. Six clones were chosen and plasmid prepared and 
digested as described in Materials and Methods. (Top) A: IkB markers; B: clone 1 
undigested; C: clone 1, EcoR I and Pst I (O.SkB); D: clone 1, EcoR 1 and A va I 
(0.6kB); E: clone 2, undigested; F: clone 2, EcoR I and A va I; G: clone 3, undigested; 
H: clone 3, EcoR I and A va I. (Bottom) A: IkB markers; B: clone 4 undigested; C: 
clone 4, EcoR I and Pst I (O.SkB); D: clone 4, EcoR I and A va 1 (0.6kB); E: clone 5, 
undigested; F; clone 5, EcoR I and A va I; G: clone 6, undigested; H: clone 6, EcoR 1 
and A va 1.
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5.2.2 Dot blot of TG l/pNirB/p24
A number of colonies were screened by dot blotting, using a murine derived 
polyclonal antiserum against p24 (Fig. 5.5). A number of transformed TGI colonies 
were stained using this antibody, and these were chosen for further westen blot 
analysis.
Figure. 5.5; Dot blot of TGl/pNirB/p24 using a polyclonal antiserum against 
p24/LACK. Colonies expressing p24/LACK were stained using a HR? conjugate.
5.2.3 Western blotting
A western blot of TGl/pNirB/p24 lysates also showed considerable cross­
reactivity at a number of protein bands, although there was detection of a protein band 
at the correct molecular weight in the transformed bacteria that was not present in TGI 
controls or uninduced bacteria (Fig. 5.6A).
After electroporation of pNirB/p24 into BRD509, further western blots were 
performed to detect expression of p24 by this construct (Fig. 5.6B). Again, there were 
a number of cross-reactive antigens detected by this anti serum although again there
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was detection of an induceable protein that corresponded to the correct molecular 
weight. Various alterations to the blocking stage of the blotting procedure such as 
blocking with 10 or 20% FCS did not remove the majority of the cross-reactive 
proteins deteeted. Similar problems have been encountered using this antiserum to 
detect p24 expression in BCG (Prof. N. Glaichenhaus, unpublished observations). 
There is currently no monoclonal antibody against this protein as it has only been 
recently described. While the polyclonal antiserum shows considerable crossreaction 
with a number of bacterial antigens, the consistent detection of a protein band at the 
correct molecular weight which is only expressed under anaerobic stimulus suggest 
that p24/LACK is being expressed in this construct, which was termed GID202.
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Figure 5.6: Western blot of p24/LACK expression in TGl and BRD509. Blotting was 
performed as described in Materials and Methods. TGI A: TGl/NirB/p24 (anaerobic); 
B: TGl/NirB/p24 (aerobic); C: TGI (anaerobic); D: TGI (aerobic). BRD509 A: 
BRD509/NirB/p24 (anaerobic); B: BRD509/NirB/p24 (aerobic); C: BRD509 
(anaerobic); D: BRD509 (aerobic).
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5.3 Plasmid Stability
5.3.1 Plasmid Stability in vivo
After oral administration of BALB/c mice with 1 x 10^° GID202 bacteria 
spleen, liver and mesenteric lymph nodes were removed at various time points to 
determine bacterial growth in vivo and plasmid stability, as described in Materials and 
Methods. Stable inheritance of the plasmid was observed in all organs examined (Fig. 
5.7).
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Fig. 5.7: Plasmid stability of GID202 in vivo . Bacteria (1 x 10^°) were administered 
orally and colonies in spleen liver and MLN detected at various time points after 
administration. Data represent mean and SEM of 3 pooled mice.
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5.4 Vaccination against L. major
The construct GID202 was used to vaccinate resistant, CBA, and susceptible, 
BALB/c, mice against L, major infection. Mice were administered orally with one or 
two doses of 1 X bacteria (either BRD509 or GID202) or were given PBS only. 
Three weeks after the last dose, mice were challenged in the footpad with 5 x 10"^  L. 
major promastigotes and lesions monitored to assess infection. In some experiments, 
BALB/c mice were injected sub-cutaneously with recombinant p24/LACK in the 
footpad and also received a single intra-peritoneal injection of recombinant IL-12 
(lOOng) before infection with L. major.
5.4.1 Vaccination of CBA mice
CBA mice which received one oral dose of GID202 before infection 
demonstrated a slight decrease in lesion development compared with BRD509 treated 
mice (Fig. 5.8A). CBA mice which received two oral doses of GID202 developed 
significantly smaller lesions at the early stage of infection compared with control mice 
but then later developed a profoundly exacerbated infection (Fig. 5.8B). Mice given 
two oral doses of GID202 had a mean peak lesion size which was approximately 100% 
greater than controls (1.008 +/- 0.139 compared with controls of 0.489 +/- 0.041 [PBS] 
and 0.442 +/- 0.058 [BRD509].
5.4.2 Vaccination of BALB/c mice
BALB/c mice which were administered one or two oral doses of GID202 three 
weeks before infection with L. major also developed exacerbated lesions compared to 
mice administered BRD509 or PBS (Fig. 5.9A and B). Control mice administered two 
subcutaneous injections of recombinant p24 and IL-12 had reduced lesion sizes, as 
previously reported (379).
- i / i
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Figure 5.8; Exacerbation of L. major infection in CBA mice by GID202. Mice 
received one (A) or two (B) oral doses of GID202, BRD509 or PBS before challenge 
with 5x1 Q4 L. major three weeks later. Each point represents mean +/- SEM of six 
mice per group. The data are representative of two individual experiments. * p < 0.05 
compared to BRD509 control mice.
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Fig. 5.9: Exacerbation of L. major infection in BALB/c mice by GID202. Mice 
received one or two oral doses of either GID202, BRD509 or PBS before infection 
with 5 X 10"^  L. major three weeks later. Each point represents the mean and SEM of 
six mice per group except the p24 + rIL-12 group which shows the mean and SEM of 
four mice. Data are representative of two individual experiments. * p < 0.05 compared 
to BRD509 controls.
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5.5 Immune response in vaccinated BALB/c mice
5.5.1 DTH response
BALB/c and CBA mice administered one or two oral doses of GID202 did not 
develop a detectable DTH response when injected subcutaneously with live L. major 
in the footpad (data not shown).
5.5.2 Proliferative response in vitro
Spleen cells from BALB/c mice which received one oral dose of GID202 were 
cultured in vitro with the immunodominant peptide from p24 (previously 
demonstrated to account for the majority of class II, I-E^ restricted responses [Prof. 
Glaichenhaus, personal communication]) or with recombinant p24 to assess recall 
responses to this antigen in vitro . Antigen specific proliferation occuiTed in cultures of 
cells from GID202 administered mice in response to peptide while no proliferation was 
observed in control cultures (Fig. 5.10). Cells from mice immunised with GID202 also 
proliferated in vitro in response to recombinant p24, although control cultures also 
demonstrated a degree of proliferation presumably due to contaminants in the p24 
preparation.
5.5.3 Cytokine response in vitro
Cells from GID202 administered mice also produced substantial amounts of 
IFN-y in response to peptide in vitro (Fig. 5.11 A) while there was no detectable IL-4 
production in any of the cultures (data not shown). These cells also produced IFN-y 
but no IL-4 in response to rp24 although at the highest concentrations of antigen, 
control cultures also produced IFN-y (Fig. 5.1 IB).
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F ig . 5 .10 ; Proliferation to the immunodominant peptide of p24 
(FSPSLEHPIVVSGSWD) and recombinant p24 by spleen and MLN cells from 
BALB/c mice immunised with either BRD509, GID202 or PBS only. Data represent 
mean and SD of pooled cells from 3 mice. * p < 0.05 compared to BRD509 group.
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Fig. 5.11; Antigen specific IFN-y production in vitro by spleen and MLN cells from 
immunised mice. Data represent mean and SD of pooled cells from 3 mice. p < 0.05 
compared to BRD509 group.
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5.6 Discussion
A S, typhimurium  construct was created which has the plasmid 
pNirB/p24/LACK, containing the cDNA encoding p24/LACK of L. major placed 
downstream of the inducible NirB promoter. This construct expresses a product of 23 - 
24KDa under anaerobic conditions which can be detected by western blot using a 
polyclonal antiserum against p24/LACK. This product is not expressed in the control 
strain BRD509 in aerobic or anaerobic conditions. Although other bands were detected 
by this anti serum the 23-24KDa band is likely to represent p24 production. A 
monoclonal antibody against p24 is currently being developed to confiim this.
After oral administration of GID202 to BALB/c mice, the construct can be 
found in the MLN 3 days later and persists for up to 3 weeks. Spleen and liver 
colonisation also take place but at a much lower level, similar to that observed with the 
control strain BRD509 (Chapter 3). The numbers of bacteria which were grown on L- 
Agar and L-Agar containing ampicillin were very similar, indicating that little plasmid 
segregation had occurred in vivo, as previously noted using the NirB promoter (Chapter
4).
BALB/c mice which received one or two oral doses of GID202 displayed 
profound exacerbation of disease after L. major infection compared to control mice, 
while mice administered subcutaneously with recombinant p24 and IL-12 were 
protected from disease. CBA mice administered two doses of GID202 also developed 
exacerbated infection after challenge. Thus, subcutaneous immunisation with p24 
generated a protective response, while oral immunisation with the same antigen 
expressed in S. typhimurium caused exacerbation of infection. The diverse course of 
infection after these immunisation protocols using p24 indicate that responses to this 
antigen may be critical in determining the outcome of disease. Therefore this antigen 
represents a good candidate antigen for vaccination against leishmaniasis although
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these data indicate that attenuated S. typhimurium may not be appropriate vaccine 
vectors in this instance.
A weak protective response was induced in CBA mice which received a single 
oral dose of GID202 while mice receiving two doses exacerbated infection, suggesting 
that the induction of exacerbation and protective immunity using p24/LACK may 
depend on the dose of antigen administered. Further experiments with vaiying doses of 
GID202 will be required to examine the effects of antigen dose upon the generation of 
protective immunity or exacerbation.
Although CBA mice administered GID202 did eventually cure of infection the 
exacerbation seen after 2 oral doses of this construct demonstrate that vaccination can 
generate an inappropriate response to antigen which can impair the generation of 
natural resistance. If p24/LACK is to be used as a vaccine in the future care must be 
taken to avoid the generation of such inappropriate responses. It will be of interest to 
determine whether further doses of GID202 before challenge can generate a non­
healing response in these animals.
A Thl response is induced after subcutaneous immunisation with p24 and IL- 
12 which accounts for the protective response obseiwed using this vaccination protocol 
(379). Surprisingly, cells from mice immunised with GID202 responded in vitro to 
p24 or a peptide from p24 by producing IFN-y but no IL-4, similar to the response 
generated using the gp63 construct (Chapter 3 and 4). Thus exacerbation did not 
correlate with the presence of a Th2-like response to p24 as may be expected. The 
generation of a Thl response which correlates with exacerbation suggests that further 
diversity of T cell subsets may exist, as previously suggested (377). A Th 1-like cell 
clone which transfers exacerbation to resistant and susceptible mice has been described 
previously (127). However, exacerbation of infection is unlikely to be due directly to 
the production of IFN-y, as IFN-y can activate macrophages to kill resident parasites 
and can block Th2 cell induction (143, 155). Other cytokines such as ÏL-10 and TGF-(3
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which have been shown to inhibit protective responses may be involved in the 
exacerbation observed here. An examination of these possibilities will require further 
in vitro and in vivo studies.
These data demonstrate that delivery of antigens to the immune system using 
attenuated S. typhimurium may not always generate a protective response and may in 
fact have an adverse effect upon disease. A detailed examination of immune responses 
induced after vaccination with heterologous S. typhimurium is required in order to 
understand the relative merits and pitfalls associated with this system.
5.7 Summary
A plasmid was generated which contains the cDNA for p24/LACK under 
control of the inducible NirB  promoter. This plasmid was introduced into the 
attenuated S. typhimurium strain BRD509. Expression of p24 by this construct 
(GID202) under anaerobic conditions was demonstrated by western blotting. After oral 
administration of GID202 to BALB/c mice bacteria were detected in the spleen, liver 
and MLN until 21-28 days later. Plasmid stability of the construct during colonisation 
was found be around 100%. BALB/c mice which were orally administered one or two 
doses of GID202 before L. major infection developed exacerbated disease. CBA mice 
given two oml doses of GID202 also generated an exacerbated infection although CBA 
mice which received a single dose were slightly protected. Spleen and MLN cells from 
mice administered GID202 responded in vitro in a Th 1-like manner to both 
recombinant p24 and the immunodominant peptide of p24. These data demonstrate a 
disease-promoting effect of vaccination with p24 expressed in S. typhimurium which 
correlates with a Thl response in vitro.
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6.1 Conclusions
A Salmonella typhimurium vaccine construct, GIDIOI, was examined with 
respect to il s protective effects upon L. major infection and the immune responses 
induced after immunisation. GIDlOl represents a considerable improvement over the 
previous vaccine strain SL3261/gp63 in that after 2 oral immunisations it reduced 
lesion development in susceptible, BALB/c mice after L. major challenge infection, 
while SL3261/gp63 does not. Spleen and MLN cells from immunised BALB/c mice 
respond in vitro to parasite antigens to produce substantial amounts of IFN-y and IL-2, 
while no IL-4 or IL-5 was detected. The production of these cytokines was CD4^~cell 
dependent and serum from immunised mice contain parasite specific IgG2a, but no 
parasite specific IgGl, indicating the generation of a Thl-like response to antigen in 
vivo and upon restimulation in vitro. While the cytokine profile and antibody response 
suggested a Thl-like profile, there was no detectable DTH response to L. major after 
immunisation.
L. major gp63 was expressed in S. typhimurium strain, BRD509, under the 
control of either the NirB promoter which responds to anaerobic conditions (GID105) 
or OsmC which is induced under high salt conditions (GID106). These constructs were 
compared to GIDlOl to determine if use of inducable promoters could confer
protection after a single immunising dose. The construct GID105 displayed extremely 
stable plasmid retention as it colonised in vivo as compared to the constitutive
construct GIDlOl which experienced significant plasmid loss. The construct GID106 
was found not to colonise spleen or liver at all after oral delivery and loses plasmid 
more quickly than GIDlOl in vivo . An antibody response to gp63 is generated in 
BALB/c mice after one oral dose of GIDlOl, GID105 or GID106, while only the 
anaerobic construct, GID105, is able to induce a detectable cellular response to antigen 
after a single oral dose. Spleen and MLN cells from mice administered with GID105 
respond in vitro in a Thl-like manner but no DTH is conferred to immunised mice. A 
single oral delivery of GID105 or GID106 is sufficient to reduce lesion swelling in
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susceptible mice after L. major infection, while a single dose of GIDlOl does not 
confer any protection. Two doses of GID105 also provides protection against L. 
donovani infection, while GIDlOl or GID106 do not. Thus it was possible to generate 
a protective response after a single administration of constructs using inducible 
promoters although these varied in terms of protective capacity and immune response 
elicited.
A further construct was made expressing a recently discovered L. major antigen 
which can elicit better protective responses than gp63 when used in combination with 
IL-12. A plasmid was generated which contains the cDNA for p24/LACK under the 
control of the inducible NirB promoter and was introduced into the attenuated S. 
typhimurium strain BRD509. Expression of p24 by this construct (GID202) under 
anaerobic conditions was demonstrated by western blotting. After oral administration 
of GID202 to BALB/c mice, bacteria were detected in the spleen, liver and MLN until 
21-28 days later and plasmid stability of the construct during colonisation was found be 
around 100%. BALB/c mice which were orally administered one or two doses of 
GID202 before L. major infection developed exacerbated disease. CBA mice given 
two oral doses of GID202 also generated an exacerbated infection although CBA mice 
which received a single dose were slightly protected. Spleen and MLN cells from mice 
administered GID202 responded in vitro in a Thl-like manner to both recombinant p24 
and the immunodominant peptide of p24. These data demonstrate a disease-promoting 
effect of vaccination with p24 expressed in S. typhimurium which correlates with a Thl 
response in vitro.
6.2 What determines T cell subset induction in vaccination against 
leishmaniasis ?
A number factors responsible for the development of uncommitted CD4^ T 
cells to polarised Thl and Th2 subsets have been uncovered in recent years. The 
nature of antigen, lineage of antigen presenting cell (APC) and the presence of soluble
171
have the capacity to select for certain T cell subsets, although the relative importance of 
these in pathogenesis an( 
responses are not known.
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or membrane bound costimulatory molecules have all been demonstrated to affect the 
generation of T cell subsets (98). The relative importance of each of these factors in 
the development of T cell responses during leishmaniasis is not clear but an 
understanding of the process of lineage commitment may have consequences with 
regard to vaccination against leishmaniasis.
An analysis of TcR usage in BALB/c and C57BL/6 mice demonstrated the 
expansion of a Va8V p4 population early during L. major infection of both strains, 
suggesting that responses to diverse antigens are not the primary cause of differential T 
cell polarisation (380). However, certain leishmanial antigens have been shown to 
preferentially induce Thl or Th2 cells after immunisation of BALB/c mice (137). 
Immunisation of BALB/c mice with peptides from gp63 also suggests that certain 
sequences have an inherent tendency to drive Thl or Th2 responses (276). In addition, 
a recently cloned antigen from L. braziliensis has the capacity to generate Thl 
responses in PBMC's from patients with leishmanial infection whereas unstimulated 
cells or cells stimulated with parasite lysate produced a mixed Thl/Th2 profile of 
cytokine secretion (381). Therefore, certain antigens or peptides from Leishmania 
parasites have the capacity to generate a polarised T cell response. This phenomenom 
may account for the capacity of certain antigens such as p24/LACK to generate cure of
disease in immunised susceptible mice while others such as gp63 cannot (379).
1
In agreement with the antigen-driven selection of T cell subsets in 
leishmaniasis, immunisation of mice with RSV proteins using identical protocols
demonstrated that in this model induction of Thl, Th2 or CTL responses depended i1upon the antigen used (243). These experiments demonstrate that certain antigens do
d the mechanism by which antigens can select for differing h
In addition to the contribution of antigens themselves in selecting T cell 
subsets, the lineage of antigen presenting cell can influence polarisation. Injection of 
killed leishmanial antigens intravenously or intraperitonealy confers the ability to cure 
disease in the susceptible BALB/c strain while subcutaneous injection of the same 
preparation causes exacerbation of infection (124, 129). These diverse outcomes may 
result from antigen presentation by different cell populations selected by the route of 
immunisation. In agreement with this hypothesis, B cells have been found to generate 
leishmania specific Th2 cells while macrophages preferentially induced a Thl-like 
population from mice immunised with antigen from L. m, mexicana (254). The 
mechanism by which A PC's can influence the generation of T cell subsets may involve 
specific membrane interactions between the T cell and the APC or may derive from the 
activities of APC secreted products.
Costimulation of T cells via membrane interactions with APC's during antigen 
presentation can determine the polarisation of CD4^ T cell responses. In vitro and in 
vivo evidence suggest that ligation of B7-1 and B7-2 molecules on the APC membrane 
by T cell molecules during antigen presentation can select for Thl or Th2 generation 
respectively (382). Interestingly, L. donovani infection of bone-marrow macrophages 
inhibits the membrane expression of B7-1 in response to activating stimuli, although 
whether this process can modulate subsequent T cell subset generation was not 
addressed (383).
Costimulation by soluble factors during TcR ligation can also affect subsequent 
T cell responses although these may derive from other cell sources in addition to the 
APC. Initial cytokine responses in susceptible and resistant mice after infection with L, 
major are of a mixed ThO type with mRNA of both IFN-y and IL-4 detected in the 
draining lymph node during the first week of infection (184). In resistant mice the 
initial IL-4 mRNA is rapidly controlled which may account for the development of a 
Thl phenotype in response to infection. Conversely, the maintenance of elevated lL-4 
production in BALB/c mice after the first week of infection may be required for the
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generation of Th2 responses. Consistent with this, immunological interventions which 
restrict early IL-4 production in BALB/c mice also induce healing, and excess lL-4 
production in a transgenic resistant strain render it deficient in the control of infection 
(98, 152). Thus a leishmanial specific Th2-cell response requires the presence of IL-4 
at T cell priming, as has been observed in other disease models (185).
The source of IL-4 during early L. major infection may derive from CD4’*' cells 
themselves, as SCID mice and anti-CD4 treated BALB/c mice do not generate this 
early response (184). An unusual cell population which are CD4'^, N K l.H  has been 
described which accounts for early cytokine production hours after the injection of 
anti-CD3 monoclonal antibody (384). This cell may be the source of early lL-4 
production after L. major infection. While mast cells and basophils have also been 
suggested to contribute to Th2 cell generation via the production of lL-4, the activating 
mechanisms for early cytokine production by these cell types is undefined.
The relative contribution of antigen, lineage of presenting cell and 
costimulation in the induction of T cell subsets after L. major infection is not clear. 
An increased understanding of these processes may lead to improved antigens for 
vaccination and the generation of defined adjuvants which can differentially select T 
cell subset differentiation.
With this in mind, the capacity of Salmonella vectors to initiate a restricted 
Thl-like response to gp63 after oml administration suggests that Salmonella may alter 
the cytokine environment during T cell priming. As purified gp63 is not intrinsically 
able to induce a Thl response after subcutaneous immunisation (373), it is likely that 
the induction of strong Th-1 like responses after Salmonella delivery of gp63 is due to 
costimulatory effects mediated by the Salmonella themselves. It may be that 
salmonella alter membrane costimulatory molecule expression on infected 
macrophages to select for B7-1 expression, but it is more likely that they alter the local 
cytokine environment. BCG and Toxoplasma gondii induce the production of various
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cytokines by the macrophage during entry, including TNF-a, IL-12 and IL-1 (98). It is 
therefore possible that Salmonella do likewise, and indeed preliminary in vitro 
experiments using attenuated salmonella (BRD509) to infect the macrophage cell line 
J774 also induced IL-12 production (Author's unpublished observations). There is little 
data available on the induction of cytokines during macrophage infection by 
Salmonella in vitro or in vivo. The secretion of IL-12 by infected macrophages in vivo, 
as they present Salmonella and heterologous antigens, will preferentially select for Thl 
responses. Further work in this area is required in order to determine the factors 
involved in T cell subset selection during Salmonella infection but it seems likely that 
the non-specific induction of cytokines by Salmonella themselves may serve to polarise 
T cell responses. '!■■
6.3 Further T cell heterogeneity
While the involvement of Thl and Th2-like CD4^ T cells in the regulation of 
immunity in experimental cutaneous leishmaniasis is well documented, there are 
indications that further heterogeneity of the T cell compartment exists. BALB/c mice 
immunised intravenously with killed L. major recover from cutaneous disease and this 
immunity from infection can be transferred to naive BALB/c mice by transfer of the 
CD4 + Y_cell population (117). However, unlike the CD4^ cells from mice which have
recovered from infection, these cells do not confer DTH responses to injected parasite 
antigen. Indeed, transfer of these cells can suppress a DTH response which normally '!
occurs in cured mice (125). In addition to these data, protection of BALB/c mice after 
oral administration of a S. typhimurium construct expressing L. major gp63 did not 
correlate with the induction of a DTH response to injected parasites (Chapter 3).
Therefore at least two functionally distinct protective populations exist which differ in 
the ability to transfer DTH responses, although it remains to be determined whether 
these represent further distinct T cell subsets or are developmental stages of Thl cells.
to Thl and Th2 cells. Foreign antigens delivered by attenuated S. typhimurium vectors 
tend to induce Thl-like recall responses in vitro (278, 356, 357) yet a feature of 
Salmonella infection is the production of antigen specific IgA which is characteristic of 
a Th2-like response (284). While this may be attributed to different localised T cell 
responses in the mucosal and systemic immune system compartments, the detection of 
elevated serum IgA in addition to IgA at mucosal surfaces suggests that a more general 
interplay of Thl and Th2 responses occurs.
Thus, while murine L. major infection represents a clear model of differential 
activation of T cell subsets, there is evidence to suggest further CD4'*' T cell subset 
diversity. The further elucidation of the true nature of T cell responses after 
immunisation in the murine model may aid the generation of defined vaccines to 
stimulate protective T cell compartments.
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A Thl like cell clone has also been described which transfers DTH responses to 
parasite antigens and an exacerbative effect to both resistant and susceptible mice upon 
L. major infection (127). Chapter 5 of this thesis describes a S. typhimurium construct 
expressing p24/LACK, which generates a Thl-like response to p24, causes 
exacerbation to L. major infection yet does not mediate DTH. Therefore the 
differential capacity to generate DTH responses while mediating exacerbation is also 
consistent with further diversity of T cell subsets.
These observations in the L. major model are supported by additional data from 
T cell lines and clones. Cytokine expression by individual T cells is thought to be 
independently regulated in that although populations of T cells may display a profound 
bias in terms of cytokine secretion, single cells within this population display 
considerable diversity in the degree of polarisation (386). Thus a "Thl population" 
does not represent a homogeneous population and groups of cells may exist which can |
be further subdivided.
,
Further evidence suggests that other diverse T cell subsets may exist in addition
I
I
6.4 Plasmid stability and immunogenicity
The sustained inheritance of plasmid by Salmonella vectors as they colonise in 
vivo is thought to determine the immune response to heterologously expressed 
antigens. This simple correlation between plasmid stability in vivo and increased 
immunogenicity is, however, not always observed. While the integration of foreign 
genes into the chromosome of attenuated salmonella strains increases the capacity to 
maintain antigen expression throughout the life cycle in vivo , it also reduces the level 
of protein expression and reduces immunogenicity (387).
The use of inducible promoters to control antigen expression in vivo can 
enhance plasmid stability while maintaining high levels of expression (372). However, 
sustained protein expression in vivo using inducible promoters does not always 
increase immunogenicity as the highly unstable construct G1D106 described in this 
thesis confer protection to L. major infection while a more stable construct, GIDIOI, 
does not (Chapter 4). Thus although plasmid stability and protein expression can alter 
immunogenicity, the factors responsible for the generation of these responses are not 
clearly defined.
The stage in Salmonella colonisation at which inducable promoters initiate 
transcription may be critical in the generation of immune responses, as this will 
determine how antigen presentation takes place. Antigen which is expressed after 
macrophage invasion by Salmonella in the visceral tissues may generate different 
responses from antigens expressed only in the local mucosal environment at the 
initiation of infection as these may mimic antigen delivery by different routes of 
immunisation.
In addition, the ability of salmonella strains to initiate the secretion of cytokines 
after infection of macrophages may also determine immunogenicity. Different 
attenuated strains of Salmonella may differ in the capacity to generate such responses
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and therefore vary in the capacity to induce immune responses to foreign antigens as 
the cytokine environment is altered during T cell priming (see 6.1). The presence of 
these cytokines may aid or hinder the generation of immune responses to 
heterologously expressed antigens. With this in mind, it is of interest that galE 
Salmonella mutants which have defective LPS structures are poorly immunogenic and 
LPS is known to induce macrophage cytokine production. Thus the choice of bacterial 
strains which can elicit non-specific cytokine production by macrophages may allow 
the selection of better immunogenic Salmonella. Therefore, while it is clear that 
increased plasmid stability can alter the immunogenicity of antigens expressed in 
attenuated Salmonella other factors may also modulate the generation of immune 
responses and may contribute to the generation of an effective Salmonella vaccine 
against leishmaniasis.
6.5 Salmonella as vaccine vectors against diverse pathogens
The ability of many Salmonella constructs to generate Thl-like responses to 
expressed antigens suggests that Salmonella vectors may be useful in vaccine design 
against pathogens which require such responses to clear infection. The induction of 
Thl responses after vaccination with gp63 or p24 in S. typhimurium (Chapter 3, 4 and
5) suggests that responses to heterologous antigens may be restricted to a Thl 
phenotype. Therefore while attenuated S. typhimurium may be useful vectors for 
vaccination against intracellular pathogens they may not represent an ideal carrier for 
vaccination against extracellular infections which require protective Th2 responses.
This issue is important when considering attenuated Salmonella as a base for 
vaccination against diverse pathogens. While a vaccine construct has been described 
which can induce immune responses against Salmonella, Tetanus toxin fragment C and 
Schistosoma mansoni, the protective nature of these responses was not examined (359). 
The induction of immune responses to diverse pathogens by a single Salmonella 
construct does suggests that multivalent immunisation is possible, however the nature
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of immune responses induced in multivalent vaccine constructs may do little to prevent 
disease against the respective pathogens and may in fact increase pathology. As 
demonstrated in this study, disease exacerbating responses can be induced following 
vaccination with leishmanial antigens (Chapter 5). Further studies on the nature of 
immune response induced following vaccination with attenuated Salmonella may give 
a clearer indication of the potential to vaccinate against diverse organisms. The 
restricted use of attenuated Salmonella to vaccinate against pathogens which require 
similar protective immune responses may be a rational approach to future vaccine 
design.
6.6 Factors affecting host response to vaccination
A further consideration in the generation of protective immune responses to 
leishmaniasis after vaccination is the predisposition of the host to generate Thl or Th2 
responses. The predisposition of BALB/c mice to generate Th2 responses maps to a 
region on chromosome 11 (71). This area contains the genes for IL-4, IL-12 and iNOS 
and it has been suggested that the tendency for BALB/c mice to develop Th2 responses 
results from a defect in the lL-4 gene (98). A vaccine which induces a protective Thl 
response in BALB/c mice overcomes this inherent defect. However, in addition to 
genetic factors, there are also certain environmental factors which can affect the 
outcome of immune responses and should be taken into account when considering 
vaccination.
Pregnancy is associated with elevated Th2-like responses to antigen due to 
interactions between the endocrine and immune system (387). Pregnant mice develop 
exacerbated lesions during L. major infection due to the decreased ability to mount 
Thl responses. Interestingly, such mice also demonstrate increase foetal rejection due 
to an elevated Thl response to the parasite. Thus responses to the parasite and to the 
foetus can be adversely altered due to environmental influences, irrespective of the 
genetic tendency of the host. A similar effect may take place in during vaccination to
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generate Thl responses using S. typhimurium, although these issues have not been 
addressed to date.
As much of the population in developing countries have resident parasitic worm 
infestations in the gut which require Th2 responses for clearance, this may also alter 
immune reponses to vaccination. A dominant response to the vaccine or to the worm 
may have adverse effects upon the resident infection or limit vaccine immunogenicity. 
The effect of pregnancy and infection upon leishmanial vaccination have not been 
directly addressed although experimental models suggest that factors which cause the 
presence of Th2 cytokines during infection can lead to the generation of exacerbated 
disease in preference to cure of infection (98). Therefore environmental influences 
such as pregnancy and secondary infections may have considerable influence upon the 
induction of protective immunity against leishmaniasis. When considering vaccination 
against a pathogen such as Leishmania these factors must be considered and further 
study of the nature of environmental influences in vaccination is required.
6.7 Future directions
Gp63 Salmonella constructs
It is clear from the data presented in this thesis that gp63 can provide a degree 
of protection to susceptible mice when expressed in the S. typhimurium strain BRD509 
and when inducible promoters are used. Thus the present system seems to be 
optimised to generate protective immunity using an antigen which has performed 
poorly in other vaccine studies. However, it is also clear that a reduction in lesion size 
after immunisation with these constructs does nothing to protect susceptible mice from 
fatal infection, as lesions are not ultimately controlled. Thus these constructs may 
represent the optimal protection that is possible using gp63. This may be due to the 
fact that the expression of gp63 is probably turned off or at least downmodulated 
following the transition from promastigote to amastigote stage. Thus a strong Thl-like
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;response to gp63 is not beneficial during later infection as there is little gp63 expressed 
at this stage. While these results are discouraging there are positive conclusions that 
can be drawn from these studies.
(1) These studies represent an optimisation of vaccination using an antigen that was
Î
V 
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thought to be important during disease as it is the major surface antigen of 
promastigotes. While use of this antigen in Salmonella does not allow mice to 
ultimately resist disease, other antigens used in this system may do so. Thus 
identification of further L. major antigens which are expressed on both amastigote and 
promastigote stage may aid the construction of an effective vaccine, using the strain 
BRD509 and the promoter NirB shown to be optimal in these studies.
■
(2) While the gp63 constructs do not in themselves constitute an effective vaccine, the 
use of these with other vaccine constructs such as G1D202 (expressing p24) may be 
effective as inducing immune responses against gp63 should limit the initial parasite 
growth. It seems likely that an effective vaccine against leishmaniasis should include 
more than one antigen due to the success of whole parasite antigen vaccination and the 
relatively poor results using single antigens. Studies using both gp63 and p24 
constructs to vaccinate susceptible mice are currently ongoing. I
(3) The performance of the GID105 construct in reducing parasite burdens during 
experimental L. donovani infection indicate that this construct may be useful against 
this pathogen. A dog vaccination trial is currently underway in Portugal using the
construct GID105 to assess immunogenicity and protection against L. infantum 
infection which is an endemic pathogen in this area.
P24 Salmonella construct
The exacerbative effect of the GID202 construct upon experimental cutaneous 
leishmaniasis suggests that responses to this antigen are critical in modulating disease.
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The exacerbative effect of this construct may be due to clonal exhaustion of p24 
reactive cells. Thus the exacerbation during disease may represent an inability to 
respond to p24/LACK during infection. Vaccination with lower doses of GID202 may 
define a critical inoculum which can induce immune responses but does not exhaust the 
cells. In agreement with an effect of dosage upon the exacerbative effect, CBA mice 
administered one dose of GID202 were slightly protected. Therefore further dose 
experiments and an examination of tolerance induction by the construct GID202 are 
underway.
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